US20210038748A1 - Compositions And Methods For In Vivo Imaging - Google Patents
Compositions And Methods For In Vivo Imaging Download PDFInfo
- Publication number
- US20210038748A1 US20210038748A1 US16/874,361 US202016874361A US2021038748A1 US 20210038748 A1 US20210038748 A1 US 20210038748A1 US 202016874361 A US202016874361 A US 202016874361A US 2021038748 A1 US2021038748 A1 US 2021038748A1
- Authority
- US
- United States
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- azd2281
- imaging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 79
- 239000000203 mixture Substances 0.000 title claims description 50
- 238000011503 in vivo imaging Methods 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 173
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 118
- 201000011510 cancer Diseases 0.000 claims abstract description 53
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 claims abstract description 5
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 claims description 91
- 238000003384 imaging method Methods 0.000 claims description 75
- 229960000572 olaparib Drugs 0.000 claims description 57
- -1 BSI101 Chemical compound 0.000 claims description 48
- 239000003795 chemical substances by application Substances 0.000 claims description 42
- 150000003839 salts Chemical class 0.000 claims description 32
- 239000000463 material Substances 0.000 claims description 29
- 238000011282 treatment Methods 0.000 claims description 29
- 239000003112 inhibitor Substances 0.000 claims description 25
- 238000002600 positron emission tomography Methods 0.000 claims description 18
- 102000004190 Enzymes Human genes 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 11
- 239000012661 PARP inhibitor Substances 0.000 claims description 11
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims description 11
- 238000002591 computed tomography Methods 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000000975 dye Substances 0.000 claims description 10
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 10
- 238000001356 surgical procedure Methods 0.000 claims description 9
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 8
- 239000012857 radioactive material Substances 0.000 claims description 8
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical group [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 claims description 7
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 6
- 239000002872 contrast media Substances 0.000 claims description 6
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical compound C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 claims description 6
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 6
- MDOJTZQKHMAPBK-UHFFFAOYSA-N 4-iodo-3-nitrobenzamide Chemical compound NC(=O)C1=CC=C(I)C([N+]([O-])=O)=C1 MDOJTZQKHMAPBK-UHFFFAOYSA-N 0.000 claims description 5
- WWRAFPGUBABZSD-UHFFFAOYSA-N 6-amino-5-iodochromen-2-one Chemical compound O1C(=O)C=CC2=C(I)C(N)=CC=C21 WWRAFPGUBABZSD-UHFFFAOYSA-N 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 238000012544 monitoring process Methods 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- IJAPPYDYQCXOEF-UHFFFAOYSA-N phthalazin-1(2H)-one Chemical compound C1=CC=C2C(=O)NN=CC2=C1 IJAPPYDYQCXOEF-UHFFFAOYSA-N 0.000 claims description 5
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 claims description 5
- 229950004707 rucaparib Drugs 0.000 claims description 5
- 150000003384 small molecules Chemical class 0.000 claims description 5
- 239000000758 substrate Substances 0.000 claims description 5
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 239000002105 nanoparticle Substances 0.000 claims description 4
- 238000012285 ultrasound imaging Methods 0.000 claims description 4
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical compound C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 claims description 3
- GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-aminobenzamide Chemical compound NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 claims description 3
- LQJVOLSLAFIXSV-UHFFFAOYSA-N 4h-thieno[2,3-c]isoquinolin-5-one Chemical compound C12=CC=CC=C2C(=O)NC2=C1C=CS2 LQJVOLSLAFIXSV-UHFFFAOYSA-N 0.000 claims description 3
- 239000012116 Alexa Fluor 680 Substances 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 125000000641 acridinyl group Chemical class C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 150000002484 inorganic compounds Chemical class 0.000 claims description 3
- 229910010272 inorganic material Inorganic materials 0.000 claims description 3
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical compound C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 claims description 3
- DZRLVSOGARUEGQ-UHFFFAOYSA-N kinome_3609 Chemical compound C1CN(C)CCN1CC1=CC=C(OC=2C3=C(C(NN=C33)=O)C=CC=2)C3=C1 DZRLVSOGARUEGQ-UHFFFAOYSA-N 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 claims description 3
- 150000004866 oxadiazoles Chemical class 0.000 claims description 3
- 150000004893 oxazines Chemical class 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 150000003220 pyrenes Chemical class 0.000 claims description 3
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims description 3
- 125000001834 xanthenyl group Chemical class C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 claims description 3
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 2
- 238000003390 bioluminescence detection Methods 0.000 claims description 2
- 238000002038 chemiluminescence detection Methods 0.000 claims description 2
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 238000001917 fluorescence detection Methods 0.000 claims description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 2
- WGLUNLJVYNJMBU-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-n-[(3-methyl-1-oxo-2,4-dihydroisoquinolin-3-yl)methyl]decanamide Chemical compound C1=CC=C2C(=O)NC(CN(CCN(C)C)C(=O)CCCCCCCCC)(C)CC2=C1 WGLUNLJVYNJMBU-UHFFFAOYSA-N 0.000 claims description 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims description 2
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims 2
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 claims 1
- 229950011257 veliparib Drugs 0.000 claims 1
- 102000015087 Poly (ADP-Ribose) Polymerase-1 Human genes 0.000 abstract description 2
- 230000008685 targeting Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 139
- 101001113483 Homo sapiens Poly [ADP-ribose] polymerase 1 Proteins 0.000 description 81
- 239000000243 solution Substances 0.000 description 48
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 47
- 239000002953 phosphate buffered saline Substances 0.000 description 47
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 46
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 44
- 238000006243 chemical reaction Methods 0.000 description 40
- FDLYAMZZIXQODN-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FDLYAMZZIXQODN-UHFFFAOYSA-N 0.000 description 37
- 238000004128 high performance liquid chromatography Methods 0.000 description 32
- 238000002360 preparation method Methods 0.000 description 32
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 26
- 239000011541 reaction mixture Substances 0.000 description 24
- URYYVOIYTNXXBN-OWOJBTEDSA-N trans-cyclooctene Chemical compound C1CCC\C=C\CC1 URYYVOIYTNXXBN-OWOJBTEDSA-N 0.000 description 23
- 230000000694 effects Effects 0.000 description 21
- 239000000523 sample Substances 0.000 description 20
- MFFUYEOGICAKCK-UHFFFAOYSA-N 4-[[4-fluoro-3-(piperazine-1-carbonyl)phenyl]methyl]-2h-phthalazin-1-one Chemical compound FC1=CC=C(CC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N1CCNCC1 MFFUYEOGICAKCK-UHFFFAOYSA-N 0.000 description 18
- 238000000746 purification Methods 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- 125000005647 linker group Chemical group 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- 238000003556 assay Methods 0.000 description 14
- 229910052796 boron Inorganic materials 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- 0 *C1=CC=C(C2=NNC=C3CCCC(C(=O)CCCC(=O)CC(=O)N4CCN(C(=O)C5=CC(CC6=NNC(=O)C7=CC=CC=C76)=CC=C5F)CC4)CCC32)C=C1.CC1=CC(C)=N2C1=CC1=CC=C(CCC(=O)N3CCN(C(=O)C4=CC(CC5=NNC(=O)C6=CC=CC=C65)=CC=C4F)CC3)N1B2(F)F.O=C(CCCC(=O)N1CCN(C(=O)C2=CC(CC3=NNC(=O)C4=CC=CC=C43)=CC=C2F)CC1)CCC1=CC=C(C2=NN=CC3=C2CCC(OCC[18F])CCC3)C=C1.O=C(COC1=CC=C(/C=C/C2=CC=C3C=C4C=CC(C5=CC=CN5)=N4=B(F)(F)N32)C=C1)NCCCCCC(=O)N1CCN(C(=O)C2=CC(CC3=NNC(=O)C4=CC=CC=C43)=CC=C2F)CC1.O=C1NN=C(CC2=CC=C(F)C(C(=O)N3CCN(C(=O)CCC4=CC=C5C=C6C=CC(C7=CC=CN7)=N6B(F)(F)N54)CC3)=C2)C2=CC=CC=C12 Chemical compound *C1=CC=C(C2=NNC=C3CCCC(C(=O)CCCC(=O)CC(=O)N4CCN(C(=O)C5=CC(CC6=NNC(=O)C7=CC=CC=C76)=CC=C5F)CC4)CCC32)C=C1.CC1=CC(C)=N2C1=CC1=CC=C(CCC(=O)N3CCN(C(=O)C4=CC(CC5=NNC(=O)C6=CC=CC=C65)=CC=C4F)CC3)N1B2(F)F.O=C(CCCC(=O)N1CCN(C(=O)C2=CC(CC3=NNC(=O)C4=CC=CC=C43)=CC=C2F)CC1)CCC1=CC=C(C2=NN=CC3=C2CCC(OCC[18F])CCC3)C=C1.O=C(COC1=CC=C(/C=C/C2=CC=C3C=C4C=CC(C5=CC=CN5)=N4=B(F)(F)N32)C=C1)NCCCCCC(=O)N1CCN(C(=O)C2=CC(CC3=NNC(=O)C4=CC=CC=C43)=CC=C2F)CC1.O=C1NN=C(CC2=CC=C(F)C(C(=O)N3CCN(C(=O)CCC4=CC=C5C=C6C=CC(C7=CC=CN7)=N6B(F)(F)N54)CC3)=C2)C2=CC=CC=C12 0.000 description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000011324 bead Substances 0.000 description 12
- 150000001993 dienes Chemical class 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 210000004940 nucleus Anatomy 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 239000003643 water by type Substances 0.000 description 11
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- 150000001336 alkenes Chemical class 0.000 description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000001413 cellular effect Effects 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 9
- 239000002243 precursor Substances 0.000 description 9
- 239000007858 starting material Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- UCPDHOTYYDHPEN-UPHRSURJSA-N (4z)-cyclooct-4-en-1-ol Chemical compound OC1CCC\C=C/CC1 UCPDHOTYYDHPEN-UPHRSURJSA-N 0.000 description 8
- FVSWDDFPDPLAIU-NSCUHMNNSA-N 2-[(4e)-cyclooct-4-en-1-yl]oxyethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCOC1CC/C=C/CCC1 FVSWDDFPDPLAIU-NSCUHMNNSA-N 0.000 description 8
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 8
- 229920002536 Scavenger resin Polymers 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 208000009956 adenocarcinoma Diseases 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- 239000011347 resin Substances 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- NFMXXBBCDIEIJX-UPHRSURJSA-N 2-[(4z)-cyclooct-4-en-1-yl]oxyethanol Chemical compound OCCOC1CCC\C=C/CC1 NFMXXBBCDIEIJX-UPHRSURJSA-N 0.000 description 7
- 206010025323 Lymphomas Diseases 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000013058 crude material Substances 0.000 description 7
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 7
- HKVLOZLUWWLDFP-UHFFFAOYSA-M hydron;tetrabutylazanium;carbonate Chemical compound OC([O-])=O.CCCC[N+](CCCC)(CCCC)CCCC HKVLOZLUWWLDFP-UHFFFAOYSA-M 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000003039 volatile agent Substances 0.000 description 7
- NFMXXBBCDIEIJX-OWOJBTEDSA-N 2-[(4e)-cyclooct-4-en-1-yl]oxyethanol Chemical compound OCCOC1CCC\C=C\CC1 NFMXXBBCDIEIJX-OWOJBTEDSA-N 0.000 description 6
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- DLCNRTMWVGPGIY-UHFFFAOYSA-N C1=CC=C(C2=NC=CC3=C2CCCCCC3)C=C1.CC.CC.CC.CC.[H]C12CCCCCCC1=CNN=C2C1=CC=CC=C1 Chemical compound C1=CC=C(C2=NC=CC3=C2CCCCCC3)C=C1.CC.CC.CC.CC.[H]C12CCCCCCC1=CNN=C2C1=CC=CC=C1 DLCNRTMWVGPGIY-UHFFFAOYSA-N 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 238000000132 electrospray ionisation Methods 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 229910052737 gold Inorganic materials 0.000 description 6
- 239000010931 gold Substances 0.000 description 6
- 238000001972 liquid chromatography-electrospray ionisation mass spectrometry Methods 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- PBMIETCUUSQZCG-UHFFFAOYSA-N n'-cyclohexylmethanediimine Chemical compound N=C=NC1CCCCC1 PBMIETCUUSQZCG-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 229920005990 polystyrene resin Polymers 0.000 description 6
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- DGEJVSRVPGDQFN-UHFFFAOYSA-N 4-[[4-fluoro-3-[2-[2-(4-methylphenyl)sulfonylacetyl]piperazine-1-carbonyl]phenyl]methyl]-2h-phthalazin-1-one Chemical compound C1=CC(C)=CC=C1S(=O)(=O)CC(=O)C1N(C(=O)C=2C(=CC=C(CC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)CCNC1 DGEJVSRVPGDQFN-UHFFFAOYSA-N 0.000 description 5
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 229930040373 Paraformaldehyde Natural products 0.000 description 5
- 206010039491 Sarcoma Diseases 0.000 description 5
- DPOPAJRDYZGTIR-UHFFFAOYSA-N Tetrazine Chemical compound C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 description 5
- 150000001345 alkine derivatives Chemical class 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 238000006352 cycloaddition reaction Methods 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- KRHYYFGTRYWZRS-BJUDXGSMSA-M fluorine-18(1-) Chemical compound [18F-] KRHYYFGTRYWZRS-BJUDXGSMSA-M 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000002357 laparoscopic surgery Methods 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- 239000012280 lithium aluminium hydride Substances 0.000 description 5
- 230000004807 localization Effects 0.000 description 5
- 229920002866 paraformaldehyde Polymers 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000002953 preparative HPLC Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 150000004892 pyridazines Chemical class 0.000 description 5
- 230000002285 radioactive effect Effects 0.000 description 5
- 239000012508 resin bead Substances 0.000 description 5
- 206010041823 squamous cell carcinoma Diseases 0.000 description 5
- 150000004905 tetrazines Chemical class 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- TUTCZQDKAAWPFH-UHFFFAOYSA-N 4-[[4-fluoro-3-[2-(6-hydroxyhexanoyl)piperazine-1-carbonyl]phenyl]methyl]-2h-phthalazin-1-one Chemical compound OCCCCCC(=O)C1CNCCN1C(=O)C1=CC(CC=2C3=CC=CC=C3C(=O)NN=2)=CC=C1F TUTCZQDKAAWPFH-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 206010024612 Lipoma Diseases 0.000 description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
- 208000007660 Residual Neoplasm Diseases 0.000 description 4
- 239000013504 Triton X-100 Substances 0.000 description 4
- 229920004890 Triton X-100 Polymers 0.000 description 4
- JGCOJRPYFRRONJ-UHFFFAOYSA-N [4-(1,2,4,5-tetrazin-3-yl)phenyl]methanamine Chemical compound C1=CC(CN)=CC=C1C1=NN=CN=N1 JGCOJRPYFRRONJ-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 238000000799 fluorescence microscopy Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000030648 nucleus localization Effects 0.000 description 4
- 230000002611 ovarian Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- BKPCVKMDKAOKSQ-OWOJBTEDSA-N (1e)-5-(2-fluoroethoxy)cyclooctene Chemical compound FCCOC1CCC\C=C\CC1 BKPCVKMDKAOKSQ-OWOJBTEDSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 230000005778 DNA damage Effects 0.000 description 3
- 231100000277 DNA damage Toxicity 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 238000005698 Diels-Alder reaction Methods 0.000 description 3
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 3
- 201000008808 Fibrosarcoma Diseases 0.000 description 3
- 101001113440 Homo sapiens Poly [ADP-ribose] polymerase 2 Proteins 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 description 3
- ZJYAGHMCBYXCOC-RVDMUPIBSA-N O=C(COC1=CC=C(/C=C/C2=CC=C3C=C4C=CC(C5=CC=CN5)=N4B(F)(F)N32)C=C1)NCCCCCC(=O)N1CCN(C(=O)C2=CC(CC3=NNC(=O)C4=CC=CC=C43)=CC=C2F)CC1 Chemical compound O=C(COC1=CC=C(/C=C/C2=CC=C3C=C4C=CC(C5=CC=CN5)=N4B(F)(F)N32)C=C1)NCCCCCC(=O)N1CCN(C(=O)C2=CC(CC3=NNC(=O)C4=CC=CC=C43)=CC=C2F)CC1 ZJYAGHMCBYXCOC-RVDMUPIBSA-N 0.000 description 3
- 102100023652 Poly [ADP-ribose] polymerase 2 Human genes 0.000 description 3
- 206010043276 Teratoma Diseases 0.000 description 3
- OUGQJOKGFAIFAQ-OWOJBTEDSA-N [(4e)-cyclooct-4-en-1-yl] (2,5-dioxopyrrolidin-1-yl) carbonate Chemical compound O=C1CCC(=O)N1OC(=O)OC1CCC\C=C\CC1 OUGQJOKGFAIFAQ-OWOJBTEDSA-N 0.000 description 3
- HMHYTYGWEUHDKI-MICDWDOJSA-N [2H]CCN1CCN(C(=O)C2=CC(CC3=NNC(=O)C4=CC=CC=C43)=CC=C2F)CC1 Chemical compound [2H]CCN1CCN(C(=O)C2=CC(CC3=NNC(=O)C4=CC=CC=C43)=CC=C2F)CC1 HMHYTYGWEUHDKI-MICDWDOJSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000001588 bifunctional effect Effects 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 238000007398 colorimetric assay Methods 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 206010016629 fibroma Diseases 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 201000011066 hemangioma Diseases 0.000 description 3
- 239000012216 imaging agent Substances 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000000696 magnetic material Substances 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YWFPXWMSGJXUFS-UPHRSURJSA-N (4z)-9-oxabicyclo[6.1.0]non-4-ene Chemical compound C1C\C=C/CCC2OC21 YWFPXWMSGJXUFS-UPHRSURJSA-N 0.000 description 2
- QYMGRIFMUQCAJW-UHFFFAOYSA-N 1,2-dihydropyrazine Chemical compound C1NC=CN=C1 QYMGRIFMUQCAJW-UHFFFAOYSA-N 0.000 description 2
- JNAHVYVRKWKWKQ-UHFFFAOYSA-N 2-(2-methyl-2-pyrrolidinyl)-1H-benzimidazole-4-carboxamide Chemical compound N=1C2=C(C(N)=O)C=CC=C2NC=1C1(C)CCCN1 JNAHVYVRKWKWKQ-UHFFFAOYSA-N 0.000 description 2
- ZVJNYABHPQDPNJ-UPHRSURJSA-N 2-[(4z)-cyclooct-4-en-1-yl]oxyacetic acid Chemical compound OC(=O)COC1CCC\C=C/CC1 ZVJNYABHPQDPNJ-UPHRSURJSA-N 0.000 description 2
- MRWHJWDSJXOQKW-UHFFFAOYSA-N 4-[[4-fluoro-3-[2-(2-hydroxyacetyl)piperazine-1-carbonyl]phenyl]methyl]-2h-phthalazin-1-one Chemical compound OCC(=O)C1CNCCN1C(=O)C1=CC(CC=2C3=CC=CC=C3C(=O)NN=2)=CC=C1F MRWHJWDSJXOQKW-UHFFFAOYSA-N 0.000 description 2
- MBHDPDRQOSMRKE-UHFFFAOYSA-N 4-[[4-fluoro-3-[2-[6-(4-methylphenyl)sulfonylhexanoyl]piperazine-1-carbonyl]phenyl]methyl]-2h-phthalazin-1-one Chemical compound C1=CC(C)=CC=C1S(=O)(=O)CCCCCC(=O)C1N(C(=O)C=2C(=CC=C(CC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)CCNC1 MBHDPDRQOSMRKE-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 201000003076 Angiosarcoma Diseases 0.000 description 2
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 2
- NCKZJFPYXYDLGU-UHFFFAOYSA-N CC(C)(C)C(=O)CCCC(=O)CC(=O)C(C)(C)C.CC(C)(C)CCC(=O)C(C)(C)C.CC(C)(C)CCC(=O)CC(=O)C(C)(C)C.CC(C)(C)OCC(=O)NCC(=O)C(C)(C)C Chemical compound CC(C)(C)C(=O)CCCC(=O)CC(=O)C(C)(C)C.CC(C)(C)CCC(=O)C(C)(C)C.CC(C)(C)CCC(=O)CC(=O)C(C)(C)C.CC(C)(C)OCC(=O)NCC(=O)C(C)(C)C NCKZJFPYXYDLGU-UHFFFAOYSA-N 0.000 description 2
- CMESEORLDXZGBR-JDZWFZAZSA-N CC1=CC=C(S(=O)(=O)OCCOC2CC/C=C/CCC2)C=C1.O=C(O)COC1CC/C=C\CCC1.OC1CC/C=C\CCC1.OCCOC1CC/C=C/CCC1.OCCOC1CC/C=C\CCC1.[19F]CCOC1CC/C=C/CCC1 Chemical compound CC1=CC=C(S(=O)(=O)OCCOC2CC/C=C/CCC2)C=C1.O=C(O)COC1CC/C=C\CCC1.OC1CC/C=C\CCC1.OCCOC1CC/C=C/CCC1.OCCOC1CC/C=C\CCC1.[19F]CCOC1CC/C=C/CCC1 CMESEORLDXZGBR-JDZWFZAZSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 238000006117 Diels-Alder cycloaddition reaction Methods 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 238000001327 Förster resonance energy transfer Methods 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 208000002927 Hamartoma Diseases 0.000 description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- IHBRXFXEMIWKHF-WHJSKQSASA-N NCC1=CC=C(C2=CC=CC=C2)C=C1.O=C(CCCC(=O)N1CCN(C(=O)C2=CC(CC3=NNC(=O)C4=CC=CC=C43)=CC=C2F)CC1)CCC1=CC=C(C2=NN=CC3=C2CCC(OCC[18F])CCC3)C=C1.O=C(CCCC(=O)N1CCN(C(=O)C2=CC(CC3=NNC(=O)C4=CC=CC=C43)=CC=C2F)CC1)CCC1=NN=CN=N1.[18F]CCOC1CC/C=C/CCC1 Chemical compound NCC1=CC=C(C2=CC=CC=C2)C=C1.O=C(CCCC(=O)N1CCN(C(=O)C2=CC(CC3=NNC(=O)C4=CC=CC=C43)=CC=C2F)CC1)CCC1=CC=C(C2=NN=CC3=C2CCC(OCC[18F])CCC3)C=C1.O=C(CCCC(=O)N1CCN(C(=O)C2=CC(CC3=NNC(=O)C4=CC=CC=C43)=CC=C2F)CC1)CCC1=NN=CN=N1.[18F]CCOC1CC/C=C/CCC1 IHBRXFXEMIWKHF-WHJSKQSASA-N 0.000 description 2
- LITULFDMQYRUMX-UHFFFAOYSA-N NCCCC(=O)CCCC(=O)N1CCN(C(=O)C2=CC(CC3=NNC(=O)C4=CC=CC=C43)=CC=C2F)CC1.O=C1NN=C(CC2=CC=C(F)C(C(=O)N3CCN(C(=O)C4CC4)CC3)=C2)C2=CC=CC=C12 Chemical compound NCCCC(=O)CCCC(=O)N1CCN(C(=O)C2=CC(CC3=NNC(=O)C4=CC=CC=C43)=CC=C2F)CC1.O=C1NN=C(CC2=CC=C(F)C(C(=O)N3CCN(C(=O)C4CC4)CC3)=C2)C2=CC=CC=C12 LITULFDMQYRUMX-UHFFFAOYSA-N 0.000 description 2
- 201000004404 Neurofibroma Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- PPDICDLXRWPZAA-YIRRUZDBSA-N O=C(CC(=O)N1CCN(C(=O)C2=CC(CC3=NNC(=O)C4=CC=CC=C43)=CC=C2F)CC1)NCCNC(=O)C1C[C@@H]2C=C[C@H]1C2.O=C(CC(=O)N1CCN(C(=O)C2=CC(CC3=NNC(=O)C4=CC=CC=C43)=CC=C2F)CC1)NCCNC(=O)OC1CC/C=C/CCC1.O=C(O)C1C[C@@H]2C=C[C@H]1C2.O=C(OC1CC/C=C/CCC1)ON1C(=O)CCC1=O Chemical compound O=C(CC(=O)N1CCN(C(=O)C2=CC(CC3=NNC(=O)C4=CC=CC=C43)=CC=C2F)CC1)NCCNC(=O)C1C[C@@H]2C=C[C@H]1C2.O=C(CC(=O)N1CCN(C(=O)C2=CC(CC3=NNC(=O)C4=CC=CC=C43)=CC=C2F)CC1)NCCNC(=O)OC1CC/C=C/CCC1.O=C(O)C1C[C@@H]2C=C[C@H]1C2.O=C(OC1CC/C=C/CCC1)ON1C(=O)CCC1=O PPDICDLXRWPZAA-YIRRUZDBSA-N 0.000 description 2
- LPKGZRJGWCKWGE-UHFFFAOYSA-N O=C(O)CCCC(=O)N1CCN(C(=O)C2=CC(CC3=NNC(=O)C4=CC=CC=C43)=CC=C2F)CC1 Chemical compound O=C(O)CCCC(=O)N1CCN(C(=O)C2=CC(CC3=NNC(=O)C4=CC=CC=C43)=CC=C2F)CC1 LPKGZRJGWCKWGE-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 238000003332 Raman imaging Methods 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 238000010533 azeotropic distillation Methods 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 229940054066 benzamide antipsychotics Drugs 0.000 description 2
- FYGUSUBEMUKACF-UHFFFAOYSA-N bicyclo[2.2.1]hept-2-ene-5-carboxylic acid Chemical compound C1C2C(C(=O)O)CC1C=C2 FYGUSUBEMUKACF-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000004700 cellular uptake Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- VANNPISTIUFMLH-UHFFFAOYSA-N glutaric anhydride Chemical compound O=C1CCCC(=O)O1 VANNPISTIUFMLH-UHFFFAOYSA-N 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 235000011167 hydrochloric acid Nutrition 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 125000000879 imine group Chemical group 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 150000002475 indoles Chemical class 0.000 description 2
- 229950002133 iniparib Drugs 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 201000010260 leiomyoma Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002514 liquid chromatography mass spectrum Methods 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 description 2
- 238000012014 optical coherence tomography Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000003345 scintillation counting Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000012536 storage buffer Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000001931 thermography Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- UCPDHOTYYDHPEN-CMLYIYFCSA-N (1r,4e)-cyclooct-4-en-1-ol Chemical compound O[C@@H]1CCC\C=C\CC1 UCPDHOTYYDHPEN-CMLYIYFCSA-N 0.000 description 1
- 150000003920 1,2,4-triazines Chemical class 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CDAISMWEOUEBRE-LKPKBOIGSA-N 1D-chiro-inositol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-LKPKBOIGSA-N 0.000 description 1
- UWZYICUGNHLGSA-UHFFFAOYSA-N 1h-imidazo[4,5-d]pyridazine Chemical class N1=NC=C2NC=NC2=C1 UWZYICUGNHLGSA-UHFFFAOYSA-N 0.000 description 1
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 1
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 1
- HHLZCENAOIROSL-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound OC(=O)CN1CCNCCN(CC(O)=O)CCN(CC(O)=O)CC1 HHLZCENAOIROSL-UHFFFAOYSA-N 0.000 description 1
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 description 1
- YQOUWOJPPGRPPW-UHFFFAOYSA-N 2-bis(4-methylphenyl)phosphanylethyl-bis(4-methylphenyl)phosphane Chemical compound C1=CC(C)=CC=C1P(C=1C=CC(C)=CC=1)CCP(C=1C=CC(C)=CC=1)C1=CC=C(C)C=C1 YQOUWOJPPGRPPW-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- KKOWNHGGOHEQTE-UHFFFAOYSA-N 2h-triazolo[4,5-d]pyridazine Chemical class C1=NN=CC2=C1N=NN2 KKOWNHGGOHEQTE-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 150000003928 4-aminopyridines Chemical class 0.000 description 1
- QEYONPKSDTUPAX-UHFFFAOYSA-N 4-bromo-2-chloro-6-fluorophenol Chemical compound OC1=C(F)C=C(Br)C=C1Cl QEYONPKSDTUPAX-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- IWHLYPDWHHPVAA-UHFFFAOYSA-N 6-hydroxyhexanoic acid Chemical compound OCCCCCC(O)=O IWHLYPDWHHPVAA-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 206010073106 Bone giant cell tumour malignant Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- CXUXKSSJJAONRM-ZDDHNKAZSA-N CC1=CC(C)=C2=CC3C=CC(CCC(=O)N4CCN(C(=O)C5=CC(CC6=NNC(=O)C7=CC=CC=C76)=CC=C5F)CC4)=N3B([18F])([19F])N12.O=C(COC1=CC=C(/C=C/C2=N3C(=CC4=CC=C(C5=CC=CN5)N4B3([18F])[19F])C=C2)C=C1)NCCCCCC(=O)N1CCN(C(=O)C2=CC(CC3=NNC(=O)C4=CC=CC=C43)=CC=C2F)CC1.O=C1NN=C(CC2=CC=C(F)C(C(=O)N3CCN(C(=O)CCC4=N5C(C=C4)C=C4=CC=C(C6=CC=CN6)N4B5([18F])[19F])CC3)=C2)C2=CC=CC=C12 Chemical compound CC1=CC(C)=C2=CC3C=CC(CCC(=O)N4CCN(C(=O)C5=CC(CC6=NNC(=O)C7=CC=CC=C76)=CC=C5F)CC4)=N3B([18F])([19F])N12.O=C(COC1=CC=C(/C=C/C2=N3C(=CC4=CC=C(C5=CC=CN5)N4B3([18F])[19F])C=C2)C=C1)NCCCCCC(=O)N1CCN(C(=O)C2=CC(CC3=NNC(=O)C4=CC=CC=C43)=CC=C2F)CC1.O=C1NN=C(CC2=CC=C(F)C(C(=O)N3CCN(C(=O)CCC4=N5C(C=C4)C=C4=CC=C(C6=CC=CN6)N4B5([18F])[19F])CC3)=C2)C2=CC=CC=C12 CXUXKSSJJAONRM-ZDDHNKAZSA-N 0.000 description 1
- KTYZRRUYBVNYJQ-ZDDHNKAZSA-N CC1=CC(C)=C2C=C3C=CC(CCC(=O)N4CCN(C(=O)C5=CC(C/C6=N/NC(=O)C7=C6C=CC=C7)=CC=C5F)CC4)=N3B([18F])([19F])N12.O=C(COC1=CC=C(/C=C/C2=N3C(=CC4=CC=C(C5=CC=CN5)N4B3([18F])[19F])C=C2)C=C1)NCCCCCC(=O)N1CCN(C(=O)C2=CC(C/C3=N/NC(=O)C4=C3C=CC=C4)=CC=C2F)CC1.O=C1N/N=C(/CC2=CC=C(F)C(C(=O)N3CCN(C(=O)CCC4=N5C(=CC6=CC=C(C7=CC=CN7)N6B5([18F])[19F])C=C4)CC3)=C2)C2=C1C=CC=C2 Chemical compound CC1=CC(C)=C2C=C3C=CC(CCC(=O)N4CCN(C(=O)C5=CC(C/C6=N/NC(=O)C7=C6C=CC=C7)=CC=C5F)CC4)=N3B([18F])([19F])N12.O=C(COC1=CC=C(/C=C/C2=N3C(=CC4=CC=C(C5=CC=CN5)N4B3([18F])[19F])C=C2)C=C1)NCCCCCC(=O)N1CCN(C(=O)C2=CC(C/C3=N/NC(=O)C4=C3C=CC=C4)=CC=C2F)CC1.O=C1N/N=C(/CC2=CC=C(F)C(C(=O)N3CCN(C(=O)CCC4=N5C(=CC6=CC=C(C7=CC=CN7)N6B5([18F])[19F])C=C4)CC3)=C2)C2=C1C=CC=C2 KTYZRRUYBVNYJQ-ZDDHNKAZSA-N 0.000 description 1
- IDNLMZYMJISHAE-ZDDHNKAZSA-N CC1=CC(C)=C2C=C3C=CC(CCC(=O)N4CCN(C(=O)C5=CC(CC6=NNC(=O)C7=C6C=CC=C7)=CC=C5F)CC4)=N3B([18F])([19F])N12.O=C(COC1=CC=C(/C=C/C2=N3/C(\C=C/2)CC2=CC=C(C4=CC=CN4)N2B3([18F])[19F])C=C1)NCCCCCC(=O)N1CCN(C(=O)C2=CC(CC3=NNC(=O)C4=C3C=CC=C4)=CC=C2F)CC1.O=C1NN=C(CC2=CC=C(F)C(C(=O)N3CCN(C(=O)CCC4=N5C(=CC6=CC=C(C7=CC=CN7)N6B5([18F])[19F])C=C4)CC3)=C2)C2=C1C=CC=C2 Chemical compound CC1=CC(C)=C2C=C3C=CC(CCC(=O)N4CCN(C(=O)C5=CC(CC6=NNC(=O)C7=C6C=CC=C7)=CC=C5F)CC4)=N3B([18F])([19F])N12.O=C(COC1=CC=C(/C=C/C2=N3/C(\C=C/2)CC2=CC=C(C4=CC=CN4)N2B3([18F])[19F])C=C1)NCCCCCC(=O)N1CCN(C(=O)C2=CC(CC3=NNC(=O)C4=C3C=CC=C4)=CC=C2F)CC1.O=C1NN=C(CC2=CC=C(F)C(C(=O)N3CCN(C(=O)CCC4=N5C(=CC6=CC=C(C7=CC=CN7)N6B5([18F])[19F])C=C4)CC3)=C2)C2=C1C=CC=C2 IDNLMZYMJISHAE-ZDDHNKAZSA-N 0.000 description 1
- DZMHWJPAIJRJQN-UHFFFAOYSA-N CC1=CC(C)=N2C1=CC1=CC=C(CCC(=O)N3CCN(C(=O)C4=CC(CC5=NNC(=O)C6=CC=CC=C65)=CC=C4F)CC3)N1B2(F)F.CC1=CC(C)=N2C1=CC1=CC=C(CCC(=O)OC3C(=O)CCC3=O)N1B2(F)F.O=C1NN=C(CC2=CC=C(F)C(C(=O)N3CCNCC3)=C2)C2=CC=CC=C12 Chemical compound CC1=CC(C)=N2C1=CC1=CC=C(CCC(=O)N3CCN(C(=O)C4=CC(CC5=NNC(=O)C6=CC=CC=C65)=CC=C4F)CC3)N1B2(F)F.CC1=CC(C)=N2C1=CC1=CC=C(CCC(=O)OC3C(=O)CCC3=O)N1B2(F)F.O=C1NN=C(CC2=CC=C(F)C(C(=O)N3CCNCC3)=C2)C2=CC=CC=C12 DZMHWJPAIJRJQN-UHFFFAOYSA-N 0.000 description 1
- SWNUPTROAPVTQU-JDDFCBCQSA-N CN.CN.CN.CN.CNC(=O)OC1CC/C=C/CCC1.CNC(=O)OC1CC/C=C/CCC1.CNC(=O)OC1CC/C=C/CCC1.CNC(=O)OC1CC/C=C/CCC1 Chemical compound CN.CN.CN.CN.CNC(=O)OC1CC/C=C/CCC1.CNC(=O)OC1CC/C=C/CCC1.CNC(=O)OC1CC/C=C/CCC1.CNC(=O)OC1CC/C=C/CCC1 SWNUPTROAPVTQU-JDDFCBCQSA-N 0.000 description 1
- WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical compound COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 201000005262 Chondroma Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 208000007033 Dysgerminoma Diseases 0.000 description 1
- 208000000471 Dysplastic Nevus Syndrome Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 208000007659 Fibroadenoma Diseases 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000000527 Germinoma Diseases 0.000 description 1
- 208000007569 Giant Cell Tumors Diseases 0.000 description 1
- 201000005409 Gliomatosis cerebri Diseases 0.000 description 1
- 206010018404 Glucagonoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010019629 Hepatic adenoma Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001077719 Homo sapiens Serine protease inhibitor Kazal-type 5 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 208000005045 Interdigitating dendritic cell sarcoma Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 208000002404 Liver Cell Adenoma Diseases 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 229910052765 Lutetium Inorganic materials 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- LAIQIHBWKPDUBK-UHFFFAOYSA-N NCCCC(=O)CCCC(=O)N1CCN(C(=O)C2=CC(CC3=NNC(=O)C4=CC=CC=C43)=CC=C2F)CC1 Chemical compound NCCCC(=O)CCCC(=O)N1CCN(C(=O)C2=CC(CC3=NNC(=O)C4=CC=CC=C43)=CC=C2F)CC1 LAIQIHBWKPDUBK-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- CAAUJSGNDBNJSI-WHZDWUEFSA-N O=C(CCCNC(=O)C1C[C@@H]2C=C[C@H]1C2)CCCC(=O)N1CCN(C(=O)C2=CC(CC3=NNC(=O)C4=CC=CC=C43)=CC=C2F)CC1 Chemical compound O=C(CCCNC(=O)C1C[C@@H]2C=C[C@H]1C2)CCCC(=O)N1CCN(C(=O)C2=CC(CC3=NNC(=O)C4=CC=CC=C43)=CC=C2F)CC1 CAAUJSGNDBNJSI-WHZDWUEFSA-N 0.000 description 1
- SOXWJXOUDBCAQV-OWOJBTEDSA-N O=C(CCCNC(=O)OC1CC/C=C/CCC1)CCCC(=O)N1CCN(C(=O)C2=CC(CC3=NNC(=O)C4=CC=CC=C43)=CC=C2F)CC1 Chemical compound O=C(CCCNC(=O)OC1CC/C=C/CCC1)CCCC(=O)N1CCN(C(=O)C2=CC(CC3=NNC(=O)C4=CC=CC=C43)=CC=C2F)CC1 SOXWJXOUDBCAQV-OWOJBTEDSA-N 0.000 description 1
- ZJYAGHMCBYXCOC-JRQNRYLUSA-N O=C(COC1=CC=C(/C=C/C2=N3C(=CC4=CC=C(C5=CC=CN5)N4B3([18F])[19F])C=C2)C=C1)NCCCCCC(=O)N1CCN(C(=O)C2=CC(CC3=NNC(=O)C4=CC=CC=C43)=CC=C2F)CC1 Chemical compound O=C(COC1=CC=C(/C=C/C2=N3C(=CC4=CC=C(C5=CC=CN5)N4B3([18F])[19F])C=C2)C=C1)NCCCCCC(=O)N1CCN(C(=O)C2=CC(CC3=NNC(=O)C4=CC=CC=C43)=CC=C2F)CC1 ZJYAGHMCBYXCOC-JRQNRYLUSA-N 0.000 description 1
- AHCWFDJGVNQEQC-UCKWGEQQSA-N O=C1NN=C(CC2=CC=C(F)C(C(=O)N3CCN(C(=O)CF)CC3)=C2)C2=CC=CC=C12.O=C1NN=C(CC2=CC=C(F)C(C(=O)N3CCN(C(=O)CO)CC3)=C2)C2=CC=CC=C12.O=C1NN=C(CC2=CC=C(F)C(C(=O)N3CCN(C(=O)CO[3H]=S)CC3)=C2)C2=CC=CC=C12 Chemical compound O=C1NN=C(CC2=CC=C(F)C(C(=O)N3CCN(C(=O)CF)CC3)=C2)C2=CC=CC=C12.O=C1NN=C(CC2=CC=C(F)C(C(=O)N3CCN(C(=O)CO)CC3)=C2)C2=CC=CC=C12.O=C1NN=C(CC2=CC=C(F)C(C(=O)N3CCN(C(=O)CO[3H]=S)CC3)=C2)C2=CC=CC=C12 AHCWFDJGVNQEQC-UCKWGEQQSA-N 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000000035 Osteochondroma Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 208000027067 Paget disease of bone Diseases 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 238000006742 Retro-Diels-Alder reaction Methods 0.000 description 1
- 208000005678 Rhabdomyoma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 102100025420 Serine protease inhibitor Kazal-type 5 Human genes 0.000 description 1
- 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 208000009311 VIPoma Diseases 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical class C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 206010048214 Xanthoma Diseases 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- BKPCVKMDKAOKSQ-CAGDTYPSSA-N [18F]CCOC1CC/C=C/CCC1 Chemical compound [18F]CCOC1CC/C=C/CCC1 BKPCVKMDKAOKSQ-CAGDTYPSSA-N 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000002718 adenomatoid tumor Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940027998 antiseptic and disinfectant acridine derivative Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000033590 base-excision repair Effects 0.000 description 1
- 208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
- 150000003936 benzamides Chemical class 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 150000008375 benzopyrones Chemical class 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 208000016738 bone Paget disease Diseases 0.000 description 1
- 201000009480 botryoid rhabdomyosarcoma Diseases 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000003149 breast fibroadenoma Diseases 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 201000002143 bronchus adenoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 201000005217 chondroblastoma Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 201000010305 cutaneous fibrous histiocytoma Diseases 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000007711 cytoplasmic localization Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 201000009409 embryonal rhabdomyosarcoma Diseases 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 201000002735 hepatocellular adenoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 102000049595 human PARP1 Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000010820 immunofluorescence microscopy Methods 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 239000000193 iodinated contrast media Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 1
- 229960001025 iohexol Drugs 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 235000013980 iron oxide Nutrition 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000004593 malignant giant cell tumor Diseases 0.000 description 1
- 201000000289 malignant teratoma Diseases 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- VAZWXPJOOFSNLB-UHFFFAOYSA-N methyl 4-(trifluoromethyl)benzoate Chemical compound COC(=O)C1=CC=C(C(F)(F)F)C=C1 VAZWXPJOOFSNLB-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 1
- 208000009091 myxoma Diseases 0.000 description 1
- ZTLGJPIZUOVDMT-UHFFFAOYSA-N n,n-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229940031182 nanoparticles iron oxide Drugs 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 201000011682 nervous system cancer Diseases 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 208000004649 neutrophil actin dysfunction Diseases 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 150000005480 nicotinamides Chemical class 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 150000002832 nitroso derivatives Chemical class 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 208000003388 osteoid osteoma Diseases 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 101150063226 parp-1 gene Proteins 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- JBFWVXIWQBWEKM-UHFFFAOYSA-N pyridazino[4,5-d]pyridazine Chemical class N1=NC=C2C=NN=CC2=C1 JBFWVXIWQBWEKM-UHFFFAOYSA-N 0.000 description 1
- IHYJXEQIZYROGA-UHFFFAOYSA-N pyrido[3,4-d]pyridazine Chemical class N1=NC=C2C=NC=CC2=C1 IHYJXEQIZYROGA-UHFFFAOYSA-N 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011897 real-time detection Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000004548 serous cystadenocarcinoma Diseases 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- QOFZZTBWWJNFCA-UHFFFAOYSA-N texas red-X Chemical compound [O-]S(=O)(=O)C1=CC(S(=O)(=O)NCCCCCC(=O)O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 QOFZZTBWWJNFCA-UHFFFAOYSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 1
- BENFPBJLMUIGGD-UHFFFAOYSA-I trisodium;2-[2-[carboxylatomethyl-[[3-hydroxy-2-methyl-5-(phosphonatooxymethyl)pyridin-4-yl]methyl]amino]ethyl-[[3-hydroxy-5-[[hydroxy(oxido)phosphoryl]oxymethyl]-2-methylpyridin-4-yl]methyl]amino]acetate;manganese(2+) Chemical compound [H+].[H+].[H+].[Na+].[Na+].[Na+].[Mn+2].CC1=NC=C(COP([O-])([O-])=O)C(CN(CCN(CC([O-])=O)CC=2C(=C(C)N=CC=2COP([O-])([O-])=O)[O-])CC([O-])=O)=C1[O-] BENFPBJLMUIGGD-UHFFFAOYSA-I 0.000 description 1
- 208000022271 tubular adenoma Diseases 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 208000009540 villous adenoma Diseases 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
- A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
- A61K51/1251—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules
Definitions
- This document relates to detectable compounds that bind PARP1. Also provided herein are methods for using such compounds to detect and image cells containing PARP1, for example, cancer cells.
- PARP1 Poly(ADP-ribose) polymerase 1
- DNA damage e.g., strand breaks
- levels of PARP1 are significantly increased. This is particularly true in cells lacking other DNA repair enzymes, such as cells lacking function BRCA1 and BRCA2.
- Described herein are detectable compounds that bind PARP1. Also provided herein are methods and materials for using such compounds to image cells containing PARP1, for example, cancer cells. In some cases, such cells overexpress PARP1.
- a compound of Formula (1) can be used to detect or image a cancer cell in a subject through noninvasive imaging of the subject.
- compositions provided herein provide several advantages. For example, one problem in the assessment of therapeutic efficacy of cancer therapies has been the inability to image PARP1 noninvasively at the whole-body level and to quantitate therapeutic inhibition. With the present technology it is possible to separate subjects into appropriate treatment groups and to detect emerging resistance. Given the emerging importance of positron emission tomography (PET) imaging in preclinical and clinical settings, and evidence that fluorescently labeled PARP1 inhibitors can be used for cellular imaging, the compounds provided herein function as detectable probes for whole-body PARP1 imaging. In some embodiments, a compound provided herein is useful for measuring inhibition of PARP1 by emerging therapeutic PARP1 inhibitors.
- PET positron emission tomography
- P is a PARP1 inhibitor
- L is a linker
- T is:
- D is a detectable agent; m is 0 or 1; and n is 0 or 1.
- P is selected from the group consisting of: benzamide, quinolone, dihydroisoquinolinone, isoquinolinone, isoquinolone, benzopyrone, cyclic benzamide, benzimidazole, indole, isoindolinone, nicotinamide, 3-AB, phthalazinone, and quinazolinone.
- P can be selected from the group consisting of: AZD2281 (olaparib), AG014699 (rucaparib), ABT888 (veliparib), BSI201 (iniparib), BSI101, DR2313, FR 247304, GPI15427, GPI16539, MK4827, NU1025, NU1064, NU1085, PD128763, PARP Inhibitor II (INH2BP), PARP Inhibitor III (DPQ), PARP Inhibitor VIII (PJ34), PARP Inhibitor IX (EB-47), and TIQ-A.
- P is AZD2281.
- the compound of Formula (I) is a compound of Formula (II):
- L is a linker
- T is:
- D is a detectable agent; m is 0 or 1; and n is 0 or 1.
- D comprises one or more of organic small molecules, inorganic compounds, nanoparticles, enzymes or enzyme substrates, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, and contrast agents.
- D can comprise a radioactive material, a fluorescent material, or a mixture thereof.
- Non-limiting examples of a compound of Formula (I) include:
- R is Texas Red, a cyanine dye, Alexafluor-680, a BODIPY dye, a xanthene derivatives, a naphthalene dye, a courmarin derivative, an oxadiazole derivative, a pyrene derivative, an oxazine derivative, an acridine derivative, an arylmethine derivative, and a tetrapyrrole derivative.
- the compound of Formula (1) is selected from the group consisting of:
- a compound of Formula (1) is:
- the compound of Formula (1) can be:
- composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt form thereof.
- the method comprises: administering to a subject an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt form thereof, and detecting the detectable agent in the subject.
- the compound of Formula (1) is administered before and after surgical removal of the cancer.
- detecting the detectable agent comprises using one or more of histochemistry, fluorescence detection, chemiluminescence detection, bioluminescence detection, magnetic resonance imaging, nuclear magnetic resonance imaging, positron emission tomography, single-photon emission computed tomography, X-ray imaging, X-ray computed tomography, ultrasound imaging, or photoacoustic imaging.
- the cancer is selected from the group consisting of: pancreatic cancer, ovarian cancer, and breast cancer.
- Also provided herein is a method for imaging a cancer cell, the method comprising: contacting a cancer cell with an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt form thereof, and imaging the cell.
- a method for monitoring the cancer treatment of a patient comprising: (a) administering to the patient, prior to a treatment, an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt form thereof, and imaging the patient; (b) administering to the patient, at a point following treatment, an effective amount the compound of Formula (I) and imaging the patient; and (c) comparing the image collected in step (a) with the image collected in step (b) to monitor the treatment.
- the treatment comprises administration of an anti-cancer agent.
- the method further comprises: administering to the patient an effective amount of the compound of Formula (I) during treatment and imaging the patient.
- a “subject,” as used herein, includes both humans and other animals, particularly mammals. Thus, the methods are applicable to both human therapy and veterinary applications.
- the subject is a mammal, for example, a primate. In some embodiments, the subject is a human.
- an “effective” amount of a compound provided herein is typically one which is sufficient to allow detection of the compound (e.g., detection of a cancer cell) and may vary according to the detection method utilized and the detection limit of the compound.
- a compound provided herein, or salt thereof is substantially isolated.
- substantially isolated is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected.
- Partial separation can include, for example, a composition enriched in the compound provided herein.
- Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compound provided herein, or salt thereof. Methods for isolating compounds and their salts are routine in the art.
- phrases “pharmaceutically acceptable” is used herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- FIG. 1A is an HPLC trace of AZD2281-TCO (7); Texas Red-tetrazine (8; one isolated stereoisomer shown); and AZD2281-Texas Red (9; crude reaction mixture).
- FIG. 1B shows an LC-MS spectrum of AD2281-Texas Red (9; LC-MS of major product peak shown).
- FIG. 2A illustrates the reaction of AZD2281-TCO (7) and Texas Red-Tz (8) in MDA-MB436 cells.
- FIG. 2A shows AZD2281-TCO reacted with Texas Red-Tz; speckles outside the cells, presumably resulting from precipitated Texas Red-Tz (8), were removed;
- FIG. 2B shows anti-PARP1 monoclonal antibody staining;
- FIG. 2C is a composite overlay on phase contrast; and
- FIG. 2D illustrates the ratio of nuclear/cytoplasmic signal for AZD2281-TCO/Texas Red-Tz in the absence (not blocked: circle) and presence (blocked: square) of blocking reagent AZD2281. Scale Bar: 20 mm.
- FIG. 3 shows IC 50 curves for the bifunctional 1(2H)-phthalazinone-based targeted probes.
- FIG. 4 is a line graph representing IC 50 curves for PARP1 inhibitors (9) (circle), (10 19F ) (square), (17 19F ) (inverted triangle) and trans-cyclooctene (6 19F ) (triangle).
- FIG. 5A is a schematic illustrating the synthesis of 18 F-AZD2281 (6); 18 F-labeled TCO 3 and AZD2281-Tz (5) were combined and incubated for 3 minutes; magnetic TCO-scavenger resin was added, incubated for 5 minutes, and removed; purified 18 F-AZD2281 was reconstituted and brought into an injectable volume.
- FIG. 5B illustrates the synthesis of the magnetic TCO-scavenger resin from amine-decorated beads and NETS-activated TCO (1).
- FIG. 5C illustrates the synthesis of 18 F-labeled TCO (3).
- FIG. 5D provides the structure of AZD2281 (4).
- FIG. 5A is a schematic illustrating the synthesis of 18 F-AZD2281 (6); 18 F-labeled TCO 3 and AZD2281-Tz (5) were combined and incubated for 3 minutes; magnetic TCO-scavenger resin was added, incubated for 5 minutes, and
- FIG. 5E shows the synthesis and structure of 18 F-AZD2281 ((6); only one isomer shown).
- FIG. 5F illustrates the radioactivity and absorption traces of the 18 F-AZD2281 reaction mixture before and after purification with the magnetic TCO-scavenger resin.
- FIG. 6 shows the results of competitive in vitro inhibition assays with 18 F-AZD2281.
- Cells containing either a high (MDA-MB-436) or a low amount of PARP1 (MDA-MB-231) were treated with 5 mCi of 18 F-AZD2281 in the presence of different concentrations of AZD2281 (10 ⁇ M-0.01 nM). After the cells were washed, cell-associated activity was determined by measurement of the g-radiation. For the control measurement, no unlabeled AZD2281 was added.
- FIGS. 7A-C illustrate an in vivo evaluation of 18 F-AZD2281.
- FIG. 7A shows combined PET/CT scans of a nontumor-bearing mouse injected with 18 F-AZD2281 recorded 10, 30, and 50 minutes after injection.
- FIG. 7B shows the three-dimensional reconstruction of a tumor-bearing animal injected with 18 F-AZD2281 with and without pre-injection of AZD2281 (bladder segmented out for clarity).
- FIG. 7C illustrates quantification of uptake through the tumor in hind legs with and without intraperitoneal pre-injection of unlabeled AZD2281 (SUV: standardized uptake value).
- FIG. 8A illustrates the ability of FDG and 18 F-AZD2281 to distinguish between muscle and tumor cells.
- FIG. 9A shows that AZD2281-BODIPY FL (green) localizes with the nucleus (as confirmed with the red signal, Chromatin (essentially a DNA stain)).
- FIGS. 9B and 9C show the amount of fluorescence present in cells using AZD2281 and a PARP1/PARP2 antibody.
- FIG. 10 illustrates the life cell imaging of three different AZD2281 fluorophores.
- FIG. 11 shows line graphs illustrating the life cell imaging of three different AZD2281 fluorophores.
- FIG. 12 shows the behavior of AZD281-BODIPY FL in vivo following iv administration of the compound into a mouse.
- FIG. 13A is a bar graph illustrating the uptake of AZD2281-BODIPY FL on a global level
- FIG. 13B shows the uptake of AZD2281-BODIPY FL on a cellular level.
- FIG. 14 illustrates various 18 F-AZD2281-BODIPY compounds for in vivo imaging.
- FIGS. 15A and 15B are schemes illustrating the preparation of 18 F-AZD2281-BODIPY FL compounds.
- Described herein are detectable compounds that bind PARP1. Also provided herein are methods and materials for using such compounds to image cells containing PARP1, for example, cancer cells. In some cases, such cells overexpress PARP1.
- a compound of Formula (1) or (2) can be used to detect or image a cancer cell, e.g., in a living subject, e.g., through noninvasive imaging of the subject.
- P is a PARP1 inhibitor
- L is a linker
- T is:
- D is a detectable agent; m is 0 or 1; and n is 0 or 1.
- a PARP1 inhibitor can include any compound which inhibits or reduces the activation of PARP1.
- PARP1 activation in response to DNA breaks and/or involved in cell death include compounds from various chemical classes including benzamides, quinolones, dihydroisoquinolinones, isoquinolinones, isoquinolones, benzopyrones, cyclic benzamides, benzimidazoles, indoles, isoindolinones, nicotinamides, 3-AB, phthalazinones, quinazolinones, phenanthridinones, and zinc-fingers.
- a PARP1 inhibitor is selected from the group consisting of: AZD2281 (olaparib), AG014699 (rucaparib), ABT888 (veliparib), BSI201 (iniparib), BSI101, DR2313, FR 247304, GPI15427, GPI16539, MK4827, NU1025, NU1064, NU1085, PD128763, PARP Inhibitor II (INH2BP), PARP Inhibitor III (DPQ), PARP Inhibitor VIII (PJ34), PARP Inhibitor IX (EB-47), and TIQ-A.
- a PARP1 inhibitor can be AZD2281.
- a compound of Formula (1) is a compound of Formula (2):
- L is a linker
- T is:
- D is a detectable agent; m is 0 or 1; and n is 0 or 1.
- detectable agents include various organic small molecules, inorganic compounds, nanoparticles, enzymes or enzyme substrates, fluorescent materials, luminescent materials, bioluminescent materials, chemiluminescent materials, magnetic materials, radioactive materials, and contrast agents.
- the detectable agent is a radioactive material or a fluorescent material.
- suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase
- suitable fluorescent materials include boron-dipyrromethene (BODIPY®), 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid (BODIPY® FL), 6-((4,4-difluoro-1,3-dimethyl-5-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene-2-propionyl)amino)hexanoic acid, succinimidyl ester (BODIPY® TRM-X), Oregon Green 88, 6-(((4,4-difluoro-5-(2-pyrrolyl)-4-bora-3a,4a-diaza-s-indacene-3-
- the radioactive material is complexed by a suitable ligand modality.
- a suitable ligand modality is well known in the art.
- a ligand can include DTPA, DTPE, DOTA, NOTA, DO3A, DDPE, and DOTAGA.
- a radioisotope is conjugated to the compound directly or indirectly via a linker (e.g., an alkyl or ether linker).
- contrast agents e.g., contrast agents for MM or NMR, for X-ray CT, Raman imaging, optical coherence tomography, absorption imaging, ultrasound imaging, or thermal imaging can be used.
- contrast agents include gold (e.g., gold nanoparticles), gadolinium (e.g., chelated Gd), iron oxides (e.g., superparamagnetic iron oxide (SPIO), monocrystalline iron oxide nanoparticles (MIONs), and ultrasmall superparamagnetic iron oxide (USPIO)), manganese chelates (e.g., Mn-DPDP), barium sulfate, iodinated contrast media (iohexol), microbubbles, or perfluorocarbons can also be used.
- gold e.g., gold nanoparticles
- gadolinium e.g., chelated Gd
- iron oxides e.g., superparamagnetic iron oxide (SPIO), monocrystalline iron oxide nanoparticles (MIONs), and ultrasmall superparamagnetic iron oxide (USPIO)
- manganese chelates e.g., Mn-DPDP
- barium sulfate iodinated contrast
- the detectable agent is a non-detectable pre-cursor that becomes detectable upon activation.
- examples include fluorogenic tetrazine-fluorophore constructs (e.g., tetrazine-BODIPY FL, tetrazine-Oregon Green 488, or tetrazine-BODIPY TMR-X) or enzyme activatable fluorogenic agents (e.g., PROSENSE (VisEn Medical))
- the enzymatic label is detected by determination of conversion of an appropriate substrate to product.
- the detectable agent is selected from the group consisting of: 18 F, Texas Red, BODIPY FL, BODIPY 578, and BODIPY 650.
- ELISAs enzyme linked immunosorbent assays
- IA enzyme immunoassay
- RIA radioimmunoassay
- Western blot analysis Western blot analysis.
- a detectable agent comprises one or more of the detectable agents described above.
- a fluorescent detectable agent can have one or more atoms replaced with one or more radionuclides.
- a fluorophore comprising one or more fluorine atoms can have one or more of those fluorine atoms radioactively labeled with 18 F.
- Non-limiting examples include 18 F-BODIPY FL, 18 F-BODIPY 578, and 18 F-BODIPY 650. See, for example, FIG. 14 .
- linker refers to a group of atoms, e.g., 0-500 atoms, and can be comprised of the atoms or groups of atoms such as, but not limited to, hydrogen and carbon, e.g., methylene (—CH 2 —), amino, amido, alkylamino, oxygen, polyethylene glycol (PEG), peptoid, sulfur, sulfoxide, sulfonyl, carbonyl, and imine.
- the linker can also comprise part of a saturated, unsaturated or aromatic ring, including polycyclic and heteroaromatic rings wherein the heteroaromatic ring is an aryl group containing from one to four heteroatoms, N, O or S.
- the linker is linked to the PARP1 inhibitor, the T moiety, or a detectable agent through a peptide bond.
- the linker must not interfere with the imaging methods or with the bioorthogonal conjugation reactions described herein.
- linkers provided herein include:
- p is an integer from 1 to 6 (e.g., 1, 2, 3, 4, 5, or 6).
- r is an integer from 1 to 3 (e.g., 1, 2, or 3).
- a linker is selected from the group consisting of:
- Non-limiting examples of a compound of Formula (1) or Formula (2) include:
- R is Texas Red, cyanine dyes (e.g., VivoTag-680, Cy5), Alexafluor-680, BODIPY dyes (e.g., BODIPY-FL), Xanthene derivatives (e.g., Fluorescein), Naphthalene dyes (e.g., dansyl), Courmarin derivatives, oxadiazole derivatives, pyrene derivatives, oxazine derivatives, acridine derivatives, arylmethine derivatives, tetrapyrrole derivatives.
- R is Texas Red.
- a compound of Formula (1) or Formula (2) can include:
- the compound of Formula (1) or Formula (2) is:
- AZD2281-Texas Red can be prepared, in part, as shown in the following scheme:
- preparation of AZD2281- 18 F can be as follows:
- (Z)-2-(Cyclooct-4-enyloxy)acetic acid (2) was prepared in 63% yield over two steps from commercially available 9-oxabicyclo[6.1.0]non-4-ene.
- Carboxylic acid (2) was converted to (E)-2-(cyclooct-4-enyloxy)ethanol (4) first by lithium aluminum hydride (LiAlH 4 ) reduction to give (Z)-2-(cyclooct-4-enyloxy)ethanol (3) in 78% yield, followed by photochemical cis/trans isomerization and isolation of the (E)-isomers by the previously described cycle/trap method (M. Royzen et al., J. Am. Chem. Soc.
- preparation of the compound can include the use of bioorthogonal conjugation reactions such as the inverse electron demand Diels-Alder reaction.
- T can be the reaction product of an inverse electron demand Diels-Alder reaction. This reaction employs a diene and a dienophile.
- a diene e.g., a substituted tetrazine
- a dienophile e.g., an alkene or alkyne
- a retro-Diels-Alder cycloaddition reaction to produce dinitrogen as a byproduct and the desired dihydropyrazine (after reaction with an alkene) or pyrazine (after reaction with an alkyne) products (shown below).
- the dihydropyrazine product may undergo an additional oxidation step to generate the corresponding pyrazine.
- the detectable agent carries a functional group such as an amine, alcohol, carboxylic acid or ester, or other group of atoms that can undergo a chemical reaction allowing attachment to the diene or dienophile.
- the dienophile or heterodienophile (which can be, e.g., an alkene, alkyne, nitroso, carbonyl or imine) possesses a reactive functional group for attachment to the detectable agent.
- the reactive functional group on the detectable agent and/or diene/dienophile undergoes a chemical reaction to form a link between the detectable agent and the diene or dienophile.
- the diene or dienophile can be incorporated into a PARP1 inhibitor and/or a detectable agent. In some embodiments, the diene or dienophile is incorporated through a linker.
- a linker One of skill in the art could readily synthesize such compounds using known synthetic methods or modifying the examples provided herein.
- the diene can be a substituted tetrazine or other heteroaromatic ring system with at least two nitrogens adjacent to each other, and which is a highly reactive participant in the inverse electron demand Diels-Alder reaction.
- the diene can be linked to the amino acid or unnatural amino acid through the use of a linker.
- the diene possesses a reactive group such as an amine, alcohol, carboxylic acid, ester, or activated ester, or other group that can undergo a chemical reaction with the reactive moiety on the PARP1 inhibitor or the detectable agent to form a link between the two.
- Dienes useful in the present disclosure include but are not limited to aromatic ring systems that contain two adjacent nitrogen atoms, for example, tetrazines, pyridazines, substituted or unsubstituted 1,2-diazines.
- Other 1,2-diazines can include 1,2-diazines annelated to a second ⁇ -electron-deficient aromatic ring such as pyrido[3,4-d]pyridazines, pyridazino[4,5-d]pyridazines, and 1,2,4-triazines.
- Pyridazines can also be fused with a five-membered heterocycle such as imidazo[4,5-d]pyridazines and 1,2,3-triazolo[4,5-d]pyridazines.
- the diene is an asymmetrical tetrazine as described herein, e.g., 3-(p-Benzylamino)-1,2,4,5-tetrazine (Structure I).
- Dienophiles useful in the present methods and compositions include but are not limited to carbon containing dienophiles such as alkenes or alkynes, or compounds containing nitroso, carbonyl or imine groups.
- the dienophile is a strained dienophile.
- a “strained” dienophile has a dihedral angle that deviates from the idealized 180 degree dihedral angle.
- non-strained dienophiles e.g., sytrenes
- electron rich electrophiles e.g., eneamines or vinyl ethers
- Alkenes as used herein refer to an alkyl group having one or more double carbon-carbon bonds such as an ethylene, propylene, and the like. Alkenes can also include cyclic, ring-strained alkenes such as trans-cyclooctene or norbornene carrying a double bond which induces significant ring strain and is thus highly reactive. Alkenes can also include more complex structures such as indoles and azaindoles, electron rich enamines. Heterodienophiles containing carbonyl, nitroso or imine groups can also be used. In some embodiments, the dienophile is a trans-cyclooctene or a trans-cyclooctenol, e.g., (E)-cyclooct-4-enol.
- the detectable agent is chemically attached to the dienophile.
- the strained alkene is chemically coupled to a detectable agent, e.g., a trans-cyclooctene modified with a radioactive isotope, e.g., 18 F (see Structure II below).
- AZD2281-BODIPY FL is reacted with trialkylsilyl triflates (e.g. trimethylsilyl triflate) and in some cases followed by dialkylaminopyridines (e.g. dimethylaminopyridine, DMAP).
- 18 F-Fluoride is added and the 18 F-AZD2281-BODIPY FL is being produced through the exchange of triflate or DMAP at the BODIPY boron core with 18 F-fluoride.
- trialkylsilyls triflates are immobilized on a solid support (e.g. magnetic materials, dextrans, polystyrenes, latex, biological macromolecules).
- 4-amino pyridines are immobilized on a solid support (e.g. magnetic materials, dextrans, polystyrenes, latex, biological macromolecules).
- a solid support e.g. magnetic materials, dextrans, polystyrenes, latex, biological macromolecules.
- the reactive solid support is then treated with AZD2281-BODIPY FL.
- Incubation with 18 -fluoride is followed by filtration of the solid support, resulting in high specific activity labeled material (e.g. high specific activity PARP1 imaging agents). See, for example, FIG. 15 .
- the resulting mixtures can be purified by HPLC to remove the excess starting material, which in most cases will compete with the radiolabeled probe for the targeted binding sites. In some embodiments, however, to avoid lengthy HPLC purifications, the resulting materials can be purified using a scavenger resin as provided herein.
- the resins can include those of Formula (3):
- R is a resin bead
- L is a linker
- X is a moiety that reacts with the unreacted starting material.
- the resin bead can be made of many types of materials known to those of skill in the art as long as the bead is large enough to be filtered.
- the resin bead can be magnetic, a modified filter, a modified column material, etc.
- the resin can be made of dextran, silica, glass, or any other non-reactive solid support.
- the resin bead is a magnetic resin bead.
- X is a trans-cyclooctene.
- a non-limiting example of a resin includes:
- a method of purifying a composition comprising an 18 F-labeled compound e.g., a compound of Formula (1).
- the method can include contacting a composition comprising a 18 F-labeled compound and excess of non-labeled starting material with an excess of a resin of Formula (3); and separating out the product of the starting material and the resin of Formula (3).
- the method can result in a composition comprising at least about 75% of an 18 F-labeled compound (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 93%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, and at least about 99%).
- a resin of Formula (3) can be prepared, for example, by reaction of commercially available magnetic amine-decorated beads in a solution of DMF/PBS with a 75 mm solution of NHS-activated trans-cyclooctene (see FIG. 5 ).
- the reactions for preparing the compounds provided herein can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis.
- suitable solvents can be substantially non-reactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, e.g., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature.
- a given reaction can be carried out in one solvent or a mixture of more than one solvent.
- suitable solvents for a particular reaction step can be selected by the skilled artisan.
- Preparation of compounds provided herein can involve the protection and deprotection of various chemical groups.
- the need for protection and deprotection, and the selection of appropriate protecting groups, can be readily determined by one skilled in the art.
- the chemistry of protecting groups can be found, for example, in Protecting Group Chemistry, 1 st Ed., Oxford University Press, 2000 ; March's Advanced Organic chemistry: Reactions, Mechanisms, and Structure, 5 th Ed., Wiley-Interscience Publication, 2001; and Peturssion, S. et al.,“Protecting Groups in Carbohydrate Chemistry,” J. Chem. Educ., 74(11), 1297 (1997) (each of which is incorporated herein by reference in their entirety.
- Reactions can be monitored according to any suitable method known in the art.
- product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., 1 H or 13 C), infrared spectroscopy, spectrophotometry (e.g., UV-visible, fluorescence), mass spectrometry, or by chromatographic methods such as high performance liquid chromatography (HPLC), liquid chromatography-mass spectroscopy (LCMS), thin layer chromatography (TLC), or radio-thin layer chromatograph (rTLC).
- spectroscopic means such as nuclear magnetic resonance spectroscopy (e.g., 1 H or 13 C), infrared spectroscopy, spectrophotometry (e.g., UV-visible, fluorescence), mass spectrometry, or by chromatographic methods such as high performance liquid chromatography (HPLC), liquid chromatography-mass spectroscopy (LCMS), thin layer chromatography (TLC), or radio-thin layer
- compositions which include compounds identified by a method provided herein as active ingredients. Also included are the pharmaceutical compositions themselves.
- compositions typically include a pharmaceutically acceptable carrier.
- pharmaceutically acceptable carrier includes saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
- a pharmaceutical composition is typically formulated to be compatible with its intended route of administration.
- routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration.
- solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol, or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates, or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
- the parenteral preparation can be enclosed in ampoules, disposable syringes, or multiple dose vials made of glass or plastic.
- compositions suitable for injection can include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
- suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS).
- the composition must be sterile and should be fluid to the extent that easy syringability exists.
- the composition should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyetheylene glycol, and the like), and suitable mixtures thereof.
- the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
- isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, and sodium chloride in the composition.
- Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the active compound into a sterile vehicle, which contains a basic dispersion medium and the required other ingredients from those enumerated above.
- the preferred methods of preparation are vacuum drying and freeze-drying, which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- the pharmaceutical composition may be administered at once, or may be divided into a number of smaller doses to be administered at intervals of time. It is understood that the precise dosage and duration of administration may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test data. It is to be noted that concentrations and dosage values may also vary with the size of the area to be imaged. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed compositions.
- compositions containing a compound as described herein in the range of 0.005% to 100% with the balance made up from non-toxic carrier may be prepared. Methods for preparation of these compositions are known to those skilled in the art.
- the contemplated compositions may contain 0.001%-100% active ingredient, in one embodiment 0.1-95%, in another embodiment 75-85%.
- compositions can be included in a container, pack, or dispenser together with instructions for administration.
- the compounds described herein can be imaged using methods known in the art. For example, imaging can be achieved in living animals, organs, or tissues, using e.g. near infrared (NIR), MR imaging (MRI), positron emission tomography (PET), single photon computerized tomography (SPECT), or other whole body imaging modalities.
- NIR near infrared
- MRI MR imaging
- PET positron emission tomography
- SPECT single photon computerized tomography
- the detectable agent of the compound can be imaged by these whole body imaging modalities to detect cancer cells (e.g., cancer cells overexpressing PARP1).
- a compound having a fluorescent detectable agent can be detected by traditional fluorescence imaging techniques allowing for the facile tracking of the compounds by fluorescence microscopy or flow cytometry using methods known in the art, e.g., as described in US 2005/0249668, the content of which is incorporated by reference in its entirety.
- a compound having a radioactive agent can be imaged using positron emission tomography (PET).
- Detection methods can include both imaging ex vivo and in vivo imaging methods, e.g., immunohistochemistry, bioluminescence imaging (BLI), Magnetic Resonance Imaging (MM), positron emission tomography (PET), Single-photon emission computed tomography (SPECT), electron microscopy, X-ray computed tomography, Raman imaging, optical coherence tomography, absorption imaging, thermal imaging, fluorescence reflectance imaging, fluorescence microscopy, fluorescence molecular tomographic imaging, nuclear magnetic resonance imaging, X-ray imaging, ultrasound imaging, photoacoustic imaging, lab assays, or in any situation where tagging/staining/imaging is required.
- one or more imaging techniques can be used in the methods provided herein. For example, fluorescence, PET and/or SPECT imaging can be used.
- the compounds and compositions described herein can be used in in vivo imaging methods to detect, quantify and evaluate PARP1 (e.g., PARP1 in a cancer).
- such methods include administering to a subject one or more compounds of Formula (1) or Formula (2) described herein; optionally allowing the compound to distribute within the subject; and imaging the subject, e.g., by fluoroscopy, radiography, computed tomography (CT), MM, PET, SPECT, laparoscopy, endomicroscopy, or other whole body imaging modality to detect the presence of PARP1.
- CT computed tomography
- MM computed tomography
- PET SPECT
- laparoscopy laparoscopy
- endomicroscopy or other whole body imaging modality
- the methods can be repeated at intervals to evaluate the subject and detect any changes in PARP1 concentration over time.
- Information provided by such in vivo imaging for example, the presence, absence, or level of emitted signal, can be used to detect and/or monitor the
- a compound described here can be used: 1) for the early detection cancers (e.g., cancers that overexpress PARP1 such as pancreatic cancer); 2) as an aid to surgeons during surgery (e.g., by allowing for real-time detection of cancer cells); and 3) as a method for monitoring the progress of a cancer treatment (e.g., by quantifying the amount of PARP1 present before, during, and after treatment).
- early detection cancers e.g., cancers that overexpress PARP1 such as pancreatic cancer
- an aid to surgeons during surgery e.g., by allowing for real-time detection of cancer cells
- 3) as a method for monitoring the progress of a cancer treatment e.g., by quantifying the amount of PARP1 present before, during, and after treatment.
- the methods provided herein include methods for detecting a cancer, i.e., a cancer that overexpresses PARP1.
- the methods include administering an effective amount of a compound (i.e., active ingredient) as provided herein (i.e., a compound of Formula (1)) to a subject who is in need of, or who has been determined to be in need of, such detection and detecting the compound.
- a compound i.e., active ingredient
- a compound of Formula (1) i.e., a compound of Formula (1)
- methods for imaging a cancer cell include contacting a cell with an effective amount of a compound as provided herein and imaging the cell. Such methods may be conducted in vitro or in vivo.
- the compounds according to Formula (1) can be used to detect any cancer that overexpresses PARP1, are believed effective to detect and image a broad range of cancers types, including but not limited to breast cancer, ovarian cancer, and prostate cancer.
- the cancer is an epithelial cancer.
- the methods and compositions described herein can be used to help a physician or surgeon to identify and characterize cancers.
- the methods and compositions described herein can also be used in the detection, characterization, and/or determination of the localization of the cancer, especially early in the disease, the severity of a cancer, the staging of a cancer, and/or monitoring a cancer.
- the presence, absence, or level of an emitted signal can be indicative of the state of the cancer.
- Cancers that may be detected and/or imaged by the compounds, compositions and methods described herein include, but are not limited to, the following:
- Cancers may be solid tumors that may or may not be metastatic. Cancers may also occur, as in leukemia, as a diffuse tissue. Thus, the term “cancer cell”, as provided herein, includes a cell afflicted by any one of the above identified disorders.
- the compounds according to Formula (1) can also be administered to a subject in combination with surgical methods to treat cancers, e.g., resection of tumors.
- the compounds can be administered to the individual prior to, during, or after the surgery.
- the compounds can be administered parenterally, intravenous or injected into the tumor or surrounding area after tumor removal, e.g., to image or detect residual cancer cells.
- the compound may be used to detect the presence of a tumor and to guide surgical resection.
- the compound can be used to detect the presence of residual cancer cells and to guide continued surgical treatment until at least a portion (e.g., all) such cells are removed from the subject.
- a method of guided surgery to remove at least a portion of a tumor from a subject comprising providing a compound of Formula (1); causing the compound to be present in at least some cancer cells in an effective amount to inhibit PARP1 and for detection of the compound to be observable; observing the image (e.g., fluorescence, PET or SPECT scan); and performing surgery on the subject to remove at least a portion of the tumor that comprises detected cancer cells.
- a compound of Formula (1) comprising providing a compound of Formula (1); causing the compound to be present in at least some cancer cells in an effective amount to inhibit PARP1 and for detection of the compound to be observable; observing the image (e.g., fluorescence, PET or SPECT scan); and performing surgery on the subject to remove at least a portion of the tumor that comprises detected cancer cells.
- a compound of Formula (1) or Formula (2) is imaged in vivo using PET or SPECT imaging.
- PET or SPECT can be used to diagnose cancer by imaging the accumulation of a compound provided herein in cancer cells expressing PARP1.
- the use of PET and/or SPECT as an imaging modality can be useful during surgery to locate cancer cells (e.g., residual cancer cells following excision of a tumor mass).
- a compound of Formula (1) or Formula (2) is imaged in vivo using laparoscopy and endomiscroscopy.
- laparoscopy permits the facile, real-time imaging and localization of cancers labeled with a compound having a fluorescent detectable agent.
- laparoscopy can be used to diagnose cancer by imaging the accumulation of a compound provided herein in cancer cells expressing PARP1.
- the use of laparoscopy as an imaging modality can be useful during surgery to locate cancer cells (e.g., residual cancer cells following excision of a tumor mass).
- a compound can be imaged using fiber optic endomicroscopy.
- in vivo imaging can be used to assess the effect of an anti-cancer therapy on cells expressing PARP1, by using the compounds described herein, wherein the subject is imaged prior to, during, and/or after treatment with the therapy, and the corresponding signal/images are compared.
- a subject with a cancer can be imaged prior to and after treatment with chemotherapy or radiation therapy to determine the response of the PARP1-expressing cancer cells to treatment.
- a compound of Formula (1) accumulates in PARP1 expressing cells (e.g., PARP1 overexpressing cancer cells). This accumulation, however, can be quantifiably inhibited by administration of an unlabeled PARP1 inhibitor, e.g., the parent PARP1 inhibitor present in the compound of Formula (1) or any other PARP inhibitor. Accordingly, further provided herein is a method for measuring PARP1 inhibition by any PARP1 inhibitor or compound that has an effect on PARP expression or activity level.
- the method includes contacting a cell (e.g., administering to a subject) an effective amount of a compound of Formula (1) and a therapeutic PARP1 inhibitor (i.e., non-labeled), and imaging the cell (e.g., the subject) to determine the amount of the compound of Formula (1) present.
- a cell e.g., administering to a subject
- a therapeutic PARP1 inhibitor i.e., non-labeled
- An exemplary in vitro imaging method comprises: contacting a sample, for example, a biological sample (e.g., a cell such as a cancer cell), with one or more compounds of Formula (1) or Formula (2); allowing the conjugate(s) to interact with a biological target in the sample; optionally, removing unbound agents; illuminating the sample with light of a wavelength absorbable by a fluorophore of the agents; and detecting a signal emitted from fluorophore thereby to determine whether the agent has been activated by or bound to the biological target.
- a biological sample e.g., a cell such as a cancer cell
- a compound After a compound has been designed, synthesized, and optionally formulated, it can be tested in vitro by one skilled in the art to assess its biological and performance characteristics. For instance, different types of cells grown in culture can be used to assess the biological and performance characteristics of the compound. Cellular uptake, binding or cellular localization of the agent can be assessed using techniques known in the art, including, for example, fluorescent microscopy, fluorescence-activated cell sorting (FACS) analysis, immunohistochemistry, immunoprecipitation, in situ hybridization and Forster resonance energy transfer (FRET) or fluorescence resonance energy transfer.
- FACS fluorescence-activated cell sorting
- FRET Forster resonance energy transfer
- the compound can be contacted with a sample for a period of time and then washed to remove any free compound.
- the sample can then be viewed using an appropriate detection device such as a fluorescent microscope equipped with appropriate filters matched to the optical properties of a fluorescent agent. Fluorescence microscopy of cells in culture or scintillation counting is also a convenient means for determining whether uptake and binding has occurred. Tissues, tissue sections and other types of samples such as cytospin samples can also be used in a similar manner to assess the biological and performance characteristics of the compounds.
- Other detection methods including, but not limited to flow cytometry, immunoassays, hybridization assays, and microarray analysis can also be used.
- the compounds can be used in an in vitro assay for detecting agents that inhibit PARP1.
- Texas Red-Tz (8) was synthesized similar to methods described earlier. (See N. K. Devaraj et al., Angew. Chem., Int. Ed. 2010, 49, 2869-2872; N. K. Devaraj et al., Angew. Chem., Int. Ed. 2009, 48, 7013-7016, S7013/1-S7013/6; and N. K. Devaraj et al., Bioconj. Chem. 2008, 19, 2297-2299.
- Cyclohexylcarbodiimide polystyrene resin (634 mg, 2.3 mmol/g) was added to a solution of 4-[[4-Fluoro-3-(4-(5-oxopentanamide)piperazine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one (3) (350 mg, 0.73 mmol) in dichloromethane (20 mL) and the resulting mixture stirred gently for 7 hours at room temperature. Subsequently, ethylenediamine (976 ⁇ L, 14.6 mmol) was added and the reaction mixture stirred for another 60 minutes, before the reaction mixture was filtered and volatiles removed in vacuo. The crude material was purified via HPLC, yielding the title compound as a clear solid (62 mg, 0.12 mmol, 16%).
- Cyclohexylcarbodiimide polystyrene resin (33 mg, 2.3 mmol/g) and triethylamine (16 ⁇ L, 0.11 mmol) were added to a solution of 4-[[4-Fluoro-3-(4-(N-(2-aminoethyl)-5-oxo-pentanamide)piperazine-1-carbonyl)phenyl] methyl]-2H-phthalazin-1-one (4) (20 mg, 38 ⁇ mol) and 5-norbornene-2-carboxylic acid (11 mg, 77 ⁇ mol) in dichloromethane (1 mL) and the resulting mixture stirred gently over night at room temperature. Subsequently, the reaction mixture was filtered and volatiles removed in vacuo. The crude material was purified via HPLC, yielding the title compound as a clear solid (5.9 mg, 9 24%).
- Triethylamine (16 ⁇ L, 0.11 mmol) was added to a solution of 4-[[4-Fluoro-3-(4-(N-(2-aminoethyl)-5-oxo-pentanamide)piperazine-1-carbonyl)phenyl] methyl]-2Hphthalazin-1-one (4) (20 mg, 38 ⁇ mol) and (E)-cyclooct-4-enyl-2,5-dioxopyrrolidin-1-yl carbonate (5) (12 mg, 46 ⁇ mol) in dichloromethane (1 mL) and the resulting mixture stirred gently over night at room temperature. Subsequently, the reaction mixture was filtered and volatiles removed in vacuo. The crude material was purified via HPLC, yielding the title compound as a clear solid (11.3 mg, 17 44%).
- FIG. 1A shows the HPLC trace for the AZD2281-Texas Red (9) crude reaction mixture.
- LC-MS spectra confirmed the quantitative conversion of Texas Red-Tz (8). Multiple peaks were identified with a molecular mass corresponding to AZD2281-Texas Red (9; FIG. 1 B, m/z 1536.0 [M+H]+).
- a commercially available colorimetric assay (Trevigen, Gaithersburg, Md.) was used to measure PARP activity in vitro in the presence of inhibitors.
- Ten-fold dilutions of AZD2281-derivatives (6) (final concentration 400 nM to 0.04 nM); and (7), (9) (4 ⁇ M to 0.04 nM) were incubated with 0.5 units PARP HSA for 10 minutes in histone-coated 96-well plates. All experiments were carried out in triplicate. Control samples did not contain inhibitor and background measurement samples did not contain PARP-1.
- MDA-MB-231 and MDA-MB-436 cells were obtained from the ATCC and cultured in RPMI 1640 supplemented with 10% fetal bovine serum, L-glutamine, and penicillin/streptomycin.
- MDA-MB-231 and MDA-MD-436 cells stably expressing PARP-GFP were derived by transfection with Lipofectamine 2000 (Invitrogen) and isolation of individual G418-resistant clones. Cells were maintained in growth medium containing 1 mg/mL G418. Expression of PARP-GFP in MDA-MB-436 cells was verified using immunofluorescence microscopy to show nuclear localization of PARP-GFP, and western blotting for PARP-GFP.
- MDA-MB-436 cells 500 ⁇ L, 80.000 cells/mL were seeded into glycerine-treated 8-well chamber slides (Lab TekTM, Thermo Scientific, Rochester, N.Y.), and allowed to attach overnight. Cells were then incubated with Texas Red-Tz (8) (25 ⁇ L, 20 ⁇ M) for 20 minutes (37° C.) before the medium was removed and cells were washed (1 ⁇ , medium, 500 ⁇ L).
- MDA-MB-436 cells 500 ⁇ L, 80.000 cells/mL were seeded into glycerine-treated 8-well chamber slides (Lab TekTM, Thermo Scientific, Rochester, N.Y.), and allowed to attach overnight. Cells were then incubated with Texas Red-Tz (8) (25 ⁇ L, 20 ⁇ M) for 20 minutes (37° C.) before the medium was removed and cells were washed (1 ⁇ , medium, 500 ⁇ L).
- the fluorescence signal for the total cell and the signal in the nuclear area was calculated using the corresponding mask as a spatial filter. The two signals were then normalized for their total areas. The ratio of the fluorescent signal in the cytosol region over the signal in the nuclear region was then calculated. Background subtraction was performed on the normalized signal using the cell's negative masks. For all cells we chose an optimal ratio between 0.35 and 0.48 for the cytosol area over the nucleus area.
- MDA-MB-436 cells 500 ⁇ L, 80.000 cells/mL were seeded into glycerine-treated 8-well chamber slides (Lab TekTM, Thermo Scientific, Rochester, N.Y.), and allowed to attach overnight. They were incubated with Texas Red-Tz (8) (25 ⁇ L, 20 ⁇ M) for 20 minutes (37° C.) before the medium was removed and cells were washed (1 ⁇ , medium, 500 ⁇ L). Subsequently, 500 ⁇ L medium and AZD2281-TCO (7) (25 ⁇ L, in PBS, 3% DMSO, 30 ⁇ M) were added and incubated at 37° C. for 20 min.
- Cells were permeabilized using Triton-X-100 (2% in PBS, 10 min) and incubated with anti-PARP-1 Mab (EMD biosciences, Gibbstown, N.J.) for 3 hours, before stained with secondary IgG-GFP Pab (EMD biosciences, Gibbstown, N.J.). PBS was removed and cells mounted using Prolong Gold (Invitrogen, Carlsbad, Calif.) before imaging.
- FIG. 2A Staining patterns for the Texas Red dye ( FIG. 2A ) showed that it not only localized in the nucleus, but also accumulated in the nucleolus. Whilst anti-PARP1 Mabs showed similar nuclear localization ( FIG. 2B ), there was an absence of Mab signal in the nucleoli. This was presumably due to steric hindrance and not to the absence of PARP in the nucleolus, as earlier reports have indicated (V. S. Meder et al., J. Cell Sci. 2005, 118, 211-222; and J.-F. Haince et al., J. Biol. Chem. 2008, 283, 1197-1208). The results in FIG. 2C confirm that there was excellent spatial correlation between the small molecules (AZD2281-TCO (7)/Texas Red-Tz (8)).
- a PARP1-GFP fusion protein was also constructed and expressed in MDA-MB436 cells as an independent confirmation of probe localization.
- PARP-GFP was constructed by PCR of human PARP-1 from Open Biosystems clone 5193735 from the NIH_MGC_114 cDNA library, and cloning into pAcGFP-N1 between XhoI and XmaI restriction sites. The PARP-GFP construct was verified by DNA sequencing.
- LC-ESI-MS analysis and HPLC-purifications were performed on a Waters (Milford, Mass.) LC-MS system.
- a Waters XTerra® C18 5 ⁇ m column was used.
- Preparative high performance liquid chromatography (HPLC) runs for synthetic intermediates utilized an Atlantis® Prep T3 OBDTM 5 ⁇ M column (eluents 0.1% TFA (v/v) in water and MeCN; gradient: 0-1.5 min, 5-100% B; 1.5-2.0 min 100% B).
- Analytical HPLC of radiolabeled compounds was performed employing a Grace VYDAC (218TP510) C18 reversed-phase column (eluents 0.1% TFA (v/v) in water and MeCN; gradient: 0-17 min, 5-60% B; 17-21 min, 60-95% B; 21-24 min, 95% B; 24-25 min, 95-5% B; 25-30 min, 5% B; 2 mL ⁇ min ⁇ 1 ) with a dual-wavelength UV-vis detector and a flow-through gamma detector connected in series.
- HyperSep C18 cartridges were purchased from Thermo Electron (Bellefonte, Pa.) and Sep-pak VAC Alumina-N cartridges from Waters (Milford, Mass.).
- Cyclohexylcarbodiimide polystyrene resin (127 mg, 2.3 mmol/g) was added to a solution of 4-[[4-Fluoro-3-(4-(5-oxopentanamide) piperazine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one 7 (70 mg, 0.15 mmol) in dichloromethane (10 mL) and the resulting mixture was stirred gently for 7 hours at room temperature.
- Triethylamine (29 ⁇ L, 0.21 mmol) was added to a solution of p-toluenesulfonyl chloride (20 mg, 0.10 mmol) and 4-[[4-Fluoro-3-((6-hydroxyhexanoyl)piperazine-1-carbonyl) phenyl]methyl]-2H-phthalazin-1-one (12) (25 mg, 0.052 mmol) in dichloromethane (5 mL), the reaction mixture was stirred at room temperature overnight and purified via HPLC, yielding the title compound as a clear solid (7.8 mg, 0.01 mmol. 24%).
- Triethylamine (53 ⁇ L, 0.38 mmol) was added to a solution of p-toluenesulfonyl chloride (36 mg, 0.19 mmol) and 4-[[4-Fluoro-3-((2-hydroxyacetic acid)piperazine-1-carbonyl)phenyl] methyl]-2H-phthalazin-1-one (15) (40 mg, 0.094 mmol) in dichloromethane (5 mL), the reaction mixture was stirred at room temperature overnight and purified via HPLC, yielding the title compound as a clear solid (34 mg, 0.06 mmol. 32%).
- the synthesizer reagent vials were filled as follows: A2 with MeCN (350 ⁇ L), A3 with tosylate (5) (4.0 mg, 12.3 ⁇ mol) in DMSO (400 ⁇ L), A5 with DMSO (50 ⁇ L), and B2 with H 2 O (800 ⁇ L).
- the [ 18 F]-F-/TBAB solution was transferred to Reaction Vessel #1 and dried by azeotropic distillation of the acetonitrile/water solution by heating to 60° C. under reduced pressure and a flow of argon to achieve ⁇ 310 mbar for 2 minutes followed by 98° C. and 270 mbar for 4 minutes.
- Reaction Vessel #1 was cooled to 50° C., tosylate (5) in DMSO (400 ⁇ L) added, the reaction vessel pressurized to 2000 mbar, and heated to 90° C. for 10 minutes. Cooled to 30° C., the mixture was filtered through an Alumina-N cartridge (100 mg, 1 mL, Waters) into Reaction Vessel #2. The Alumina-N cartridge was washed with DMSO (50 ⁇ L) and the combined filtrates were diluted with water (800 ⁇ L). This solution was subjected to preparative HPLC purification.
- a commercially available colorimetric assay (Trevigen, Gaithersburg, Md.) was used to measure PARP activity in vitro in the presence of inhibitors.
- Tenfold dilutions of compounds (6 19F ), (10 19F ), (17 19F ) (final concentration 4 ⁇ M to 0.04 nM) and (9) (1 ⁇ M to 0.1 nM) were incubated with 0.5 units PARP HSA for 10 minutes in histone-coated 96-well plates. All experiments were carried out in triplicate. Control samples did not contain inhibitor and background measurement samples did not contain PARP1. All reaction mixtures were adjusted to a final volume of 50 ⁇ L and a maximum final concentration 0.4% DMSO in assay buffer. The remainder of the assay was performed according to the manufacturer's instructions.
- PARP activity was measured by absorbance at 450 nm in each well using a Safire2 microplate reader. IC 50 values were calculated using the Prism software package.
- 18 F-Fluoride (n.c.a.) in 18 O-enriched water was purchased from PETNET (Woburn, Mass.). Automated synthesis of 18 F-labeled trans-cyclooctene was carried out using a Synthra RN Plus automated synthesizer (Synthra GmbH, Hamburg, Germany) operated by SynthraView software. For non-radioactive compounds, LC-ESI-MS analysis and HPLC-purifications were performed on a Waters (Milford, Mass.) LC-MS system. For LC-ESI-MS analyses, a Waters XTerra® C18 5 ⁇ m column was used.
- Trans-Cyclooctene 1 was added (40 ⁇ L, 75 mM in DMF) and the mixture stirred gently for 2.5 h.
- the target well was charged with [ 18 F]-F-, n.c.a., ( ⁇ 1110 MBq, 30 ⁇ 10 mCi) in H 2 18 O (150 ⁇ L), 250 ⁇ L of a 75 mM tetrabutylammonium bicarbonate (TBAB) solution in water, and 200 ⁇ L of MeCN.
- the synthesizer reagent vials were filled as follows: A2 with MeCN (350 ⁇ L), A3 with tosylate 2 (4.0 mg, 12.3 ⁇ mol) in DMSO (400 ⁇ L), A5 with DMSO (50 ⁇ L), and B2 with H 2 O (800 ⁇ L).
- Reaction Vessel #1 was dried by azeotropic distillation of the acetonitrile/water solution by heating to 60° C. under reduced pressure and a flow of argon to achieve ⁇ 310 mbar for 2 minutes followed by 98° C. and 270 mbar for 4 minutes.
- Reaction Vessel #1 was cooled to 50° C., tosylate (2) in DMSO (400 ⁇ L) added, the reaction vessel pressurized to 2000 mbar, and heated to 90° C. for 10 minutes. Cooled to 30° C., the mixture was filtered through an Alumina-N cartridge (100 mg, 1 mL, Waters) into Reaction Vessel #2.
- 18 F-AZD2281 (6) was synthesized similar to methods described earlier (E. J. Keliher et al., ChemMedChem 2010, DOI: 10.1002/cmdc.201000426).
- AZD2281-Tz (5) (7 ⁇ L of an 18.5 mM DMSO solution (0.13 ⁇ mol)) was added to a solution of (3 18F) (2.3 mCi) and stirred at room temperature for 3 minutes. This results in quantitative conversion of 18 F-TCO (3), yielding a mixture of 18 F-AZD2281 (6) and excess AZD2281-Tz (5; FIG. 5E ).
- the solution was treated with 4 mole equivalents of TCO-beads (0.52 ⁇ mol TCO), vortexed and allowed to stand for 5 minutes.
- Treatment of this solution for 5 minutes with the TCO-decorated scavenger resin (4 mol equiv of TCO) removed unreacted AZD2281-Tz with minimal loss (approximately 4%) of radiolabeled compound (6).
- Magnetic removal of the beads provided (6) in (92.1 0.4)% dcRCY, which was then reconstituted in a medium suitable for animal injection ( FIG. 5A ).
- the amount of Oregon Green-Tz “pulled out” of the solution by trans-cyclooctene was measured by determining the solution's absorption at 504 nm and the loading (specific-non-specific adsorption) calculated to be 13 ⁇ mol/g.
- MDA-MB-231 and MDA-MB-436 cells were obtained from ATCC (Manassas, Va.) and cultured in RPMI 1640 supplemented with 10% fetal bovine serum, L-glutamine, and penicillin/streptomycin (each Invitrogen, Carlsbad, Calif.) at 37° C. and 5% CO 2 .
- the IC 50 value of 18 F-AZD2281 against PARP1 was determined to be (17.9 1.1) nm in biochemical assays using the isolated enzyme (AZD2281 itself has an IC 50 value of 5 nM). This demonstrates PARP1 to be an ideal target for the rapid screening of 18 F-labeled inhibitors, as it can accommodate relatively large prosthetic groups that do not affect binding affinity.
- MDA-MB-231 and MDA-MB-436 cells (50,000 cells/well) were seeded into 96-well plates and allowed to attach over night at 37° C. and 5% CO 2 .
- Ten-fold dilutions of AZD2281 4 (final concentration: 10 ⁇ M to 0.01 nM) were added to the wells and incubated for 10 minutes, before 5 ⁇ Ci of 18F-AZD2281 6 (5 ⁇ L, 0.2 ⁇ C/ ⁇ L) were added and the cells incubated for 20 minutes. Then, the medium was replaced and waited for another 10 minutes, before the cells were washed with PBS (3 ⁇ 100 ⁇ L) and subjected to gamma-counting.
- 18 F-AZD2281 was determined by quantification of the remaining activity after incubation and washing of the adherent cells. 18 F-AZD2281 was shown to be cell-permeable and its uptake inhibitable upon addition of excess nonradioactive AZD2281 ( FIG. 6 ). Uptake of 18 F-AZD2281 was lower for MDA-MB-231 cells than for MDA-MB-436 cells, which correlates with protein expression of PARP1 in the respective cell lines.
- Non-tumor bearing Nu/Nu mice were injected with (6 18F ) and used for organ distribution immediately after injection over a time period of 2 hours.
- Tumor-bearing mice received s.c. injections with 5 ⁇ 106 MDA-MB-436 cells (American Type Culture Collection) in Matrigel (BD Biosciences) into each flank and underwent imaging 7 days later (injection of (6 18F ) and immediate imaging over a time period of 2 hours). All mice were anesthetized (isoflurane 1.5%; O 2 2 L/min) during imaging with a gas delivery system integrated into a multimodal imaging cartridge. All animal experiments were approved by Massachusetts General Hospital's Institutional Review Committee.
- PET was reconstructed from 600 million coincidental 511 keV photon counts on a series of LSO (lutetium oxyorthosilicate) scintillating crystals. Counts were rebinned in 3D by registering photons spanning no more than 3 consecutive rings and reconstructed into sinograms using a high resolution Fourier Rebin algorithm. Sinograms also yielded a 3D mapping of positron signal using a 2D filtered back-projection algorithm and a Ramp filter with a Nyquist cut-off of 0.5.
- LSO lutetium oxyorthosilicate
- Datasets were anisotropic matrices containing 128 ⁇ 128 ⁇ 159 pixels, measuring 0.796 mm/pixel in the z direction and 0.861 mm/pixel in the x and y directions. Calibration of PET signal preceded all scans by scanning an 8.0 cm in diameter cylindrical phantom containing a known amount of 18 F isotope. Data are expressed as standard uptake values (SUV), which normalizes activity measurements to body weight and injected activity.
- SUV standard uptake values
- CT computed tomographic
- iodine contrast was infused into the tail vein at a rate of 35 ⁇ L/min to enhance intravascular contrast.
- Projections were acquired at end expiration of the respiratory cycle using a BioVet gating system (M2M Imaging, Cleveland, Ohio) and total CT acquisition time was ⁇ 10 minutes.
- PET-CT fusion and image analysis were performed using Inveon Research Workplace 3.0 (Siemens). Three-dimensional visualizations were produced with the DICOM viewer OsiriX (The OsiriX foundation, Geneva, Switzerland).
- FIG. 7A displays the distribution of the PET probe in the Nu/nu mice at 10, 30, and 50 minutes.
- the images clearly show initial localization of the probe to be mainly in liver, gall bladder, and intestines, consistent with hepatobiliary excretion.
- FIG. 7B shows a three-dimensional reconstruction of a tumor-bearing mouse injected with 30 mCi of 18 F-AZD2281. Uptake in the tumors is clearly visible.
- the mice were injected with 1 mg AZD2281 BID.
- FIG. 8A shows that FDG, the current gold standard in cancer imaging, is not able (based on tumor/muscle signal intensity) to distinguish between treated untreated tumors.
- RAW 264.7, Panc-1, MIA Paca2, A2780, OVCAR429, UCI 101, UCI 107, SKOV-3, OVCAR-3, and OV-90 cells (200 ⁇ L, 35,000 cells/mL) were each seeded in their respective growth medium on 96-well plates and allowed to attach for 48 hours. They were incubated with AZD2281-BODIPY FL (2 ⁇ L, 100 ⁇ L) for 20 minutes (37° C.) before the medium was removed and cells were washed (1 ⁇ , medium, 200 ⁇ L).
- FIG. 9A shows that AZD2281-BODIPY FL (green—inner halo) localizes with the nucleus (as confirmed with the red signal (inner most signal), Chromatin (essentially a DNA stain)). This is where PARP1, the target, is located. It does not go into the perinuclear region (the rest of the cell), as shown by the blue stain, which basically colors the cell walls. The composite combines all colors.
- FIG. 9B plots the amount of fluorescence present in cells using AZD2281 and a PARP1/PARP2 antibody. The more PARP1/PARP2 there is in a cell line, the more AZD2281-BODIPY FL is taken up by the cell.
- FIG. 9A shows that AZD2281-BODIPY FL (green—inner halo) localizes with the nucleus (as confirmed with the red signal (inner most signal), Chromatin (essentially a DNA stain)). This is where PARP1, the
- FIG. 9C shows the same data as FIG. 9B , but plots the data differently.
- This figure shows that the R2 (a measure for correlation) is very high, indicating that AZD2281-BODIPY FL not only targets PARP1, but targets it quantitatively, allowing for an accurate measurement of the amount of PARP1 in a given cell line (or, in a clinical setting, tumor environment).
- HT1080 cells were labeled with a 1 ⁇ M concentration of AZD2281 fluorophore conjugate in cell culture medium and imaged on an inverted Deltavision epifluorescence microscope using a 37° C. heated stage and 5% CO 2 atmosphere for various times. After subtracting the background fluorescence, the data were fitted to an exponential association curve. For clearance, cells were labeled at 1 ⁇ M for 1 hour until the cells had reached equilibrium. Cells were washed twice in cell culture media and imaged continuously (BODIPYFL conjugate) or after various time points (BODIPY578 and BODIPY650). The loss in fluorescence was fitted to a biexponential decay curve.
- FIGS. 10 and 11 three different AZD2281 fluorophores were tested using life cell imaging.
- the cells are not fixed, but in their most natural state (as close as possible to using intravital imaging).
- the compounds were added to the medium surrounding the cells, the compounds entered the cells, and when the medium (which contained AZD2281-fluorophores) was replaced, the AZD2281-fluorophores were washed out of the perinuclear region (where PARP1 is not located). However, the compounds were retained in the nuclear region (where PARP1 is located), showing that all the compounds tested work in an in vitro setting.
- Table 2 details the properties of the compounds tested, obtained by serial imaging techniques.
- mice with window chambers were implanted with 1 million HT-1080 cells expressing H2B-apple fluorescence protein.
- 75 nmol of AZD2281-BODIPYFL were dissolved in 75 ⁇ L of 1:1::DMAC:solutol and 75 ⁇ L of PBS and injected via tail vein. Images of the vessels were taken using a 20 ⁇ water immersion objective on a laser scanning confocal microscope while the mouse was anesthetized with isoflurane. After 1 hour, the non-specific uptake of the probe cleared revealing nuclear uptake of the probe.
- FIG. 12 shows the behavior of AZD281-BODIPYFL in vivo.
- the compound was injected into a mouse by iv (10 seconds). The compound is first observed in the vascular system (where it was injected) and then concentrates in each and every tumor cell of the tumor (red dots). This data shows the ability of the compound to bind to PARP1 in vivo.
- FIG. 13 shows that the uptake of AZD2281-BODIPY FL is not just specific on a cellular level, but also globally. Tumors have higher PARP1 levels than other tissue, and this is shown by the fact that very little of the compound gets taken up by muscle cells compared to the tumor tissues. This data corresponds well to the in vitro data described above.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Medicinal Chemistry (AREA)
- Nanotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
This document relates to compounds useful for targeting PARP1. Also provided herein are methods for using such compounds to detect and image cancer cells.
Description
- This application is a continuation of U.S. patent application Ser. No. 16/147,370, filed Sep. 28, 2018, which is a continuation of U.S. patent application Ser. No. 15/581,386, filed on Apr. 28, 2017, now U.S. Pat. No. 10,117,954, which is a continuation of U.S. patent application Ser. No. 13/988,790, filed with a 371 filing date of Aug. 2, 2013, now U.S. Pat. No. 9,649,394, which is a U.S. National Phase Application under 35 U.S.C. § 371 of International Patent Application No. PCT/US2011/061856, filed on Nov. 22, 2011, which claims priority under 35 U.S.C. § 119(e) to U.S. Patent Application Ser. Nos. 61/419,929, filed on Dec. 6, 2010, and 61/416,035, filed on Nov. 22, 2010, all of which are incorporated herein by reference in their entireties.
- The present invention was made with government support under Grant Nos. P50 CA86 355 and NIBI-RO1 EB-010 011 awarded by the National Cancer Institute; and Grant No. NIGMS T32 GM008313 awarded by the National Institutes of Health. The Government has certain rights in the invention.
- This document relates to detectable compounds that bind PARP1. Also provided herein are methods for using such compounds to detect and image cells containing PARP1, for example, cancer cells.
- Poly(ADP-ribose) polymerase 1 (PARP1) is an important cellular protein that senses DNA damage and initiates the base excision repair pathway. DNA damage (e.g., strand breaks) occurs during each cell cycle and must be repaired for a cell to survive. In cells undergoing rapid division and proliferation, such as cancer cells, levels of PARP1 are significantly increased. This is particularly true in cells lacking other DNA repair enzymes, such as cells lacking function BRCA1 and BRCA2.
- Described herein are detectable compounds that bind PARP1. Also provided herein are methods and materials for using such compounds to image cells containing PARP1, for example, cancer cells. In some cases, such cells overexpress PARP1. For example, a compound of Formula (1) can be used to detect or image a cancer cell in a subject through noninvasive imaging of the subject.
- The methods and compositions provided herein provide several advantages. For example, one problem in the assessment of therapeutic efficacy of cancer therapies has been the inability to image PARP1 noninvasively at the whole-body level and to quantitate therapeutic inhibition. With the present technology it is possible to separate subjects into appropriate treatment groups and to detect emerging resistance. Given the emerging importance of positron emission tomography (PET) imaging in preclinical and clinical settings, and evidence that fluorescently labeled PARP1 inhibitors can be used for cellular imaging, the compounds provided herein function as detectable probes for whole-body PARP1 imaging. In some embodiments, a compound provided herein is useful for measuring inhibition of PARP1 by emerging therapeutic PARP1 inhibitors.
- In addition to the advantage described above, one way to identify useful imaging agents is to empirically test a series of different agents in vivo. This approach, however, places considerable demands on the labeling of each compound. To overcome these lengthy sequential optimization procedures for each individual compound, provided herein is one such approach based on the combination of [4+2] inverse electron demand Diels-Alder cycloadditions; its utility is shown by the development of the novel PARP1 imaging agents described herein.
- This disclosure provides a compound of Formula (I):
-
P-Ln-Tm-D - or a pharmaceutically acceptable salt form thereof,
wherein:
P is a PARP1 inhibitor;
L is a linker; -
- D is a detectable agent;
m is 0 or 1; and
n is 0 or 1. - In some embodiments, P is selected from the group consisting of: benzamide, quinolone, dihydroisoquinolinone, isoquinolinone, isoquinolone, benzopyrone, cyclic benzamide, benzimidazole, indole, isoindolinone, nicotinamide, 3-AB, phthalazinone, and quinazolinone. For example, P can be selected from the group consisting of: AZD2281 (olaparib), AG014699 (rucaparib), ABT888 (veliparib), BSI201 (iniparib), BSI101, DR2313, FR 247304, GPI15427, GPI16539, MK4827, NU1025, NU1064, NU1085, PD128763, PARP Inhibitor II (INH2BP), PARP Inhibitor III (DPQ), PARP Inhibitor VIII (PJ34), PARP Inhibitor IX (EB-47), and TIQ-A. In some embodiments, P is AZD2281.
- In some embodiments, the compound of Formula (I) is a compound of Formula (II):
- or a pharmaceutically acceptable salt form thereof,
wherein:
L is a linker; -
- D is a detectable agent;
m is 0 or 1; and
n is 0 or 1. - In some embodiments, D comprises one or more of organic small molecules, inorganic compounds, nanoparticles, enzymes or enzyme substrates, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, and contrast agents. For example, D can comprise a radioactive material, a fluorescent material, or a mixture thereof.
- Non-limiting examples of a compound of Formula (I) include:
- wherein R is Texas Red, a cyanine dye, Alexafluor-680, a BODIPY dye, a xanthene derivatives, a naphthalene dye, a courmarin derivative, an oxadiazole derivative, a pyrene derivative, an oxazine derivative, an acridine derivative, an arylmethine derivative, and a tetrapyrrole derivative.
- In some embodiments, the compound of Formula (1) is selected from the group consisting of:
- In some embodiments, a compound of Formula (1) is:
- For example, the compound of Formula (1) can be:
- Also provided herein is a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt form thereof.
- The compounds provided herein are useful for detecting a cancer in a subject. In some embodiments, the method comprises: administering to a subject an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt form thereof, and detecting the detectable agent in the subject. In some embodiments, the compound of Formula (1) is administered before and after surgical removal of the cancer.
- In some embodiments, detecting the detectable agent comprises using one or more of histochemistry, fluorescence detection, chemiluminescence detection, bioluminescence detection, magnetic resonance imaging, nuclear magnetic resonance imaging, positron emission tomography, single-photon emission computed tomography, X-ray imaging, X-ray computed tomography, ultrasound imaging, or photoacoustic imaging.
- In some embodiments, the cancer is selected from the group consisting of: pancreatic cancer, ovarian cancer, and breast cancer.
- Also provided herein is a method for imaging a cancer cell, the method comprising: contacting a cancer cell with an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt form thereof, and imaging the cell.
- Further provided herein is a method for monitoring the cancer treatment of a patient, the method comprising: (a) administering to the patient, prior to a treatment, an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt form thereof, and imaging the patient; (b) administering to the patient, at a point following treatment, an effective amount the compound of Formula (I) and imaging the patient; and (c) comparing the image collected in step (a) with the image collected in step (b) to monitor the treatment. In some embodiments, the treatment comprises administration of an anti-cancer agent. In some embodiments, the method further comprises: administering to the patient an effective amount of the compound of Formula (I) during treatment and imaging the patient.
- For the terms “for example” and “such as,” and grammatical equivalences thereof, the phrase “and without limitation” is understood to follow unless explicitly stated otherwise. As used herein, the term “about” is meant to account for variations due to experimental error. All measurements reported herein are understood to be modified by the term “about”, whether or not the term is explicitly used, unless explicitly stated otherwise. As used herein, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise.
- A “subject,” as used herein, includes both humans and other animals, particularly mammals. Thus, the methods are applicable to both human therapy and veterinary applications. In some embodiments, the subject is a mammal, for example, a primate. In some embodiments, the subject is a human.
- An “effective” amount of a compound provided herein is typically one which is sufficient to allow detection of the compound (e.g., detection of a cancer cell) and may vary according to the detection method utilized and the detection limit of the compound.
- The term, “compound,” as used herein is meant to include all stereoisomers, geometric isomers, constitutional isomers, and tautomers of the structures depicted. Compounds herein identified by name or structure as one particular tautomeric form are intended to include other tautomeric forms unless otherwise specified.
- In some embodiments, a compound provided herein, or salt thereof, is substantially isolated. By “substantially isolated” is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected. Partial separation can include, for example, a composition enriched in the compound provided herein. Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compound provided herein, or salt thereof. Methods for isolating compounds and their salts are routine in the art.
- The phrase “pharmaceutically acceptable” is used herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Methods and materials are described herein for use in the present invention; other, suitable methods and materials known in the art can also be used. The materials, methods, and examples are illustrative only and not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.
- Other features and advantages of the invention will be apparent from the following detailed description and figures, and from the claims.
-
FIG. 1A is an HPLC trace of AZD2281-TCO (7); Texas Red-tetrazine (8; one isolated stereoisomer shown); and AZD2281-Texas Red (9; crude reaction mixture).FIG. 1B shows an LC-MS spectrum of AD2281-Texas Red (9; LC-MS of major product peak shown). -
FIG. 2A illustrates the reaction of AZD2281-TCO (7) and Texas Red-Tz (8) in MDA-MB436 cells.FIG. 2A shows AZD2281-TCO reacted with Texas Red-Tz; speckles outside the cells, presumably resulting from precipitated Texas Red-Tz (8), were removed;FIG. 2B shows anti-PARP1 monoclonal antibody staining;FIG. 2C is a composite overlay on phase contrast; andFIG. 2D illustrates the ratio of nuclear/cytoplasmic signal for AZD2281-TCO/Texas Red-Tz in the absence (not blocked: circle) and presence (blocked: square) of blocking reagent AZD2281. Scale Bar: 20 mm. -
FIG. 3 shows IC50 curves for the bifunctional 1(2H)-phthalazinone-based targeted probes. -
FIG. 4 is a line graph representing IC50 curves for PARP1 inhibitors (9) (circle), (1019F) (square), (1719F) (inverted triangle) and trans-cyclooctene (619F) (triangle). -
FIG. 5A is a schematic illustrating the synthesis of 18F-AZD2281 (6); 18F-labeledTCO 3 and AZD2281-Tz (5) were combined and incubated for 3 minutes; magnetic TCO-scavenger resin was added, incubated for 5 minutes, and removed; purified 18F-AZD2281 was reconstituted and brought into an injectable volume.FIG. 5B illustrates the synthesis of the magnetic TCO-scavenger resin from amine-decorated beads and NETS-activated TCO (1).FIG. 5C illustrates the synthesis of 18F-labeled TCO (3).FIG. 5D provides the structure of AZD2281 (4).FIG. 5E shows the synthesis and structure of 18F-AZD2281 ((6); only one isomer shown).FIG. 5F illustrates the radioactivity and absorption traces of the 18F-AZD2281 reaction mixture before and after purification with the magnetic TCO-scavenger resin. -
FIG. 6 shows the results of competitive in vitro inhibition assays with 18F-AZD2281. Cells containing either a high (MDA-MB-436) or a low amount of PARP1 (MDA-MB-231) were treated with 5 mCi of 18F-AZD2281 in the presence of different concentrations of AZD2281 (10 μM-0.01 nM). After the cells were washed, cell-associated activity was determined by measurement of the g-radiation. For the control measurement, no unlabeled AZD2281 was added. -
FIGS. 7A-C illustrate an in vivo evaluation of 18F-AZD2281.FIG. 7A shows combined PET/CT scans of a nontumor-bearing mouse injected with 18F-AZD2281 recorded 10, 30, and 50 minutes after injection.FIG. 7B shows the three-dimensional reconstruction of a tumor-bearing animal injected with 18F-AZD2281 with and without pre-injection of AZD2281 (bladder segmented out for clarity).FIG. 7C illustrates quantification of uptake through the tumor in hind legs with and without intraperitoneal pre-injection of unlabeled AZD2281 (SUV: standardized uptake value). -
FIG. 8A illustrates the ability of FDG and 18F-AZD2281 to distinguish between muscle and tumor cells.FIG. 8B shows the relative uptake of 18F-AZD2281 activity of different ovarian and pancreatic tumors (A2780 and SKOV3=ovarian, PANC1 and PACA2=pancreatic). -
FIG. 9A shows that AZD2281-BODIPY FL (green) localizes with the nucleus (as confirmed with the red signal, Chromatin (essentially a DNA stain)).FIGS. 9B and 9C show the amount of fluorescence present in cells using AZD2281 and a PARP1/PARP2 antibody. -
FIG. 10 illustrates the life cell imaging of three different AZD2281 fluorophores. -
FIG. 11 shows line graphs illustrating the life cell imaging of three different AZD2281 fluorophores. -
FIG. 12 shows the behavior of AZD281-BODIPY FL in vivo following iv administration of the compound into a mouse. -
FIG. 13A is a bar graph illustrating the uptake of AZD2281-BODIPY FL on a global level;FIG. 13B shows the uptake of AZD2281-BODIPY FL on a cellular level. -
FIG. 14 illustrates various 18F-AZD2281-BODIPY compounds for in vivo imaging. -
FIGS. 15A and 15B are schemes illustrating the preparation of 18F-AZD2281-BODIPY FL compounds. - Described herein are detectable compounds that bind PARP1. Also provided herein are methods and materials for using such compounds to image cells containing PARP1, for example, cancer cells. In some cases, such cells overexpress PARP1. For example, a compound of Formula (1) or (2) can be used to detect or image a cancer cell, e.g., in a living subject, e.g., through noninvasive imaging of the subject.
- Provided herein are compounds of Formula (1):
-
P-Ln-Tm-D - or a pharmaceutically acceptable salt form thereof,
wherein:
P is a PARP1 inhibitor;
L is a linker; -
- D is a detectable agent;
m is 0 or 1; and
n is 0 or 1. - A PARP1 inhibitor can include any compound which inhibits or reduces the activation of PARP1. For example, PARP1 activation in response to DNA breaks and/or involved in cell death. PARP1 inhibitors include compounds from various chemical classes including benzamides, quinolones, dihydroisoquinolinones, isoquinolinones, isoquinolones, benzopyrones, cyclic benzamides, benzimidazoles, indoles, isoindolinones, nicotinamides, 3-AB, phthalazinones, quinazolinones, phenanthridinones, and zinc-fingers. In some embodiments, a PARP1 inhibitor is selected from the group consisting of: AZD2281 (olaparib), AG014699 (rucaparib), ABT888 (veliparib), BSI201 (iniparib), BSI101, DR2313, FR 247304, GPI15427, GPI16539, MK4827, NU1025, NU1064, NU1085, PD128763, PARP Inhibitor II (INH2BP), PARP Inhibitor III (DPQ), PARP Inhibitor VIII (PJ34), PARP Inhibitor IX (EB-47), and TIQ-A. For example, a PARP1 inhibitor can be AZD2281.
- In some embodiments, a compound of Formula (1) is a compound of Formula (2):
- or a pharmaceutically acceptable salt form thereof,
wherein:
L is a linker; -
- D is a detectable agent;
m is 0 or 1; and
n is 0 or 1. - Examples of detectable agents include various organic small molecules, inorganic compounds, nanoparticles, enzymes or enzyme substrates, fluorescent materials, luminescent materials, bioluminescent materials, chemiluminescent materials, magnetic materials, radioactive materials, and contrast agents. In some embodiments, the detectable agent is a radioactive material or a fluorescent material. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable fluorescent materials include boron-dipyrromethene (BODIPY®), 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid (BODIPY® FL), 6-((4,4-difluoro-1,3-dimethyl-5-(4-methoxyphenyl)-4-bora-3a,4a-diaza-s-indacene-2-propionyl)amino)hexanoic acid, succinimidyl ester (BODIPY® TRM-X), Oregon Green 88, 6-(((4,4-difluoro-5-(2-pyrrolyl)-4-bora-3a,4a-diaza-s-indacene-3-yl)styryloxy)acetyl)aminohexanoic acid, succinimidyl ester (BODIPY® 650/665-X), 7-N,N-diethylaminocoumarin, sulforhodamine 101 acid chloride (Texas Red), VIVOTAG 680 (an amine-reactive near-infra-red fluorochrome, from VisEn Medical), umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include 11C, 13N, 15O, 18F, 67Ga, 81mKr, 82Rb, 86Y, 89Zr, 111In, 123I, 124I, 133Xe, 201Tl, 125I, 35S, 14C, or 3H, 64Cu, 99mTc (e.g., as pertechnetate (technetate(VII), TcO4 −) either directly or indirectly, 123I, or other radioisotope detectable by direct counting of radioemmission or by scintillation counting. In some embodiments, the radioactive material is complexed by a suitable ligand modality. Such ligands are well known in the art. For example, a ligand can include DTPA, DTPE, DOTA, NOTA, DO3A, DDPE, and DOTAGA. In some embodiments, a radioisotope is conjugated to the compound directly or indirectly via a linker (e.g., an alkyl or ether linker). In addition, contrast agents, e.g., contrast agents for MM or NMR, for X-ray CT, Raman imaging, optical coherence tomography, absorption imaging, ultrasound imaging, or thermal imaging can be used. Exemplary contrast agents include gold (e.g., gold nanoparticles), gadolinium (e.g., chelated Gd), iron oxides (e.g., superparamagnetic iron oxide (SPIO), monocrystalline iron oxide nanoparticles (MIONs), and ultrasmall superparamagnetic iron oxide (USPIO)), manganese chelates (e.g., Mn-DPDP), barium sulfate, iodinated contrast media (iohexol), microbubbles, or perfluorocarbons can also be used.
- In some embodiments, the detectable agent is a non-detectable pre-cursor that becomes detectable upon activation. Examples include fluorogenic tetrazine-fluorophore constructs (e.g., tetrazine-BODIPY FL, tetrazine-Oregon Green 488, or tetrazine-BODIPY TMR-X) or enzyme activatable fluorogenic agents (e.g., PROSENSE (VisEn Medical))
- When the compounds are enzymatically labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, the enzymatic label is detected by determination of conversion of an appropriate substrate to product.
- In some embodiments, the detectable agent is selected from the group consisting of: 18F, Texas Red, BODIPY FL,
BODIPY 578, andBODIPY 650. - In vitro assays in which these compositions can be used include enzyme linked immunosorbent assays (ELISAs), immunoprecipitations, immunofluorescence, enzyme immunoassay (EIA), radioimmunoassay (RIA), and Western blot analysis.
- In some embodiments, a detectable agent comprises one or more of the detectable agents described above. For example, a fluorescent detectable agent can have one or more atoms replaced with one or more radionuclides. In some embodiments, a fluorophore comprising one or more fluorine atoms can have one or more of those fluorine atoms radioactively labeled with 18F. Non-limiting examples include 18F-BODIPY FL, 18F-
BODIPY 578, and 18F-BODIPY 650. See, for example,FIG. 14 . - The term “linker” as used herein refers to a group of atoms, e.g., 0-500 atoms, and can be comprised of the atoms or groups of atoms such as, but not limited to, hydrogen and carbon, e.g., methylene (—CH2—), amino, amido, alkylamino, oxygen, polyethylene glycol (PEG), peptoid, sulfur, sulfoxide, sulfonyl, carbonyl, and imine. The linker can also comprise part of a saturated, unsaturated or aromatic ring, including polycyclic and heteroaromatic rings wherein the heteroaromatic ring is an aryl group containing from one to four heteroatoms, N, O or S. Specific examples include, but are not limited to, saturated alkanes, alkyl ethers, alkyl diamines, and alkyl chains having one or more peptide bonds. In some embodiments, the linker is linked to the PARP1 inhibitor, the T moiety, or a detectable agent through a peptide bond. The linker must not interfere with the imaging methods or with the bioorthogonal conjugation reactions described herein.
- Non-limiting examples of linkers provided herein include:
- wherein each p is independently an integer from 1 to 20 (e.g., 1 to 15, 1 to 12, 1 to 10, 1 to 8, 1 to 5, 2 to 20, 4 to 20, 5 to 20, 8 to 20, 12 to 20, 15 to 20, 2 to 8, and 1 to 6); and
- r is an integer from 1 to 20 (e.g., 1 to 15, 1 to 12, 1 to 10, 1 to 8, 1 to 5, 2 to 20, 4 to 20, 5 to 20, 8 to 20, 12 to 20, 15 to 20, 2 to 8, and 1 to 6).
- In some embodiments, p is an integer from 1 to 6 (e.g., 1, 2, 3, 4, 5, or 6). In some embodiments, r is an integer from 1 to 3 (e.g., 1, 2, or 3). In some embodiments, a linker is selected from the group consisting of:
- Non-limiting examples of a compound of Formula (1) or Formula (2) include:
- wherein R is Texas Red, cyanine dyes (e.g., VivoTag-680, Cy5), Alexafluor-680, BODIPY dyes (e.g., BODIPY-FL), Xanthene derivatives (e.g., Fluorescein), Naphthalene dyes (e.g., Dansyl), Courmarin derivatives, oxadiazole derivatives, pyrene derivatives, oxazine derivatives, acridine derivatives, arylmethine derivatives, tetrapyrrole derivatives. In some embodiments, R is Texas Red.
- For example, a compound of Formula (1) or Formula (2) can include:
- In some embodiments, the compound of Formula (1) or Formula (2) is:
- Compounds provided herein, including salts thereof, can be prepared using known organic synthesis techniques and can be synthesized according to any of numerous possible synthetic routes.
- For example, AZD2281-Texas Red can be prepared, in part, as shown in the following scheme:
- Briefly, for the synthesis of the bioorthogonally reactive derivatives AZD2281-NOB (6) and AZD2281-TCO (7), compound (2) was first reacted with glutaric acid anhydride to produce the glutaric acid-modified 4-(5-oxopentanamide)piperizine (3). Subsequently, an ethylene diamine spacer was attached to precursor (3), yielding the amine-functionalized AZD2281 derivative (4). Norbornene-functionalized AZD2281-NOB (6) was obtained by amide-bond formation with 5-norbornene-2-carboxylic acid in the presence of polymer supported dicyclohexylcarbodiimide (DCC) beads. In the case of AZD2281-trans-cyclooctene (AZD2281-TCO; 7), precursor (3) was reacted with (E)-cyclooct-4-
enyl 2,5-dioxopyrrolidin-1-yl carbonate (5) in the presence of triethylamine. Cycloaddition of both AZD2281-TCO (7) and Texas Red-Tz (8) was detected by mixing the two compounds (0.3 mm), agitating for several minutes, and analyzing the products by HPLC-MS. - As another example, preparation of AZD2281-18F can be as follows:
- Briefly, (Z)-2-(Cyclooct-4-enyloxy)acetic acid (2) was prepared in 63% yield over two steps from commercially available 9-oxabicyclo[6.1.0]non-4-ene. Carboxylic acid (2) was converted to (E)-2-(cyclooct-4-enyloxy)ethanol (4) first by lithium aluminum hydride (LiAlH4) reduction to give (Z)-2-(cyclooct-4-enyloxy)ethanol (3) in 78% yield, followed by photochemical cis/trans isomerization and isolation of the (E)-isomers by the previously described cycle/trap method (M. Royzen et al., J. Am. Chem. Soc. 2008, 130, 3760-3761). The major (E)-cyclooctyl stereoisomer was isolated by column chromatography and converted to the corresponding tosylate (5) in 84% yield. (E)-5-(2-Fluoroethoxy)cyclooct-1-ene (618F) was prepared in 91% yield by the treatment of (5) with tetrabutylammonium fluoride (TBAF) in THF. All previously unknown compounds were fully characterized by 1H, 13C, and 18F NMR. As a precursor for the chemoselective reactive PARP1 inhibitor AZD2281-Tz (9), 4-[[4-fluoro-3-(4-(5-oxopentanamide) piperazine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one (7) was generated as described herein (See Example 1). This precursor was reacted with (8) in the presence of polymer-supported N,N′-dicyclohexylcarbodiimide (DCC) beads to yield (9) as a pink solid. Cycloadduct (1018F) was prepared by the addition of dimethyl sulfoxide (DMSO) solutions of (9) and (618F) at room temperature and subsequent high pressure liquid chromatography (HPLC) purification.
- In some embodiments, wherein a compound of Formula (1) comprises a T moiety, preparation of the compound can include the use of bioorthogonal conjugation reactions such as the inverse electron demand Diels-Alder reaction. For example, in a compound of Formula (1) or Formula (2), T can be the reaction product of an inverse electron demand Diels-Alder reaction. This reaction employs a diene and a dienophile. The reaction of a diene (e.g., a substituted tetrazine) with a dienophile (e.g., an alkene or alkyne), produces an unstable cycloadduct that subsequently undergoes a retro-Diels-Alder cycloaddition reaction to produce dinitrogen as a byproduct and the desired dihydropyrazine (after reaction with an alkene) or pyrazine (after reaction with an alkyne) products (shown below). See e.g., Sauer et al., Chem Ber 998: 1435-1445, 1965, which is incorporated by reference in its entirety. The dihydropyrazine product may undergo an additional oxidation step to generate the corresponding pyrazine.
- A variety of tetrazines and dienophiles including cyclic and linear alkenes or alkynes have been studied in this reaction. Selection of the appropriate reaction partners allows for tuning of the coupling rate by several orders of magnitude. (Balcar J et al., 1983, Tet Lett 24:1481-1484; Thalhammer F et al., 1990, Tet Lett 47:6851-6854). See also US 2006/0269942, WO 2007/144200, US 2008/0181847 and US 2011/0268654. Bioconjugation methods using inverse electron demand Diels-Alder cycloadditions between tetrazines and highly strained dienophiles such as norbornene and trans-cyclooctene are known in the literature, however the tetrazine used has limited stability to aqueous media. (Blackman et al., 2008, J Am Chem Soc, 130, 13518-9; Devaraj et al., 2009, Angew Chem Int Ed Engl, 48, 7013-6; Devaraj et al., 2008, Bioconjug Chem, 19, 2297-9; Pipkorn et al., 2009, J Pept Sci, 15, 235-41).
- In some embodiments, the detectable agent carries a functional group such as an amine, alcohol, carboxylic acid or ester, or other group of atoms that can undergo a chemical reaction allowing attachment to the diene or dienophile. Alternatively or in addition, the dienophile or heterodienophile (which can be, e.g., an alkene, alkyne, nitroso, carbonyl or imine) possesses a reactive functional group for attachment to the detectable agent. Thus, the reactive functional group on the detectable agent and/or diene/dienophile undergoes a chemical reaction to form a link between the detectable agent and the diene or dienophile.
- In some embodiments, the diene or dienophile can be incorporated into a PARP1 inhibitor and/or a detectable agent. In some embodiments, the diene or dienophile is incorporated through a linker. One of skill in the art could readily synthesize such compounds using known synthetic methods or modifying the examples provided herein.
- In some embodiments, the diene can be a substituted tetrazine or other heteroaromatic ring system with at least two nitrogens adjacent to each other, and which is a highly reactive participant in the inverse electron demand Diels-Alder reaction. The diene can be linked to the amino acid or unnatural amino acid through the use of a linker. In this embodiment, the diene possesses a reactive group such as an amine, alcohol, carboxylic acid, ester, or activated ester, or other group that can undergo a chemical reaction with the reactive moiety on the PARP1 inhibitor or the detectable agent to form a link between the two. Dienes useful in the present disclosure include but are not limited to aromatic ring systems that contain two adjacent nitrogen atoms, for example, tetrazines, pyridazines, substituted or unsubstituted 1,2-diazines. Other 1,2-diazines can include 1,2-diazines annelated to a second π-electron-deficient aromatic ring such as pyrido[3,4-d]pyridazines, pyridazino[4,5-d]pyridazines, and 1,2,4-triazines. Pyridazines can also be fused with a five-membered heterocycle such as imidazo[4,5-d]pyridazines and 1,2,3-triazolo[4,5-d]pyridazines. In some embodiments, the diene is an asymmetrical tetrazine as described herein, e.g., 3-(p-Benzylamino)-1,2,4,5-tetrazine (Structure I).
- Dienophiles useful in the present methods and compositions include but are not limited to carbon containing dienophiles such as alkenes or alkynes, or compounds containing nitroso, carbonyl or imine groups. In some embodiments, the dienophile is a strained dienophile. As used herein, a “strained” dienophile has a dihedral angle that deviates from the idealized 180 degree dihedral angle. Alternatively, non-strained dienophiles (e.g., sytrenes) and/or electron rich electrophiles (e.g., eneamines or vinyl ethers), can also be used with nitroso compounds. Alkenes as used herein refer to an alkyl group having one or more double carbon-carbon bonds such as an ethylene, propylene, and the like. Alkenes can also include cyclic, ring-strained alkenes such as trans-cyclooctene or norbornene carrying a double bond which induces significant ring strain and is thus highly reactive. Alkenes can also include more complex structures such as indoles and azaindoles, electron rich enamines. Heterodienophiles containing carbonyl, nitroso or imine groups can also be used. In some embodiments, the dienophile is a trans-cyclooctene or a trans-cyclooctenol, e.g., (E)-cyclooct-4-enol.
- In some embodiments, the detectable agent is chemically attached to the dienophile. For example, the strained alkene is chemically coupled to a detectable agent, e.g., a trans-cyclooctene modified with a radioactive isotope, e.g., 18F (see Structure II below).
- Applicable to all other NHS esters, peptide bond formation is also possible using other standard coupling techniques (e.g. EDCI, DCI, HOBT/TBTU, and others).
- In some embodiments, AZD2281-BODIPY FL is reacted with trialkylsilyl triflates (e.g. trimethylsilyl triflate) and in some cases followed by dialkylaminopyridines (e.g. dimethylaminopyridine, DMAP). 18F-Fluoride is added and the 18F-AZD2281-BODIPY FL is being produced through the exchange of triflate or DMAP at the BODIPY boron core with 18F-fluoride. In some embodiments, trialkylsilyls triflates are immobilized on a solid support (e.g. magnetic materials, dextrans, polystyrenes, latex, biological macromolecules). In some embodiments, 4-amino pyridines are immobilized on a solid support (e.g. magnetic materials, dextrans, polystyrenes, latex, biological macromolecules). The reactive solid support is then treated with AZD2281-BODIPY FL. Incubation with 18-fluoride is followed by filtration of the solid support, resulting in high specific activity labeled material (e.g. high specific activity PARP1 imaging agents). See, for example,
FIG. 15 . - One problem during the synthesis of 18F-radiolabeled compounds is that in most cases large amounts of precursors are used to efficiently react with small quantities of 18F. The resulting mixtures can be purified by HPLC to remove the excess starting material, which in most cases will compete with the radiolabeled probe for the targeted binding sites. In some embodiments, however, to avoid lengthy HPLC purifications, the resulting materials can be purified using a scavenger resin as provided herein. The resins can include those of Formula (3):
-
R—NH-L-X - wherein:
R is a resin bead;
L is a linker; and
X is a moiety that reacts with the unreacted starting material. - The resin bead can be made of many types of materials known to those of skill in the art as long as the bead is large enough to be filtered. In some embodiments, the resin bead can be magnetic, a modified filter, a modified column material, etc. For example, the resin can be made of dextran, silica, glass, or any other non-reactive solid support. In some embodiments, the resin bead is a magnetic resin bead.
- In some embodiments, X is a trans-cyclooctene. For example, a non-limiting example of a resin includes:
- Accordingly, provided herein is a method of purifying a composition comprising an 18F-labeled compound (e.g., a compound of Formula (1). The method can include contacting a composition comprising a 18F-labeled compound and excess of non-labeled starting material with an excess of a resin of Formula (3); and separating out the product of the starting material and the resin of Formula (3). In some embodiments, the method can result in a composition comprising at least about 75% of an 18F-labeled compound (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 93%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, and at least about 99%). A resin of Formula (3) can be prepared, for example, by reaction of commercially available magnetic amine-decorated beads in a solution of DMF/PBS with a 75 mm solution of NHS-activated trans-cyclooctene (see
FIG. 5 ). - The reactions for preparing the compounds provided herein can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially non-reactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, e.g., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected by the skilled artisan.
- Preparation of compounds provided herein can involve the protection and deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups, can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in Protecting Group Chemistry, 1st Ed., Oxford University Press, 2000; March's Advanced Organic chemistry: Reactions, Mechanisms, and Structure, 5th Ed., Wiley-Interscience Publication, 2001; and Peturssion, S. et al.,“Protecting Groups in Carbohydrate Chemistry,” J. Chem. Educ., 74(11), 1297 (1997) (each of which is incorporated herein by reference in their entirety.
- Reactions can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., 1H or 13C), infrared spectroscopy, spectrophotometry (e.g., UV-visible, fluorescence), mass spectrometry, or by chromatographic methods such as high performance liquid chromatography (HPLC), liquid chromatography-mass spectroscopy (LCMS), thin layer chromatography (TLC), or radio-thin layer chromatograph (rTLC). Compounds can be purified by those skilled in the art by a variety of methods, including high performance liquid chromatography (HPLC) (“Preparative LC-MS Purification: Improved Compound Specific Method Optimization” K. F. Blom, et al., J. Combi. Chem. 6(6) (2004), which is incorporated herein by reference in its entirety) and normal phase silica chromatography.
- The methods provided herein include the manufacture and use of pharmaceutical compositions, which include compounds identified by a method provided herein as active ingredients. Also included are the pharmaceutical compositions themselves.
- Pharmaceutical compositions typically include a pharmaceutically acceptable carrier. As used herein the language “pharmaceutically acceptable carrier” includes saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
- A pharmaceutical composition is typically formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration.
- Methods of formulating suitable pharmaceutical compositions are known in the art, see, e.g., Remington: The Science and Practice of Pharmacy, 21st ed., 2005; and the books in the series Drugs and the Pharmaceutical Sciences: a Series of Textbooks and Monographs (Dekker, N.Y.). For example, solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol, or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates, or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes, or multiple dose vials made of glass or plastic.
- Pharmaceutical compositions suitable for injection can include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. The composition should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyetheylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, and sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle, which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying, which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- The pharmaceutical composition may be administered at once, or may be divided into a number of smaller doses to be administered at intervals of time. It is understood that the precise dosage and duration of administration may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test data. It is to be noted that concentrations and dosage values may also vary with the size of the area to be imaged. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed compositions.
- Dosage forms or compositions containing a compound as described herein in the range of 0.005% to 100% with the balance made up from non-toxic carrier may be prepared. Methods for preparation of these compositions are known to those skilled in the art. The contemplated compositions may contain 0.001%-100% active ingredient, in one embodiment 0.1-95%, in another embodiment 75-85%.
- The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.
- The compounds described herein can be imaged using methods known in the art. For example, imaging can be achieved in living animals, organs, or tissues, using e.g. near infrared (NIR), MR imaging (MRI), positron emission tomography (PET), single photon computerized tomography (SPECT), or other whole body imaging modalities. The detectable agent of the compound can be imaged by these whole body imaging modalities to detect cancer cells (e.g., cancer cells overexpressing PARP1). For example, a compound having a fluorescent detectable agent can be detected by traditional fluorescence imaging techniques allowing for the facile tracking of the compounds by fluorescence microscopy or flow cytometry using methods known in the art, e.g., as described in US 2005/0249668, the content of which is incorporated by reference in its entirety. In some embodiments, a compound having a radioactive agent can be imaged using positron emission tomography (PET).
- The compositions and methods described herein can be imaged using a variety of modalities that are known to one of skill in the art. Detection methods can include both imaging ex vivo and in vivo imaging methods, e.g., immunohistochemistry, bioluminescence imaging (BLI), Magnetic Resonance Imaging (MM), positron emission tomography (PET), Single-photon emission computed tomography (SPECT), electron microscopy, X-ray computed tomography, Raman imaging, optical coherence tomography, absorption imaging, thermal imaging, fluorescence reflectance imaging, fluorescence microscopy, fluorescence molecular tomographic imaging, nuclear magnetic resonance imaging, X-ray imaging, ultrasound imaging, photoacoustic imaging, lab assays, or in any situation where tagging/staining/imaging is required. In some embodiments, one or more imaging techniques can be used in the methods provided herein. For example, fluorescence, PET and/or SPECT imaging can be used.
- The compounds and compositions described herein can be used in in vivo imaging methods to detect, quantify and evaluate PARP1 (e.g., PARP1 in a cancer). In general, such methods include administering to a subject one or more compounds of Formula (1) or Formula (2) described herein; optionally allowing the compound to distribute within the subject; and imaging the subject, e.g., by fluoroscopy, radiography, computed tomography (CT), MM, PET, SPECT, laparoscopy, endomicroscopy, or other whole body imaging modality to detect the presence of PARP1. Furthermore, it is understood that the methods (or portions thereof) can be repeated at intervals to evaluate the subject and detect any changes in PARP1 concentration over time. Information provided by such in vivo imaging, for example, the presence, absence, or level of emitted signal, can be used to detect and/or monitor the loss of PARP1 or increase of PARP1, e.g., after medical treatment.
- A number of preclinical and clinical applications for a compound provided herein can be envisioned. For example, a compound described here can be used: 1) for the early detection cancers (e.g., cancers that overexpress PARP1 such as pancreatic cancer); 2) as an aid to surgeons during surgery (e.g., by allowing for real-time detection of cancer cells); and 3) as a method for monitoring the progress of a cancer treatment (e.g., by quantifying the amount of PARP1 present before, during, and after treatment).
- In some embodiments, the methods provided herein include methods for detecting a cancer, i.e., a cancer that overexpresses PARP1. Generally, the methods include administering an effective amount of a compound (i.e., active ingredient) as provided herein (i.e., a compound of Formula (1)) to a subject who is in need of, or who has been determined to be in need of, such detection and detecting the compound. In addition, provided herein are methods for imaging a cancer cell. Generally, the methods include contacting a cell with an effective amount of a compound as provided herein and imaging the cell. Such methods may be conducted in vitro or in vivo.
- The compounds according to Formula (1) can be used to detect any cancer that overexpresses PARP1, are believed effective to detect and image a broad range of cancers types, including but not limited to breast cancer, ovarian cancer, and prostate cancer. In some embodiments, the cancer is an epithelial cancer. The methods and compositions described herein can be used to help a physician or surgeon to identify and characterize cancers. The methods and compositions described herein can also be used in the detection, characterization, and/or determination of the localization of the cancer, especially early in the disease, the severity of a cancer, the staging of a cancer, and/or monitoring a cancer. The presence, absence, or level of an emitted signal can be indicative of the state of the cancer.
- Cancers that may be detected and/or imaged by the compounds, compositions and methods described herein include, but are not limited to, the following:
-
- cardiac cancers, including, for example sarcoma, e.g., angiosarcoma, fibrosarcoma, rhabdomyosarcoma, and liposarcoma; myxoma; rhabdomyoma; fibroma; lipoma and teratoma;
- lung cancers, including, for example, bronchogenic carcinoma, e.g., squamous cell, undifferentiated small cell, undifferentiated large cell, and adenocarcinoma; alveolar and bronchiolar carcinoma; bronchial adenoma; sarcoma; lymphoma; chondromatous hamartoma; and mesothelioma;
- gastrointestinal cancer, including, for example, cancers of the esophagus, e.g., squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, and lymphoma; cancers of the stomach, e.g., carcinoma, lymphoma, and leiomyosarcoma; cancers of the pancreas, e.g., ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, and vipoma; cancers of the small bowel, e.g., adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, and fibroma; cancers of the large bowel, e.g., adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, and leiomyoma;
- genitourinary tract cancers, including, for example, cancers of the kidney, e.g., adenocarcinoma, Wilm's tumor (nephroblastoma), lymphoma, and leukemia; cancers of the bladder and urethra, e.g., squamous cell carcinoma, transitional cell carcinoma, and adenocarcinoma; cancers of the prostate, e.g., adenocarcinoma, and sarcoma; cancer of the testis, e.g., seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, and lipoma;
- liver cancers, including, for example, hepatoma, e.g., hepatocellular carcinoma; cholangiocarcinoma; hepatoblastoma; angiosarcoma; hepatocellular adenoma; and hemangioma;
- bone cancers, including, for example, osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochrondroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors;
- nervous system cancers, including, for example, cancers of the skull, e.g., osteoma, hemangioma, granuloma, xanthoma, and osteitis deformans; cancers of the meninges, e.g., meningioma, meningiosarcoma, and gliomatosis; cancers of the brain, e.g., astrocytoma, medulloblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, and congenital tumors; and cancers of the spinal cord, e.g., neurofibroma, meningioma, glioma, and sarcoma;
- gynecological cancers, including, for example, cancers of the uterus, e.g., endometrial carcinoma; cancers of the cervix, e.g., cervical carcinoma, and pre tumor cervical dysplasia; cancers of the ovaries, e.g., ovarian carcinoma, including serous cystadenocarcinoma, epithelial cancer, mucinous cystadenocarcinoma, unclassified carcinoma, granulosa thecal cell tumors, Sertoli Leydig cell tumors, dysgerminoma, and malignant teratoma; cancers of the vulva, e.g., squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, and melanoma; cancers of the vagina, e.g., clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma, and embryonal rhabdomyosarcoma; and cancers of the fallopian tubes, e.g., carcinoma;
- hematologic cancers, including, for example, cancers of the blood, e.g., acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, and myelodysplastic syndrome, Hodgkin's lymphoma, non-Hodgkin's lymphoma (malignant lymphoma) and Waldenström's macroglobulinemia;
- skin cancers, including, for example, malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis; and
- adrenal gland cancers, including, for example, neuroblastoma.
- Cancers may be solid tumors that may or may not be metastatic. Cancers may also occur, as in leukemia, as a diffuse tissue. Thus, the term “cancer cell”, as provided herein, includes a cell afflicted by any one of the above identified disorders.
- The compounds according to Formula (1) can also be administered to a subject in combination with surgical methods to treat cancers, e.g., resection of tumors. The compounds can be administered to the individual prior to, during, or after the surgery. The compounds can be administered parenterally, intravenous or injected into the tumor or surrounding area after tumor removal, e.g., to image or detect residual cancer cells. For example, the compound may be used to detect the presence of a tumor and to guide surgical resection. In some embodiments, the compound can be used to detect the presence of residual cancer cells and to guide continued surgical treatment until at least a portion (e.g., all) such cells are removed from the subject. Accordingly, there is provided a method of guided surgery to remove at least a portion of a tumor from a subject comprising providing a compound of Formula (1); causing the compound to be present in at least some cancer cells in an effective amount to inhibit PARP1 and for detection of the compound to be observable; observing the image (e.g., fluorescence, PET or SPECT scan); and performing surgery on the subject to remove at least a portion of the tumor that comprises detected cancer cells.
- In some embodiments, a compound of Formula (1) or Formula (2) is imaged in vivo using PET or SPECT imaging. For example, the use of such methods permits the facile, real-time imaging and localization of cancers labeled with a compound having a radioactive detectable agent. In some embodiments, PET or SPECT can be used to diagnose cancer by imaging the accumulation of a compound provided herein in cancer cells expressing PARP1. In some embodiments, the use of PET and/or SPECT as an imaging modality can be useful during surgery to locate cancer cells (e.g., residual cancer cells following excision of a tumor mass).
- In some embodiments, a compound of Formula (1) or Formula (2) is imaged in vivo using laparoscopy and endomiscroscopy. For example, the use of laparoscopy permits the facile, real-time imaging and localization of cancers labeled with a compound having a fluorescent detectable agent. In some embodiments, laparoscopy can be used to diagnose cancer by imaging the accumulation of a compound provided herein in cancer cells expressing PARP1. In some embodiments, the use of laparoscopy as an imaging modality can be useful during surgery to locate cancer cells (e.g., residual cancer cells following excision of a tumor mass). In some embodiments, a compound can be imaged using fiber optic endomicroscopy.
- In addition, in vivo imaging can be used to assess the effect of an anti-cancer therapy on cells expressing PARP1, by using the compounds described herein, wherein the subject is imaged prior to, during, and/or after treatment with the therapy, and the corresponding signal/images are compared. For example, a subject with a cancer can be imaged prior to and after treatment with chemotherapy or radiation therapy to determine the response of the PARP1-expressing cancer cells to treatment.
- As described herein, a compound of Formula (1) accumulates in PARP1 expressing cells (e.g., PARP1 overexpressing cancer cells). This accumulation, however, can be quantifiably inhibited by administration of an unlabeled PARP1 inhibitor, e.g., the parent PARP1 inhibitor present in the compound of Formula (1) or any other PARP inhibitor. Accordingly, further provided herein is a method for measuring PARP1 inhibition by any PARP1 inhibitor or compound that has an effect on PARP expression or activity level. Generally, the method includes contacting a cell (e.g., administering to a subject) an effective amount of a compound of Formula (1) and a therapeutic PARP1 inhibitor (i.e., non-labeled), and imaging the cell (e.g., the subject) to determine the amount of the compound of Formula (1) present.
- In addition to promising approaches of PARP1 inhibitors as anti-cancer drugs, it has been shown that DNA-damage leads to rapid activation (10- to 500-fold) and recruitment of PARP1 (see, e.g., Hassa, 2008, Front. Biosci., 13, 3046-3082; Jean-François Haince and Michael J. Hendzel, 2008, J. Biol. Chem., 283, 1197-1208). Although not much is known about PARP1 protein levels and activities in tumor cells versus healthy cells (see Michele Rouleau and Guy G. Poirier, 2010, Nature Rev Cancer, 10, 293-301), different reports show increased activity and/or expression levels of PARP1 in cancer cell lines and tumors versus healthy tissue (Zaremba T, 2009, Br J Cancer., 101, 256-262; Katsuhiko Nosho, 2006, Eur. J. Cancer, 42, 2374-2381).
- With respect to in vitro imaging methods, the compounds and compositions described herein can be used in a variety of in vitro assays. An exemplary in vitro imaging method comprises: contacting a sample, for example, a biological sample (e.g., a cell such as a cancer cell), with one or more compounds of Formula (1) or Formula (2); allowing the conjugate(s) to interact with a biological target in the sample; optionally, removing unbound agents; illuminating the sample with light of a wavelength absorbable by a fluorophore of the agents; and detecting a signal emitted from fluorophore thereby to determine whether the agent has been activated by or bound to the biological target.
- After a compound has been designed, synthesized, and optionally formulated, it can be tested in vitro by one skilled in the art to assess its biological and performance characteristics. For instance, different types of cells grown in culture can be used to assess the biological and performance characteristics of the compound. Cellular uptake, binding or cellular localization of the agent can be assessed using techniques known in the art, including, for example, fluorescent microscopy, fluorescence-activated cell sorting (FACS) analysis, immunohistochemistry, immunoprecipitation, in situ hybridization and Forster resonance energy transfer (FRET) or fluorescence resonance energy transfer.
- By way of example, the compound can be contacted with a sample for a period of time and then washed to remove any free compound. The sample can then be viewed using an appropriate detection device such as a fluorescent microscope equipped with appropriate filters matched to the optical properties of a fluorescent agent. Fluorescence microscopy of cells in culture or scintillation counting is also a convenient means for determining whether uptake and binding has occurred. Tissues, tissue sections and other types of samples such as cytospin samples can also be used in a similar manner to assess the biological and performance characteristics of the compounds. Other detection methods including, but not limited to flow cytometry, immunoassays, hybridization assays, and microarray analysis can also be used.
- In some embodiments, the compounds can be used in an in vitro assay for detecting agents that inhibit PARP1.
- The invention is further described in the following examples, which do not limit the scope of the invention described in the claims. Compound numbers are independent in each of the following Examples.
- Until otherwise noted, all reagents were purchased from Sigma-Aldrich (St. Louis, Mo.) and used without further purification. Texas Red-X, succinimidyl ester was purchased from Invitrogen (Carlsbad, Calif.). Cyclohexylcarbodiimide polystyrene resin was purchased from EMD biosciences (Gibbstown, N.J.). LC-ESI-MS analysis and HPLC purifications were performed on a Waters (Milford, Mass.) LC-MS system. For LC-ESI-MS analyses, a Waters
XTerra® C18 5 μm column was used. For preparative runs, an Atlantis® PrepT3 OBD™ 5 μM column was used. High-resolution electrospray ionization (ESI) mass spectra were obtained on a Bruker Daltonics APEXIV 4.7 Tesla Fourier Transform mass spectrometer (FT-ICR-MS) in the Department of Chemistry Instrumentation Facility at the Massachusetts Institute of Technology. Cellular images were taken on a Nikon (Tokyo, Japan) Eclipse 80i microscope with either aNikon Plan Apo 40×/0.95 air or aNikon Plan Apo 60×/1.45 oil immersion objective. IC50 assays were analyzed using a Tecan (Männedorf, Switzerland) Safire microplate system. All kinetic data were analyzed using Prism 4 (GraphPad, La Jolla, Calif.) for Mac. - Texas Red-Tz (8) was synthesized similar to methods described earlier. (See N. K. Devaraj et al., Angew. Chem., Int. Ed. 2010, 49, 2869-2872; N. K. Devaraj et al., Angew. Chem., Int. Ed. 2009, 48, 7013-7016, S7013/1-S7013/6; and N. K. Devaraj et al., Bioconj. Chem. 2008, 19, 2297-2299. (Cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one (1), 4-[[4-Fluoro-3-(piperazine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one (2) and (E)-cyclooct-4-
enyl 2,5-dioxopyrrolidin-1-yl carbonate (5) were synthesized as described earlier. (See K. A. Menear et al., J. Med. Chem. 2008, 51, 6581-6591; and N. K. Devaraj et al., Angew. Chem., Int. Ed. 2009, 48, 7013-7016, S7013/1-S7013/6). -
- Glutaric anhydride (0.50 g, 4.37 mmol) and N,Ndiisopropylethylamine (2.28 mL, 13.11 mmol) were added to a solution of 4-[[4-Fluoro-3-(piperazine-1-carbonyl)phenyl] methyl]-2H-phthalazin-1-one (2) (1.60 g, 4.37 mmol) in dichloromethane (50 mL) and the reaction mixture and stirred for 30 minutes. Water (50 mL) was then added and the reaction mixture stirred for another 30 minutes. The reaction mixture was acidified with HCl to
pH 2, the organic phase separated and the aqueous phase extracted with dichloromethane (3×30 mL). The combined organic phases were dried over MgSO4 and volatiles removed in vacuo. The resulting crude material was purified using silica chromatography (0%-30% MeOH/DCM), yielding the pure product as an off-white solid (1.52 g, 3.16 mmol, 72%). -
- Cyclohexylcarbodiimide polystyrene resin (634 mg, 2.3 mmol/g) was added to a solution of 4-[[4-Fluoro-3-(4-(5-oxopentanamide)piperazine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one (3) (350 mg, 0.73 mmol) in dichloromethane (20 mL) and the resulting mixture stirred gently for 7 hours at room temperature. Subsequently, ethylenediamine (976 μL, 14.6 mmol) was added and the reaction mixture stirred for another 60 minutes, before the reaction mixture was filtered and volatiles removed in vacuo. The crude material was purified via HPLC, yielding the title compound as a clear solid (62 mg, 0.12 mmol, 16%).
-
- Cyclohexylcarbodiimide polystyrene resin (33 mg, 2.3 mmol/g) and triethylamine (16 μL, 0.11 mmol) were added to a solution of 4-[[4-Fluoro-3-(4-(N-(2-aminoethyl)-5-oxo-pentanamide)piperazine-1-carbonyl)phenyl] methyl]-2H-phthalazin-1-one (4) (20 mg, 38 μmol) and 5-norbornene-2-carboxylic acid (11 mg, 77 μmol) in dichloromethane (1 mL) and the resulting mixture stirred gently over night at room temperature. Subsequently, the reaction mixture was filtered and volatiles removed in vacuo. The crude material was purified via HPLC, yielding the title compound as a clear solid (5.9 mg, 9 24%).
-
- Triethylamine (16 μL, 0.11 mmol) was added to a solution of 4-[[4-Fluoro-3-(4-(N-(2-aminoethyl)-5-oxo-pentanamide)piperazine-1-carbonyl)phenyl] methyl]-2Hphthalazin-1-one (4) (20 mg, 38 μmol) and (E)-cyclooct-4-enyl-2,5-dioxopyrrolidin-1-yl carbonate (5) (12 mg, 46 μmol) in dichloromethane (1 mL) and the resulting mixture stirred gently over night at room temperature. Subsequently, the reaction mixture was filtered and volatiles removed in vacuo. The crude material was purified via HPLC, yielding the title compound as a clear solid (11.3 mg, 17 44%).
-
- AZD2281-TCO (7) and Texas Red-tetrazine (8) were combined in 40 μL of DMSO/PBS at a final concentration of 0.3 mM for each reagent. The solution was stirred for several minutes at room temperature, yielding AZD2281-Texas Red (9). See
FIG. 1 .FIG. 1A shows the HPLC trace for the AZD2281-Texas Red (9) crude reaction mixture. LC-MS spectra confirmed the quantitative conversion of Texas Red-Tz (8). Multiple peaks were identified with a molecular mass corresponding to AZD2281-Texas Red (9;FIG. 1 B, m/z 1536.0 [M+H]+). These were the result of different isomers formed in the tetrazine trans-cyclooctene cycloaddition. The fast and selective conversion of AZD2281-TCO (7) to AZD2281-Texas Red (9) in the presence of Texas Red-Tz (8) indicates that these small molecules also have potential applicability to in vivo experiments. - The inhibitory potentials of
AZD2281 derivatives final concentration 400 nM to 0.04 nM); and (7), (9) (4 μM to 0.04 nM) were incubated with 0.5 units PARP HSA for 10 minutes in histone-coated 96-well plates. All experiments were carried out in triplicate. Control samples did not contain inhibitor and background measurement samples did not contain PARP-1. All reaction mixtures were adjusted to a final volume of 50 μL and a maximum final concentration 0.4% DMSO in assay buffer. The remainder of the assay was performed according to the manufacturer's instructions. PARP activity was measured by absorbance at 450 nm in each well using aSafire 2 microplate reader (Tecan Group, Mannedorf, Switzerland). IC50 values were calculated using Prism software (GraphPad, La Jolla, Calif.). - Analysis of the
AZD2281 derivatives AZD2281 precursor 2 appear to be tolerated by the enzyme, and allow the design of bifunctional derivatives. The IC50 value of pre-reacted AZD2281-Texas Red (9; 15.4±1.2 nM) demonstrates that the trans-cyclooctene/tetrazine cycloaddition only minimally reduces binding of the 1(2H)-phthalazinone to PARP1, which confirms its possible application as an imaging probe. - Due to their fast reaction kinetics compared to AZD2281-NOB (6), the trans-cyclooctene conjugated AZD2281 (AZD2281-TCO; 7) and Texas Red-Tz (8) were tested under in vivo conditions in live cells.
- MDA-MB-231 and MDA-MB-436 cells were obtained from the ATCC and cultured in RPMI 1640 supplemented with 10% fetal bovine serum, L-glutamine, and penicillin/streptomycin. MDA-MB-231 and MDA-MD-436 cells stably expressing PARP-GFP were derived by transfection with Lipofectamine 2000 (Invitrogen) and isolation of individual G418-resistant clones. Cells were maintained in growth medium containing 1 mg/mL G418. Expression of PARP-GFP in MDA-MB-436 cells was verified using immunofluorescence microscopy to show nuclear localization of PARP-GFP, and western blotting for PARP-GFP.
- For AZD2281-TCO IC50 assays, MDA-MB-436 cells (500 μL, 80.000 cells/mL) were seeded into glycerine-treated 8-well chamber slides (Lab Tek™, Thermo Scientific, Rochester, N.Y.), and allowed to attach overnight. Cells were then incubated with Texas Red-Tz (8) (25 μL, 20 μM) for 20 minutes (37° C.) before the medium was removed and cells were washed (1×, medium, 500 μL). Subsequently, 500 μL medium, Hoechst 33258 (10 μL, 100× in PBS) and AZD2281-TCO (7) (25 μL, in PBS, 3% DMSO, 30 μM-100 nM) were added and incubated at 37° C. for 20 minutes. Cells were washed with PBS (3×500 μL), fixed with paraformaldehyde (4% in PBS) and washed with PBS (3×500 μL, time between each wash=5 minutes). PBS was removed and cells mounted using Prolong Gold (Invitrogen, Carlsbad, Calif.) before imaging.
- For AZD2281-TCO blocking experiments, MDA-MB-436 cells (500 μL, 80.000 cells/mL) were seeded into glycerine-treated 8-well chamber slides (Lab Tek™, Thermo Scientific, Rochester, N.Y.), and allowed to attach overnight. Cells were then incubated with Texas Red-Tz (8) (25 μL, 20 μM) for 20 minutes (37° C.) before the medium was removed and cells were washed (1×, medium, 500 μL). Subsequently, 500 μL medium, Hoechst 33258 (10 μL, 100× in PBS), AZD2281 (1) (5 μL in DMSO, 10 mM) and AZD2281-TCO (7) (25 μL, in PBS, 3% DMSO, 30 μM-100 nM) were added and incubated at 37° C. for 20 min. Cells were washed with PBS (3×500 μL), fixed with paraformaldehyde (4% in PBS) and washed with PBS (3×500 μL, time between each wash=5 min). PBS was removed and cells mounted using Prolong Gold (Invitrogen, Carlsbad, Calif.) before imaging.
- Cells were observed on a Nikon 80i (Nikon, Tokyo JP) microscope equipped with an ImagEM camera (Hammamatsu Photonics, Tokyo JP). Images detailing distinct and separate cellular regions were obtained with the following filters: (Dapi, excitation 350±50 nm, emission 460±50 nm, dichroic 400LP; IgG Pab, excitation 480±20 nm, emission 535±25 nm, dichroic 505LP; Texas Red-Tz (8), excitation 560±20 nm, emission 630±30 nm, dichroic 595DCLP; Chroma Technology, Bellows Falls, Vt.). Images in each channel were captured using identical acquisition parameters. For each image, both cell structures and nuclei structures have been obtained using the appropriate fluorescence filters and appropriate excitation signal levels to avoid collecting auto-fluorescence. The collected data was then pre-processed with Cellprofiler (A. E. Carpenter, et al.,
GenomeBiology 2006, 7, R100) and statistics collected using Matlab (The Mathworks, Waltham, Mass.). Cell structures were then identified using Otsu's method (N. Malpica, et al., Cytometry 1997, 28, 289-297; and N. Otsu, IEEE Trans. Sys. Man. Cyber. 1979, 9, 62-66) and binary masks were generated matching the boundary of each cell structure. Within each image and for each cell, the fluorescence signal for the total cell and the signal in the nuclear area was calculated using the corresponding mask as a spatial filter. The two signals were then normalized for their total areas. The ratio of the fluorescent signal in the cytosol region over the signal in the nuclear region was then calculated. Background subtraction was performed on the normalized signal using the cell's negative masks. For all cells we chose an optimal ratio between 0.35 and 0.48 for the cytosol area over the nucleus area. - MDA-MB-436 cells (500 μL, 80.000 cells/mL) were seeded into glycerine-treated 8-well chamber slides (Lab Tek™, Thermo Scientific, Rochester, N.Y.), and allowed to attach overnight. They were incubated with Texas Red-Tz (8) (25 μL, 20 μM) for 20 minutes (37° C.) before the medium was removed and cells were washed (1×, medium, 500 μL). Subsequently, 500 μL medium and AZD2281-TCO (7) (25 μL, in PBS, 3% DMSO, 30 μM) were added and incubated at 37° C. for 20 min. Cells were washed with PBS (3×500 μL), fixed with paraformaldehyde (4% in PBS) and washed with PBS (3×500 μL, time between each wash=5 min). Cells were permeabilized using Triton-X-100 (2% in PBS, 10 min) and incubated with anti-PARP-1 Mab (EMD biosciences, Gibbstown, N.J.) for 3 hours, before stained with secondary IgG-GFP Pab (EMD biosciences, Gibbstown, N.J.). PBS was removed and cells mounted using Prolong Gold (Invitrogen, Carlsbad, Calif.) before imaging.
- Results
- Staining patterns for the Texas Red dye (
FIG. 2A ) showed that it not only localized in the nucleus, but also accumulated in the nucleolus. Whilst anti-PARP1 Mabs showed similar nuclear localization (FIG. 2B ), there was an absence of Mab signal in the nucleoli. This was presumably due to steric hindrance and not to the absence of PARP in the nucleolus, as earlier reports have indicated (V. S. Meder et al., J. Cell Sci. 2005, 118, 211-222; and J.-F. Haince et al., J. Biol. Chem. 2008, 283, 1197-1208). The results inFIG. 2C confirm that there was excellent spatial correlation between the small molecules (AZD2281-TCO (7)/Texas Red-Tz (8)). - A PARP1-GFP fusion protein was also constructed and expressed in MDA-MB436 cells as an independent confirmation of probe localization. PARP-GFP was constructed by PCR of human PARP-1 from Open Biosystems clone 5193735 from the NIH_MGC_114 cDNA library, and cloning into pAcGFP-N1 between XhoI and XmaI restriction sites. The PARP-GFP construct was verified by DNA sequencing.
- PARP-1-GFP expressing MDA-MB-436 cells (500 μL, 80.000 cells/mL) were seeded into glycerine-treated 8-well chamber slides (Lab Tek™, Thermo Scientific, Rochester, N.Y.), and allowed to attach overnight. They were washed with PBS (3×500 μL), fixed with paraformaldehyde (4% in PBS) and washed with PBS (3×500 μL, time between each wash=5 min). Cells were permeabilized using Triton-X-100 (0.5% in PBS, 10 min) and incubated with anti-PARP-1 Mab (EMD biosciences, Gibbstown, N.J.) for 3 h, before stained with secondary IgG-GFP Pab (EMD biosciences, Gibbstown, N.J.). PBS was removed and cells mounted using Prolong Gold (Invitrogen, Carlsbad, Calif.) before imaging.
- In the PARP1-GFP expressing cells, GFP expression was clearly observed, primarily in the nucleoli but also in the nucleus. This pattern was identical to that seen with the AZD2281-TCO/Texas Red-Tz pair. (Table 1,
FIG. 3 ). Interestingly, incubation of live cells with Texas Red-Tz (8) without AZD2281-TCO (7) did not lead to nuclear localization of the dye. Instead, there was non-lower nuclear/cytoplasmic localization ratios (modest increase of 38±2%). The superior results of sequential treatment of MDAMB436 cells with AZD2281-TCO (7) and Texas Red-Tz (8) demonstrates the advantages of a bioorthogonal in vivo reaction, since both partners (the targetingmolecule 7 as well as the fluorophore 8) are small in size (7: 674.76 gmol−1; 8: 889.05 gmol−1), and this contributes to easier permeation. Once assembled, however, penetration is less efficient leading to trapping of the conjugate and high target-to-background ratios. -
TABLE 1 IC50 values for the bifunctional 1(2H)-phthalazinone- based targeted probes and for AZD2281-Texas Red. MW IC50 Reactive Compound Name # [gmol−1] [nm] with Reactive AZD2281- NOB 6 642.7 10.1 + 1.3 Tz-fluorochromes InhibitorAZD2281- TCO 7 674.8 11.8 + 1.4 Tz-fluorochromes Fluorescent AZD2281- Texas Red 9 1535.6 15.4 + 1.2 NA Inhibitor - Unless otherwise noted, all reagents were purchased from Sigma-Aldrich (St. Louis, Mo.) and used without further purification. Cyclohexylcarbodiimide polystyrene resin was purchased from EMD biosciences (Gibbstown, N.J.). 4-[[4-Fluoro-3-(4-(5-oxopentanamide)piperazine-1-carbonyl) phenyl]methyl]-2H-phthalazin-1-one (7), tetrazine amine (8), and 4-[[4-fluoro-3-(piperazine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one (11) were synthesized as described earlier (T. Reiner et al., ChemBioChem 2010; N. K. Devaraj et al., Bioconjug. Chem. 2008, 19, 2297-2299; and K. A. Menear et al., J. Med. Chem. 2008, 51, 6581-6591. 18F-Fluoride (n.c.a.) in 18O-enriched water was purchased from PETNET (Woburn, Mass.). Automated synthesis of 18F-labeled trans-cyclooctene was carried out using a Synthra RN Plus automated synthesizer (Synthra GmbH, Hamburg, Germany) operated by SynthraView software. For nonradioactive compounds, LC-ESI-MS analysis and HPLC-purifications were performed on a Waters (Milford, Mass.) LC-MS system. For LC-ESI-MS analyses, a Waters
XTerra® C18 5 μm column was used. Preparative high performance liquid chromatography (HPLC) runs for synthetic intermediates utilized an Atlantis® PrepT3 OBD™ 5 μM column (eluents 0.1% TFA (v/v) in water and MeCN; gradient: 0-1.5 min, 5-100% B; 1.5-2.0min 100% B). For radiolabeled compounds, preparative scale HPLC purification was achieved using a Machery-NagelNucleodur C18 Pyramid 250×10 mm Vario-Prep column (60:40 0.1% trifluoroacetic acid (v/v) in water-acetonitrile (MeCN) at 5.5 mL·min−1) with a 254 nm UV detector and radiodetector connected in series. Analytical HPLC of radiolabeled compounds was performed employing a Grace VYDAC (218TP510) C18 reversed-phase column (eluents 0.1% TFA (v/v) in water and MeCN; gradient: 0-17 min, 5-60% B; 17-21 min, 60-95% B; 21-24 min, 95% B; 24-25 min, 95-5% B; 25-30 min, 5% B; 2 mL·min−1) with a dual-wavelength UV-vis detector and a flow-through gamma detector connected in series. HyperSep C18 cartridges were purchased from Thermo Electron (Bellefonte, Pa.) and Sep-pak VAC Alumina-N cartridges from Waters (Milford, Mass.). High-resolution electrospray ionization (ESI) mass spectra were obtained on a Bruker Daltonics APEXIV 4.7 Tesla Fourier Transform mass spectrometer (FT-ICR-MS) in the Department of Chemistry Instrumentation Facility at the Massachusetts Institute of Technology. IC50 assays were analyzed using a Tecan (Männedorf, Switzerland) Safire2 microplate system. All kinetic data were analyzed using Prism 4 (GraphPad, La Jolla, Calif.) for Mac. - 9-Oxabicyclo[6.1.0]non-4-ene (4.2 g, 33.8 mmol) was added slowly to LiAlH4 (1.2 g, 30.4 mmol) suspended in diethyl ether (100 mL). After stirring at room temperature for 4 hours, the reaction was worked up by the sequential addition of 4 mL H2O, 4
mL 25% NaOH(aq), and 4 mL of H2O. The resulting mixture was filtered and the filtrate dried (Na2SO4) and filtered again. The clear ether solution was concentrated to give 4.1 g of (Z)-cyclooct-4-enol in 96.1% yield. - (Z)-Cyclooct-4-enol (2.0 g, 15.8 mmol) was added slowly to a suspension of sodium hydride (1.3 g of 60% dispersion in mineral oil, 31.7 mmol) in 50 mL THF. This was stirred at reflux for 1 hour, then a solution of iodoacetic acid (2.9 g, 15.8 mmol) in 10 mL THF was added and reflux was continued for 4 hours, then the reaction was cooled to room temperature and concentrated under reduced pressure. The residue was dissolved in 10% NaOH(aq) (50 mL) and extracted with Et2O (2×25 mL). The pH of the aqueous solution was lowered to (4) by the addition of 6N HCl and extracted again with DCM (2×25 mL). Separately, the organic solutions were dried (MgSO4), filtered, and concentrated by rotary evaporator. The ether extraction resulted in 1.0 g of starting (Z)-cyclooct-4-enol and the DCM extraction resulted in 1.9 g of (Z)-2-cyclooct-4-enyloxy)acetic acid (2) (65.5% yield).
- (Z)-2-Cyclooct-4-enyloxy)acetic acid (1.9 g, 10.3 mmol) was added to a suspension of LiAlH4 (0.4 g, 9.5 mmol) in Et2O (10 mL) at 0° C., warmed to room temperature, and was stirred for 24 hours. Unreacted LiAlH4 was quenched with 10% HCl(aq) and the reaction diluted with 30 mL H2O. The Et2O layer was separated and the aqueous solution was extracted with Et2O (2×10 mL). The combined Et2O solutions were dried (MgSO4), filtered, and concentrated. The crude mixture was subjected to column chromatography (2:3 hexanes:ethyl acetate) to give 1.4 g of (Z)-2-(cyclooct-4-enyloxy)ethanol (3) (Rf=0.58), a 78.3% yield.
- (Z)-2-(Cyclooct-4-enyloxy)ethanol (1.0 g, 5.9 mmol) was converted to the (E)-isomers following a previously described cycle/trap method (M. Royzen et al., J. Am. Chem. Soc. 2008, 130, 3760-3761) with the exception of using methyl 4-(trifluoromethyl)benzoate (1.1 g, 7.9 mmol) as the photochemical sensitizer. The (E)-isomers were released from the 10% AgNO3 silica gel with 50 mL of 30% ammonium hydroxide(aq) and 50 mL DCM by stirring for 10 minutes. The suspension was filtered, the organics separated, dried (MgSO4) and concentrated to give 500 mg of a pale yellow oil. This crude mixture was subjected to column chromatography (2:1 pentane:Et2O; starting material Rf=0.23) securing 106 mg of the minor isomer (Rf=0.31) and 262 mg of the major isomer (Rf=0.14).
- The major isomer of (E)-2-(cyclooct-4-enyloxy)ethanol (180 mg, 1.1 mmol), tosyl chloride (262 mg, 1.4 mmol), and triethylamine (214 mg, 2.1 mmol) were combined in acetonitrile (6 mL). Reaction progress was monitored by TLC (1:1 hexanes:EA; starting material Rf=0.50 and desired product Rf=0.84). After 2 hours stirring at room temperature, the reaction mixture was filtered and concentrated by rotary evaporation. The crude mixture was subjected to column chromatography (1:1 hexanes:ethyl acetate) to give 298 mg of (E)-2-(cyclooct-4-enyloxy)ethyl 4-methylbenzenesulfonate (5), a 84% yield.
- (E)-2-(Cyclooct-4-enyloxy)ethyl 4-methylbenzenesulfonate (19 mg, 58.6 μmol) diluted in THF (1 mL) was treated with a tetrabutylammonium fluoride in THF (123 μL of 1 M solution). Reaction progress was monitored by TLC (2:1 pentane:Et20; starting material Rf=0.62 and desired product Rf=0.92). After stirring for 2 hours, the mixture was concentrated and the resulting amber oil subjected to column chromatography (silica gel, pentane) isolating 9.2 mg of (E)-5-(2-fluoroethoxy)cyclooct-1-ene (619F (91.1%)).
- Cyclohexylcarbodiimide polystyrene resin (127 mg, 2.3 mmol/g) was added to a solution of 4-[[4-Fluoro-3-(4-(5-oxopentanamide) piperazine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one 7 (70 mg, 0.15 mmol) in dichloromethane (10 mL) and the resulting mixture was stirred gently for 7 hours at room temperature. Subsequently, tetrazine amine (8) (55 mg, 0.29 mmol) and triethylamine (81 μL, 0.58 mmol) was added and the mixture stirred for another 60 minutes, before the reaction mixture was filtered and volatiles removed in vacuo. The crude material was purified via HPLC, yielding the title compound as a pink solid (24 mg, 37 25%).
- A solution of AZD2281-Tz (9) in DMSO (10 μL, 1 mM, 0.01 μmol) was added to (619F) (10 uL, 1 mM in DMSO, 0.01 μmol) and agitated for 30 minutes, before the crude reaction mixture was purified via HPLC-chromatography. HRMS-ESI [M+H]+m/z calcd. for [C44H47F2N7O5]+792.368, found 792.3690.
- A solution of AZD2281-Tz (9) in DMSO (10 μL, 1 mM, 0.01 μmol) was added to 4 (10 uL, 1 mM in DMSO, 0.01 μmol) and agitated for 30 minutes, before the crude reaction mixture was purified via HPLC-chromatography. HRMS-ESI [M+H]+m/z calcd. for [C44H48FN7O6]+ 790.3723, found 790.3707.
- A solution of HPLC purified 1-AZD2281-18F (1018F) was allowed to stand at room temperature for 48 h to allow all radioactive 18F to decay. HRMS-ESI [M+H]+m/z calcd. for [C44H48FN7O518O]+ 792.3765, found 792.3753.
- 4-[[4-Fluoro-3-(piperazine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one (11) (250 mg, 0.68 mmol), HBTU (337 mg, 0.89 mmol) and triethylamine (285 μL, 1.18 mmol) were added to a solution of 6-hydroxyhexanoic acid (180 mg, 1.36 mmol) in DMF (3.0 mL) and the reaction mixture was stirred at room temperature for 60 minutes, before dichloromethane (8 mL) and water (8 mL) were added, the organic phase separated and washed with water (3×8 mL). The organic phase was dried over MgSO4, volatiles removed in vacuo and the resulting crude material purified via HPLC, yielding the title compound as a clear solid (55.6 mg, 0.12 mmol, 17%).
- Triethylamine (29 μL, 0.21 mmol) was added to a solution of p-toluenesulfonyl chloride (20 mg, 0.10 mmol) and 4-[[4-Fluoro-3-((6-hydroxyhexanoyl)piperazine-1-carbonyl) phenyl]methyl]-2H-phthalazin-1-one (12) (25 mg, 0.052 mmol) in dichloromethane (5 mL), the reaction mixture was stirred at room temperature overnight and purified via HPLC, yielding the title compound as a clear solid (7.8 mg, 0.01 mmol. 24%).
- 4-[[4-Fluoro-3-(piperazine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one (11) (86 mg, 0.24 mmol), HBTU (116 mg, 0.30 mmol) and triethylamine (164 μL, 1.18 mmol) were added to a solution of 2-hydroxyacetic acid (36 mg, 0.48 mmol) in DMF (1.5 mL) and the reaction mixture was stirred at room temperature for 40 minutes, before dichloromethane (4 mL) and water (4 mL) were added, the organic phase separated and washed with NaOH (0.2 M, 3×4 mL) and water (3×4 mL). The organic phase was dried over MgSO4, volatiles were removed in vacuo and the resulting crude material was purified via HPLC, yielding the title compound as a clear solid (24.3 mg, 0.06 μmol, 50%).
- Triethylamine (53 μL, 0.38 mmol) was added to a solution of p-toluenesulfonyl chloride (36 mg, 0.19 mmol) and 4-[[4-Fluoro-3-((2-hydroxyacetic acid)piperazine-1-carbonyl)phenyl] methyl]-2H-phthalazin-1-one (15) (40 mg, 0.094 mmol) in dichloromethane (5 mL), the reaction mixture was stirred at room temperature overnight and purified via HPLC, yielding the title compound as a clear solid (34 mg, 0.06 mmol. 32%).
- Preparation of 2-AZD2281-19F (1719F).
- Freshly dried NaF (8.4 mg, 0.2 mmol) was added to a solution of 4-[[4-fluoro-3-((2-tosyl-acetyl)piperazine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one (16) (10 mg, 0.02 mmol) in dry acetonitrile (2 mL) and was stirred for 6 hours at 40° C. before the reaction mixture was purified via HPLC, yielding the title compound as a clear solid (1.2 mg, 2.8 μmol, 16%).
- [18F]-F−, n.c.a. (no carrier added), (˜77 MBq, 2.4±0.9 mCi) in H2 18O (˜150 μL), 250 μL of a 75 mM tetrabutylammonium bicarbonate (nBu4NHCO3) solution in water, and 750 μL of MeCN were combined in a 10-mL test tube and heated (microwave) to 98° C. under a stream of argon. At 4, 8 and 12 minutes, 1 mL of MeCN was added and evaporated off. To the dried [18F]-F− (n.c.a.)/nBu4NHCO3 was added 100 μL of a 35 mM solution of tosylate (16) in dimethylformamide and heated to 40° C. for 10 minutes. To remove unreacted [18F]-fluoride, this mixture was filtered through an Alumina-N cartridge (100 mg, 1 mL, Waters) to give 16 μCi in the filtrate. HPLC coinjection of a sample of (1719F) with an aliquot of this filtrate demonstrated formation of the desired product (1718F) in 30 minutes and 0.8% dcRCY.
- 2-18F-(E)-5-(2-Fluoroethoxy)cyclooct-1-ene (18F-TCO) was prepared using Synthra RN Plus automated synthesizer (Synthra GmbH, Hamburg, Germany) operated by SynthraView software in an average time of 40 minutes. The target well was charged with [18F]-F−, n.c.a., (˜1110 MBq, 30±10 mCi) in H2 18O (150 μL), 250 μL of a 75 mM tetrabutylammonium bicarbonate (TBAB) solution in water, and 200 μL of MeCN. The synthesizer reagent vials were filled as follows: A2 with MeCN (350 μL), A3 with tosylate (5) (4.0 mg, 12.3 μmol) in DMSO (400 μL), A5 with DMSO (50 μL), and B2 with H2O (800 μL). The [18F]-F-/TBAB solution was transferred to
Reaction Vessel # 1 and dried by azeotropic distillation of the acetonitrile/water solution by heating to 60° C. under reduced pressure and a flow of argon to achieve ˜310 mbar for 2 minutes followed by 98° C. and 270 mbar for 4 minutes.Reaction Vessel # 1 was cooled to 50° C., tosylate (5) in DMSO (400 μL) added, the reaction vessel pressurized to 2000 mbar, and heated to 90° C. for 10 minutes. Cooled to 30° C., the mixture was filtered through an Alumina-N cartridge (100 mg, 1 mL, Waters) intoReaction Vessel # 2. The Alumina-N cartridge was washed with DMSO (50 μL) and the combined filtrates were diluted with water (800 μL). This solution was subjected to preparative HPLC purification. (6181) was collected (tR=10.1 min) in 4-5 mL of solvent, isolated by C18 solid phase extraction and eluted with DCM (600 μL) to give 7.7±3.4 mCi of 618F in 44.7±7.8% (n=16) decay-corrected radiochemical yield (dcRCY) in an average time of 41 min from the end of drying of [18F]-F− (n.c.a.). Analytical HPLC demonstrated >93% radiochemical purity of (618F). - To the above described (618F)/DCM solution was added AZD2281-Tz (9) (7 μL of 18.5 mM DMSO solution, 0.13 μmol) and stirred at rt for 3 minutes. The mixture was concentrated with a gentle stream of argon, reconstituted in 1:1 MeCN/H2O (to a volume of 1.3 mL), subjected to preparative HPLC purification (tR=6.0 min) and isolated by C18 solid phase extraction. Elution with MeOH (600 uL) followed by evaporation of solvent provided 2.3±0.8 mCi (n=3) of (1018F).
- A solution of HPLC purified 1-AZD2281-18F (1018F) was allowed to stand at room temperature for 48 hours to allow all radioactivity to decay. HRMS-ESI [M+H]+m/z calcd. for [C44H48FN7O518O]+ 792.3765, found 792.3753.
- To assess the effect of the TCO/Tz ligand on target affinity, a colorimetric assay was employed to measure PARP1 activity.
- A commercially available colorimetric assay (Trevigen, Gaithersburg, Md.) was used to measure PARP activity in vitro in the presence of inhibitors. Tenfold dilutions of compounds (619F), (1019F), (1719F) (
final concentration 4 μM to 0.04 nM) and (9) (1 μM to 0.1 nM) were incubated with 0.5 units PARP HSA for 10 minutes in histone-coated 96-well plates. All experiments were carried out in triplicate. Control samples did not contain inhibitor and background measurement samples did not contain PARP1. All reaction mixtures were adjusted to a final volume of 50 μL and a maximum final concentration 0.4% DMSO in assay buffer. The remainder of the assay was performed according to the manufacturer's instructions. PARP activity was measured by absorbance at 450 nm in each well using a Safire2 microplate reader. IC50 values were calculated using the Prism software package. - The published value for AZD2281 is 5 nm (K. A. Menear et al., J. Med. Chem. 2008, 51, 6581-6591; and D. V. Ferraris, J. Med. Chem. 2010, 53, 4561-4584), identical to what we observed in our assay. Conventionally fluorinated (1719F) had an IC50 value of 5.2±1.1 nm, consistent with the small side group. Compound (9) showed an IC50 value of 8.4±1.3 nm, quite remarkable given the bulkier side chain. Cycloaddition fluorinated (1019F) had an IC50 value of 17.9±1.1 nm (
FIG. 4 ), still in the low double-digit nanomolar range and likely sufficient for imaging purposes. These findings are also in agreement with previous results showing that modification of AZD2281 at the piperizine position only minimally perturbs the ability to bind PARP1 (T. Reiner, S. Earley, A. Turetsky, R. Weissleder, ChemBioChem 2010, 11, 2374-2377). - Unless otherwise noted, all reagents were purchased from Sigma-Aldrich (St. Louis, Mo.) and used without further purification. Cyclohexylcarbodiimide polystyrene resin was purchased from EMD biosciences (Gibbstown, N.J.). Magnetic amine-decorated beads were purchased from Invitrogen (Dynabeads® M270 amine, Carlsbad, Calif.). Oregon Green-Tz[1], 4-[[4-fluoro-3-(piperazine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one (AZD2281, (4)), AZD2281-Tz (5) and (E)-2-(Cyclooct-4-enyloxy)ethyl 4-methylbenzenesulfonate (2) were synthesized as described earlier (K. A. Menear et al., J. Med. Chem. 2008, 51, 6581-6591; and E. J. Keliher et al., ChemMedChem 2010, DOI: 10.1002/cmdc.201000426). 18F-Fluoride (n.c.a.) in 18O-enriched water was purchased from PETNET (Woburn, Mass.). Automated synthesis of 18F-labeled trans-cyclooctene was carried out using a Synthra RN Plus automated synthesizer (Synthra GmbH, Hamburg, Germany) operated by SynthraView software. For non-radioactive compounds, LC-ESI-MS analysis and HPLC-purifications were performed on a Waters (Milford, Mass.) LC-MS system. For LC-ESI-MS analyses, a Waters
XTerra® C18 5 μm column was used. Preparative high performance liquid chromatography (HPLC) runs for synthetic intermediates utilized an Atlantis® PrepT3 OBD™ 5 μM column (eluents 0.1% TFA (v/v) in water and MeCN; gradient: 0-1.5 min, 5-100% B; 1.5-2.0min 100% B). For radiolabeled compounds, preparative scale HPLC purification was achieved using a Machery-NagelNucleodur C18 Pyramid 250×10 mm Vario-Prep column (60:40 0.1% trifluoroacetic acid (v/v) in water-acetonitrile (MeCN) at 5.5 mL·min−1) with a 254 nm UV detector and radiodetector connected in series. Analytical HPLC of radiolabeled compounds was performed employing a Grace VYDAC (218TP510) C18 reversed-phase column (eluents 0.1% TFA (v/v) in water and MeCN; gradient: 0-17 min, 5-60% B; 17-21 min, 60-95% B; 21-24 min, 95% B; 24-25 min, 95-5% B; 25-30 min, 5% B; 2 mL·min-1) with a dual-wavelength UV-vis detector and a flow-through gamma detector connected in series. HyperSep C18 cartridges were purchased from Thermo Electron (Bellefonte, Pa.) and Sep-pak VAC Alumina-N cartridges from Waters (Milford, Mass.). High-resolution electrospray ionization (ESI) mass spectra were obtained on a Bruker Daltonics APEXIV 4.7 Tesla Fourier Transform mass spectrometer (FT-ICR-MS) in the Department of Chemistry Instrumentation Facility at the Massachusetts Institute of Technology. IC50 assays were analyzed using a Tecan (Männedorf, Switzerland) Safire2 microplate system. All kinetic data were analyzed using Prism 4 (GraphPad, La Jolla, Calif.) for Mac. - One problem during the synthesis of 18F-radiolabeled compounds is that in most cases large amounts of precursors are used to efficiently react with small quantities of 18F. The resulting mixtures are typically purified by HPLC to remove the excess starting material, which in most cases will compete with the radiolabeled probe for the targeted binding sites. To avoid lengthy HPLC purifications, we designed a trans-cyclooctene resin to “pull out” excess tetrazine-conjugated AZD2281 derivatives from the reaction mixture (
FIG. 5A ). - Magnetic amine-decorated beads (400 μL, approx. 12 mg) were separated from the storage buffer and washed with a mixture of
PBS 1× and DMF (3×400 μL,PBS 1×/DMF=1/1) and were resuspended inPBS 1×/DMF (400 μL, 1/1). Trans-Cyclooctene 1 was added (40 μL, 75 mM in DMF) and the mixture stirred gently for 2.5 h. Subsequently, the beads were washed with a mixture ofPBS 1× and DMF (4×400 μL,PBS 1×/DMF=1/1), resuspended inPBS 1×/DMF (400 μL, 1/1) and stored at 4° C. (FIG. 5B ). - (2-[18F]-1-ene (3) was synthesized similar to methods described earlier (E. J. Keliher et al., ChemMedChem 2010, DOI: 10.1002/cmdc.201000426;
FIG. 5C ). Briefly, 2-[18F]-(E)-5-(2-fluoroethoxy)cyclooct-1-ene (′8F-TCO) was prepared using Synthra RN Plus automated synthesizer (Synthra GmbH, Hamburg, Germany) operated by SynthraView software in an average time of 40 minutes. The target well was charged with [18F]-F-, n.c.a., (˜1110 MBq, 30±10 mCi) in H2 18O (150 μL), 250 μL of a 75 mM tetrabutylammonium bicarbonate (TBAB) solution in water, and 200 μL of MeCN. The synthesizer reagent vials were filled as follows: A2 with MeCN (350 μL), A3 with tosylate 2 (4.0 mg, 12.3 μmol) in DMSO (400 μL), A5 with DMSO (50 μL), and B2 with H2O (800 μL). The [18F]-F-/TBAB solution was transferred toReaction Vessel # 1 and dried by azeotropic distillation of the acetonitrile/water solution by heating to 60° C. under reduced pressure and a flow of argon to achieve ˜310 mbar for 2 minutes followed by 98° C. and 270 mbar for 4 minutes.Reaction Vessel # 1 was cooled to 50° C., tosylate (2) in DMSO (400 μL) added, the reaction vessel pressurized to 2000 mbar, and heated to 90° C. for 10 minutes. Cooled to 30° C., the mixture was filtered through an Alumina-N cartridge (100 mg, 1 mL, Waters) intoReaction Vessel # 2. The Alumina-N cartridge was washed with DMSO (50 μL) and the combined filtrates were diluted with water (800 μL). This solution was subjected to preparative HPLC purification. 18F-TCO (3) was collected (tR=10.1 min) in 4-5 mL of solvent, isolated by C18 solid phase extraction and eluted with DCM (600 μL), concentrated with a gentle stream of argon, reconstituted in 1:1 MeCN/H2O (to a volume of 1.0 mL) to give 6.7±2.2 mCi of (318) in 37.0±1.9% (n=4) decay-corrected radiochemical yield (dcRCY) in an average time of 41 minutes from the end of drying of [18F]-F− (n.c.a.). Analytical HPLC demonstrated >93% radiochemical purity (RCP) of (318F). - 18F-AZD2281 (6) was synthesized similar to methods described earlier (E. J. Keliher et al., ChemMedChem 2010, DOI: 10.1002/cmdc.201000426). AZD2281-Tz (5) (7 μL of an 18.5 mM DMSO solution (0.13 μmol)) was added to a solution of (318F) (2.3 mCi) and stirred at room temperature for 3 minutes. This results in quantitative conversion of 18F-TCO (3), yielding a mixture of 18F-AZD2281 (6) and excess AZD2281-Tz (5;
FIG. 5E ). The solution was treated with 4 mole equivalents of TCO-beads (0.52 μmol TCO), vortexed and allowed to stand for 5 minutes. The beads were removed by magnetic separation and the reaction mixture analyzed by HPLC, 92.1±0.4% dcRCY and 96.0±2.0% (n=3) RC purity. Treatment of this solution for 5 minutes with the TCO-decorated scavenger resin (4 mol equiv of TCO) removed unreacted AZD2281-Tz with minimal loss (approximately 4%) of radiolabeled compound (6). Magnetic removal of the beads provided (6) in (92.1 0.4)% dcRCY, which was then reconstituted in a medium suitable for animal injection (FIG. 5A ). HPLC analysis of the reaction mixture before and after treatment with the TCO-decorated scavenger resin shows that the absorption peak resulting from AZD2281-Tz completely vanishes, whereas the activity peak resulting from 18F-AZD2281 persists (FIG. 5F ). - Loading of the magnetic TCO-scavenger resin was determined by separating both the beads and their unmodified precursors (each 50 μL, approx. 1.5 mg) from the storage solution (
PBS 1×/DMF=1/1) and storage-buffer, respectively and washing with a mixture ofPBS 1× and DMF (3×50 μL,PBS 1×/DMF=1/1). They were resuspended in a solution of Oregon Green-Tz (500 μM, 50 μL;PBS 1×/DMF=1/1), and stirred gently for 50 min. The amount of Oregon Green-Tz “pulled out” of the solution by trans-cyclooctene was measured by determining the solution's absorption at 504 nm and the loading (specific-non-specific adsorption) calculated to be 13 μmol/g. - MDA-MB-231 and MDA-MB-436 cells were obtained from ATCC (Manassas, Va.) and cultured in RPMI 1640 supplemented with 10% fetal bovine serum, L-glutamine, and penicillin/streptomycin (each Invitrogen, Carlsbad, Calif.) at 37° C. and 5% CO2.
- PARP1 expression in MDA-MB-231 and MDA-MB-436 cells was determined by immunoblot analysis. Cells were lysed in RIPA buffer (Cell Signaling Technology, Danvers, Mass.) containing complete protease inhibitors (Roche Applied Science, Indianapolis, Ind.), and protein concentration was quantified using the microBCA assay (Pierce, Rockford, Ill.). Lysates containing SDS loading buffer were boiled for 10 minutes, proteins were separated by SDS-PAGE, then transferred to PVDF membranes using the iBlot (Invitrogen, Carlsbad, Calif.). Membranes were blocked overnight at 4° C. using 5% milk (for PARP1 blot) and 5% BSA (for GAPDH blot) in
TBSTween 20, probed with antibodies against PARP1 (XY-7, Santa Cruz Biotechnologies, Santa Cruz, Calif.) and GAPDH (Millipore, Temecula, Calif.) for 1 hour at room temperature, then washed with PBS. Membranes were then incubated with appropriate secondary antibodies conjugated to HRP for 1 hour at room temperature. After washing, membranes were incubated with SuperSignal West Pico chemiluminescent substrate (Pierce, Rockford, Ill.) for 5 minutes, and exposed to film. - The IC50 value of 18F-AZD2281 against PARP1 was determined to be (17.9 1.1) nm in biochemical assays using the isolated enzyme (AZD2281 itself has an IC50 value of 5 nM). This demonstrates PARP1 to be an ideal target for the rapid screening of 18F-labeled inhibitors, as it can accommodate relatively large prosthetic groups that do not affect binding affinity.
- For cell based assays, MDA-MB-231 and MDA-MB-436 cells (50,000 cells/well) were seeded into 96-well plates and allowed to attach over night at 37° C. and 5% CO2. Ten-fold dilutions of AZD2281 4 (final concentration: 10 μM to 0.01 nM) were added to the wells and incubated for 10 minutes, before 5 μCi of 18F-AZD2281 6 (5 μL, 0.2 μC/μL) were added and the cells incubated for 20 minutes. Then, the medium was replaced and waited for another 10 minutes, before the cells were washed with PBS (3×100 μL) and subjected to gamma-counting.
- Cellular uptake of 18F-AZD2281 was determined by quantification of the remaining activity after incubation and washing of the adherent cells. 18F-AZD2281 was shown to be cell-permeable and its uptake inhibitable upon addition of excess nonradioactive AZD2281 (
FIG. 6 ). Uptake of 18F-AZD2281 was lower for MDA-MB-231 cells than for MDA-MB-436 cells, which correlates with protein expression of PARP1 in the respective cell lines. - Non-tumor bearing Nu/Nu mice were injected with (618F) and used for organ distribution immediately after injection over a time period of 2 hours. Tumor-bearing mice received s.c. injections with 5×106 MDA-MB-436 cells (American Type Culture Collection) in Matrigel (BD Biosciences) into each flank and underwent
imaging 7 days later (injection of (618F) and immediate imaging over a time period of 2 hours). All mice were anesthetized (isoflurane 1.5%; O2 2 L/min) during imaging with a gas delivery system integrated into a multimodal imaging cartridge. All animal experiments were approved by Massachusetts General Hospital's Institutional Review Committee. - Images were acquired on the Siemens Inveon PET-CT. Each PET acquisition was 120 minutes in duration. PET was reconstructed from 600 million coincidental 511 keV photon counts on a series of LSO (lutetium oxyorthosilicate) scintillating crystals. Counts were rebinned in 3D by registering photons spanning no more than 3 consecutive rings and reconstructed into sinograms using a high resolution Fourier Rebin algorithm. Sinograms also yielded a 3D mapping of positron signal using a 2D filtered back-projection algorithm and a Ramp filter with a Nyquist cut-off of 0.5. Datasets were anisotropic matrices containing 128×128×159 pixels, measuring 0.796 mm/pixel in the z direction and 0.861 mm/pixel in the x and y directions. Calibration of PET signal preceded all scans by scanning an 8.0 cm in diameter cylindrical phantom containing a known amount of 18F isotope. Data are expressed as standard uptake values (SUV), which normalizes activity measurements to body weight and injected activity.
- For anatomic reference of PET signal, x-rays were projected over 360 degrees to create a computed tomographic (CT) image. X-ray projections had a cone beam angle of 9.3 degrees and a power of 80 keV. A 500 μA anode source was located 347 mm from the center of rotation and x-rays were incident on a CCD detector containing 2048 transaxial and 3072 axial pixels. Projections were calibrated using 70 dark and 70 light images, interpolated bilinearly, processed through a Shepp-Logan filter, and then reconstructed using a filtered back projection algorithm. CT datasets were isotropic matrices with a total of 512×512×768 pixels measuring 110 μm3. During CT acquisition, iodine contrast was infused into the tail vein at a rate of 35 μL/min to enhance intravascular contrast. Projections were acquired at end expiration of the respiratory cycle using a BioVet gating system (M2M Imaging, Cleveland, Ohio) and total CT acquisition time was ˜10 minutes. PET-CT fusion and image analysis were performed using Inveon Research Workplace 3.0 (Siemens). Three-dimensional visualizations were produced with the DICOM viewer OsiriX (The OsiriX foundation, Geneva, Switzerland).
-
FIG. 7A displays the distribution of the PET probe in the Nu/nu mice at 10, 30, and 50 minutes. The images clearly show initial localization of the probe to be mainly in liver, gall bladder, and intestines, consistent with hepatobiliary excretion. After 50 minutes (FIG. 7A ), the majority of the probe had left the bloodstream (t1/2=6 min) and was excreted through the large intestines.FIG. 7B shows a three-dimensional reconstruction of a tumor-bearing mouse injected with 30 mCi of 18F-AZD2281. Uptake in the tumors is clearly visible. Immediately after imaging, the mice were injected with 1 mg AZD2281 BID. Re-injection of 30 mCi of 18F-AZD2281 confirmed inhibition of the probe s uptake into the tumors (FIGS. 7B and 7C ). Therefore, owing to the rapid decay rate of 18F, each mouse serves as its own control on subsequent days of imaging, facilitating direct comparisons of standardized uptake value (SUVs). - 18F-AZD2281 was synthesized as described herein. Nu/Nu mice bearing either A2780 tumors (treatment response) or A2780, Paca2, Panc1 and SKOV3 (differential uptake) were injected with the hot probe (500-750 μCi) and imaged ˜1.5 hours thereafter. Treatment consisted of injection of 0.5-1.0 mg AZD2281 (Olaparib) 18 hours before imaging (ip, interperitoneal) or −1.5-3.5 hours before imaging (iv, intravenous). Uptake was determined non-invasively by drawing SUVs (Standard Uptake Values).
-
FIG. 8A shows that FDG, the current gold standard in cancer imaging, is not able (based on tumor/muscle signal intensity) to distinguish between treated untreated tumors. Injection of Olaparib (AZD2281; Tx=treatment, starting betweenday 0 and day 1) into tumors lets the signal of 18F-AZD2281 drop, which is a major advantage in terms of predicting if a human tumor will respond to treatment with Olaparib or other PARP inhibitors.FIG. 8B shows the relative uptake of 18F-AZD2281 activity of different ovarian and pancreatic tumors (A2780 and SKOV3=ovarian, PANC1 and PACA2=pancreatic). This data indicates that a wide variety of tumors respond to 18F-AZD2281 treatment, and that those cancers can be detected using the compounds provided herein. - RAW 264.7, Panc-1, MIA Paca2, A2780, OVCAR429, UCI 101, UCI 107, SKOV-3, OVCAR-3, and OV-90 cells (200 μL, 35,000 cells/mL) were each seeded in their respective growth medium on 96-well plates and allowed to attach for 48 hours. They were incubated with AZD2281-BODIPY FL (2 μL, 100 μL) for 20 minutes (37° C.) before the medium was removed and cells were washed (1×, medium, 200 μL). Cells were then fixed with paraformaldehyde (4% in PBS) and washed with ice cold PBS/0.1% Triton X-100/0.5% bovine serum albumin (3×200 μL, 3rd wash left for 30 min). Cells were incubated with anti-PARP-1/2 Rab (1:50; SCBT, Santa Cruz, Calif.) at 4° C. overnight. Cells were washed with PBS/0.1% Triton X-100 (3×200 μL) before stained with secondary IgG-Cy5 Gab (1:100; Millipore, Billerica, Mass.) for 3 h at 4° C. Cells were then washed with PBS (1×, 200 μL), stained with Hoechst (Invitrogen, Carlsbad, Calif.) and blue whole cell stain (Thermo Scientific, Waltham, Mass.) for 30 minutes at room temperature, and washed with PBS (3×, 200 μL) before imaging and quantification of the respective fluorescence signals.
-
FIG. 9A shows that AZD2281-BODIPY FL (green—inner halo) localizes with the nucleus (as confirmed with the red signal (inner most signal), Chromatin (essentially a DNA stain)). This is where PARP1, the target, is located. It does not go into the perinuclear region (the rest of the cell), as shown by the blue stain, which basically colors the cell walls. The composite combines all colors.FIG. 9B plots the amount of fluorescence present in cells using AZD2281 and a PARP1/PARP2 antibody. The more PARP1/PARP2 there is in a cell line, the more AZD2281-BODIPY FL is taken up by the cell.FIG. 9C shows the same data asFIG. 9B , but plots the data differently. This figure shows that the R2 (a measure for correlation) is very high, indicating that AZD2281-BODIPY FL not only targets PARP1, but targets it quantitatively, allowing for an accurate measurement of the amount of PARP1 in a given cell line (or, in a clinical setting, tumor environment). - For in vitro kinetic studies, HT1080 cells were labeled with a 1 μM concentration of AZD2281 fluorophore conjugate in cell culture medium and imaged on an inverted Deltavision epifluorescence microscope using a 37° C. heated stage and 5% CO2 atmosphere for various times. After subtracting the background fluorescence, the data were fitted to an exponential association curve. For clearance, cells were labeled at 1 μM for 1 hour until the cells had reached equilibrium. Cells were washed twice in cell culture media and imaged continuously (BODIPYFL conjugate) or after various time points (BODIPY578 and BODIPY650). The loss in fluorescence was fitted to a biexponential decay curve.
- In
FIGS. 10 and 11 , three different AZD2281 fluorophores were tested using life cell imaging. The cells are not fixed, but in their most natural state (as close as possible to using intravital imaging). First, the compounds were added to the medium surrounding the cells, the compounds entered the cells, and when the medium (which contained AZD2281-fluorophores) was replaced, the AZD2281-fluorophores were washed out of the perinuclear region (where PARP1 is not located). However, the compounds were retained in the nuclear region (where PARP1 is located), showing that all the compounds tested work in an in vitro setting. Table 2 details the properties of the compounds tested, obtained by serial imaging techniques. -
TABLE 2 AZD2281 Uptake Clearance (weighted) Properties BODIPYFL Perinuclear = 1.2 min Perinuclear = 1.7 min MW = 640 Nucleus = 1.1 min Nucleus = slow (remeasure) BODIPY578 Perinuclear = 5.4 min Perinuclear = 6.9 min MW = 677 Nucleus = 3.6 min Nucleus = 23.8 min BODIPY650 Perinuclear = 21.2 min Perinuclear = 12.8 min MW = 895 Da Nucleus = 8.3 min Nucleus = slow (remeasure) - For the in vivo studies, mice with window chambers were implanted with 1 million HT-1080 cells expressing H2B-apple fluorescence protein. 75 nmol of AZD2281-BODIPYFL were dissolved in 75 μL of 1:1::DMAC:solutol and 75 μL of PBS and injected via tail vein. Images of the vessels were taken using a 20× water immersion objective on a laser scanning confocal microscope while the mouse was anesthetized with isoflurane. After 1 hour, the non-specific uptake of the probe cleared revealing nuclear uptake of the probe.
-
FIG. 12 shows the behavior of AZD281-BODIPYFL in vivo. The compound was injected into a mouse by iv (10 seconds). The compound is first observed in the vascular system (where it was injected) and then concentrates in each and every tumor cell of the tumor (red dots). This data shows the ability of the compound to bind to PARP1 in vivo. - For 18F-AZD2281 standardized uptake values, five Nu/Nu mice each received four subcutaneous injections containing SKOV-3, MIA Paca2, A2780, or Panc-1 cells in the flanks and shoulders (2.5×106 cells in 100 μL 70:30 PBS/BD matrigel per injection) (BD Biosciences, Bedford, Mass.). Tumors were allowed to grow for two weeks before imaging. 75 nmol of AZD2281-BODIPYFL were dissolved in 75 μL of 1:1::DMAC:solutol and 75 μL of PBS and injected via tail vein. The agent was allowed to circulate and clear for 45 minutes, before the mice were sacrificed, tumors and muscle tissue excised and the relative fluorescence uptake of tissues quantified against mice which were injected with just 1:1::DMAC:solutol.
-
FIG. 13 shows that the uptake of AZD2281-BODIPY FL is not just specific on a cellular level, but also globally. Tumors have higher PARP1 levels than other tissue, and this is shown by the fact that very little of the compound gets taken up by muscle cells compared to the tumor tissues. This data corresponds well to the in vitro data described above. - It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
Claims (19)
2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein P is selected from the group consisting of: benzamide, quinolone, dihydroisoquinolinone, isoquinolinone, isoquinolone, benzopyrone, cyclic benzamide, benzimidazole, indole, isoindolinone, nicotinamide, 3-AB, phthalazinone, and quinazolinone.
3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein P is selected from the group consisting of AZD2281, AG014699, ABT888, BSI201, BSI101, DR2313, FR 247304, GPI15427, GPI16539, MK4827, NU1025, NU1064, NU1085, PD128763, PARP Inhibitor II, PARP Inhibitor III, PARP Inhibitor VIII, PARP Inhibitor IX, and TIQ-A.
4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein P is AZD2281.
6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein D comprises one or more of organic small molecules, inorganic compounds, nanoparticles, enzymes or enzyme substrates, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, and contrast agents.
7. The compound of claim 6 , or a pharmaceutically acceptable salt thereof, wherein D comprises a radioactive material, a fluorescent material, or a mixture thereof.
8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound of Formula (I) is selected from the group consisting of:
11. A pharmaceutical composition comprising a compound of claim 1 ,
or a pharmaceutically acceptable salt thereof, and
a pharmaceutically acceptable carrier or diluent.
12. A method for detecting a cancer in a subject, the method comprising:
(a) administering to a subject an effective amount of a compound of claim 1 ,
or a pharmaceutically acceptable salt form thereof,
and
(b) detecting the detectable agent in the subject.
13. The method of claim 12 , wherein detecting the detectable agent comprises using histochemistry, fluorescence detection, chemiluminescence detection, bioluminescence detection, magnetic resonance imaging, nuclear magnetic resonance imaging, positron emission tomography, single-photon emission computed tomography, X-ray imaging, X-ray computed tomography, ultrasound imaging, or photoacoustic imaging.
14. The method of claim 12 , wherein the cancer is selected from the group consisting of pancreatic cancer, ovarian cancer, and breast cancer.
15. The method of claim 12 , wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered before and after surgical removal of the cancer.
16. A method for imaging a cancer cell, the method comprising:
(a) contacting a cancer cell with an effective amount of a compound of claim 1 ,
or a pharmaceutically acceptable salt form thereof,
and
(b) imaging the cell.
17. A method for monitoring the cancer treatment of a patient, the method comprising:
(a) administering to the patient, prior to a treatment, an effective amount of a compound of claim 1 ,
or a pharmaceutically acceptable salt form thereof,
and
imaging the patient;
(b) administering to the patient, at a point following treatment, an effective amount the compound, or a pharmaceutically acceptable salt thereof, and imaging the patient; and
(c) comparing the image collected in step (a) with the image collected in step (b) to monitor the treatment.
18. The method of claim 17 , wherein the treatment further comprises administration of an anti-cancer agent.
19. The method of claim 17 , wherein the method further comprises: administering to the patient an effective amount of the compound, or a pharmaceutically acceptable salt thereof, during treatment and imaging the patient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/874,361 US20210038748A1 (en) | 2010-11-22 | 2020-05-14 | Compositions And Methods For In Vivo Imaging |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41603510P | 2010-11-22 | 2010-11-22 | |
US41992910P | 2010-12-06 | 2010-12-06 | |
PCT/US2011/061856 WO2012074840A2 (en) | 2010-11-22 | 2011-11-22 | Compositions and methods for in vivo imaging |
US201313988790A | 2013-08-02 | 2013-08-02 | |
US15/581,386 US10117954B2 (en) | 2010-11-22 | 2017-04-28 | Compositions and methods for in vivo imaging |
US16/147,370 US10653805B2 (en) | 2010-11-22 | 2018-09-28 | Compositions and methods for in vivo imaging |
US16/874,361 US20210038748A1 (en) | 2010-11-22 | 2020-05-14 | Compositions And Methods For In Vivo Imaging |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/147,370 Continuation US10653805B2 (en) | 2010-11-22 | 2018-09-28 | Compositions and methods for in vivo imaging |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210038748A1 true US20210038748A1 (en) | 2021-02-11 |
Family
ID=46172471
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/988,790 Active 2032-01-15 US9649394B2 (en) | 2010-11-22 | 2011-11-22 | Compositions and methods for in vivo imaging |
US15/581,386 Active US10117954B2 (en) | 2010-11-22 | 2017-04-28 | Compositions and methods for in vivo imaging |
US16/147,370 Active US10653805B2 (en) | 2010-11-22 | 2018-09-28 | Compositions and methods for in vivo imaging |
US16/874,361 Abandoned US20210038748A1 (en) | 2010-11-22 | 2020-05-14 | Compositions And Methods For In Vivo Imaging |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/988,790 Active 2032-01-15 US9649394B2 (en) | 2010-11-22 | 2011-11-22 | Compositions and methods for in vivo imaging |
US15/581,386 Active US10117954B2 (en) | 2010-11-22 | 2017-04-28 | Compositions and methods for in vivo imaging |
US16/147,370 Active US10653805B2 (en) | 2010-11-22 | 2018-09-28 | Compositions and methods for in vivo imaging |
Country Status (2)
Country | Link |
---|---|
US (4) | US9649394B2 (en) |
WO (1) | WO2012074840A2 (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012074840A2 (en) * | 2010-11-22 | 2012-06-07 | The General Hospital Corporation | Compositions and methods for in vivo imaging |
WO2013012754A1 (en) * | 2011-07-15 | 2013-01-24 | University Of Southern California | Boron-based dual imaging probes, compositions and methods for rapid aqueous f-18 labeling, and imaging methods using same |
EP3545978B1 (en) | 2013-01-14 | 2021-09-08 | Molecular Insight Pharmaceuticals, Inc. | Triazine based radiopharmaceuticals and radioimaging agents |
EP2948186A4 (en) * | 2013-01-25 | 2016-10-05 | Sloan Kettering Inst Cancer | Tetrazines/trans-cyclooctenes in solid phase synthesis of labeled peptides |
US20150087043A1 (en) * | 2013-04-11 | 2015-03-26 | Coferon, Inc | Monomers capable of multimerizing in an aqueous solution that employ bioorthogonal chemistries, and methods of using same |
JP6622192B2 (en) | 2013-06-19 | 2019-12-18 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Chemical structure for local delivery of therapeutic agents |
WO2015112804A1 (en) * | 2014-01-23 | 2015-07-30 | The General Hospital Corporation | System and method for generating magnetic resonance imaging (mri) images using structures of the images |
AU2015229014B2 (en) | 2014-03-14 | 2019-07-25 | The Regents Of The University Of California | TCO conjugates and methods for delivery of therapeutic agents |
WO2016025480A1 (en) * | 2014-08-11 | 2016-02-18 | The General Hospital Corporation | Cyclooctenes for bioorthogonol reactions |
US10512700B2 (en) | 2014-08-27 | 2019-12-24 | Memorial Sloan Kettering Cancer Center | Radiohalide-labeled targeted diagnostics and therapeutics |
EP3268050B1 (en) * | 2015-03-09 | 2021-07-14 | The Trustees of Columbia University in the City of New York | Pore-forming protein conjugate compositions and methods |
WO2016164771A1 (en) * | 2015-04-10 | 2016-10-13 | Memorial Sloan Kettering Cancer Center | METHODS OF CANCER DETECTION USING PARPi-FL |
US10828373B2 (en) | 2015-09-10 | 2020-11-10 | Tambo, Inc. | Bioorthogonal compositions |
KR20240023665A (en) * | 2016-12-23 | 2024-02-22 | 더 존스 홉킨스 유니버시티 | Tumor and immune cell imaging based on pd-l1 expression |
CN111093708A (en) | 2017-04-07 | 2020-05-01 | 坦伯公司 | Bioorthogonal compositions |
US11161865B2 (en) * | 2017-05-24 | 2021-11-02 | The Trustees Of The University Of Pennsylvania | Radiolabeled and fluorescent PARP inhibitors for imaging and radiotherapy |
MA52642A (en) * | 2018-05-14 | 2021-03-24 | Nuvation Bio Inc | COMPOUNDS TARGETING NUCLEAR ANTI-CANCER HORMONAL RECEPTORS |
CN111773394A (en) * | 2019-04-04 | 2020-10-16 | 复旦大学 | Beta-galactosidase fluorescent probe nano-microsphere and preparation method and application thereof |
SG11202111402PA (en) | 2019-05-14 | 2021-11-29 | Nuvation Bio Inc | Anti-cancer nuclear hormone receptor-targeting compounds |
US11952349B2 (en) | 2019-11-13 | 2024-04-09 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
US20210346525A1 (en) * | 2020-05-11 | 2021-11-11 | The University Of Chicago | Composition and methods for tumor imaging and treatment |
WO2022144501A1 (en) * | 2020-12-28 | 2022-07-07 | Turun Yliopisto | A tracer compound and a preparation method thereof |
BR112023019420A2 (en) | 2021-03-23 | 2023-10-24 | Nuvation Bio Inc | ANTI-CANCER NUCLEAR HORMONE RECEPTOR TARGETING COMPOUNDS |
CN113788827B (en) * | 2021-10-18 | 2023-04-25 | 中国药科大学 | Phthalazinone compound, preparation method and medical application thereof |
WO2023077126A1 (en) * | 2021-10-29 | 2023-05-04 | Tambo, Inc. | Trans-cyclooctene conjugates |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19921567A1 (en) | 1999-05-11 | 2000-11-16 | Basf Ag | Use of phthalazine derivatives |
US20030044353A1 (en) * | 2001-01-05 | 2003-03-06 | Ralph Weissleder | Activatable imaging probes |
US20060093552A1 (en) * | 2002-03-11 | 2006-05-04 | Molecular Insight Pharmaceuticals, Inc. | Technetium-and rhenium-bis(heteroaryl) complexes, and methods of use thereof |
AU2003228418A1 (en) | 2002-03-29 | 2003-10-13 | The General Hospital Corporation | Nir-fluorescent cyanine dyes, their synthesis and biological use |
US7449464B2 (en) * | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
EP1799273A2 (en) | 2004-10-07 | 2007-06-27 | Koninklijke Philips Electronics N.V. | Use of the staudinger ligation in imaging and therapy end kits for imaging and therapy |
GB0428012D0 (en) * | 2004-12-22 | 2005-01-26 | Hammersmith Imanet Ltd | Radiolabelling methods |
JP4790012B2 (en) | 2005-04-27 | 2011-10-12 | シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド | In situ click chemistry method for screening high affinity molecular imaging probes |
JP5122454B2 (en) | 2005-08-02 | 2013-01-16 | センテナリ インスティチュート オブ キャンサー メディシン アンド セル バイオロジー | Method for identifying regulatory T cells |
WO2007056388A2 (en) * | 2005-11-07 | 2007-05-18 | The General Hospital Corporation | Compositions and methods for modulating poly (adp-ribose) polymerase activity |
WO2008030887A2 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Methods for designing parp inhibitors and uses thereof |
US20080118432A1 (en) * | 2006-09-07 | 2008-05-22 | Ivan Bergstein | Monitoring cancer stem cells |
GB0625523D0 (en) * | 2006-12-21 | 2007-01-31 | Ge Healthcare Ltd | In vivo imaging agents |
JP5439380B2 (en) | 2007-10-03 | 2014-03-12 | エーザイ インク. | PARP inhibiting compounds, compositions and methods of use |
GB0819280D0 (en) * | 2008-10-21 | 2008-11-26 | Gen Electric | Imgaing and radiotherapy methods |
WO2010051530A2 (en) * | 2008-10-31 | 2010-05-06 | The General Hospital Corporation | Compositions and methods for delivering a substance to a biological target |
WO2012074840A2 (en) * | 2010-11-22 | 2012-06-07 | The General Hospital Corporation | Compositions and methods for in vivo imaging |
-
2011
- 2011-11-22 WO PCT/US2011/061856 patent/WO2012074840A2/en active Application Filing
- 2011-11-22 US US13/988,790 patent/US9649394B2/en active Active
-
2017
- 2017-04-28 US US15/581,386 patent/US10117954B2/en active Active
-
2018
- 2018-09-28 US US16/147,370 patent/US10653805B2/en active Active
-
2020
- 2020-05-14 US US16/874,361 patent/US20210038748A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20190201562A1 (en) | 2019-07-04 |
WO2012074840A2 (en) | 2012-06-07 |
US10653805B2 (en) | 2020-05-19 |
US20130309170A1 (en) | 2013-11-21 |
US20180015186A1 (en) | 2018-01-18 |
US10117954B2 (en) | 2018-11-06 |
WO2012074840A3 (en) | 2013-02-14 |
US9649394B2 (en) | 2017-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210038748A1 (en) | Compositions And Methods For In Vivo Imaging | |
US8323621B2 (en) | Multi-use multimodal imaging chelates | |
ES2451642T3 (en) | Tetracyclic indole derivatives as imaging agents in vivo and having affinity for peripheral benzodiazepine receptors (PBR) | |
BRPI1006246A2 (en) | "kit for marked medical imaging and / or therapies, effector probe and method" | |
AU2002323528A1 (en) | Multi-use multimodal imaging chelates | |
US10918741B2 (en) | PSMA-targeting imaging agents | |
US9642922B2 (en) | Caspase-triggered nano-aggregation probes and methods of use | |
JP2013514326A (en) | Labeled integrin binding agent | |
KR20130080245A (en) | Dual mri/ct contrast agent and a process for the preparation thereof | |
CA3208649A1 (en) | Precursor and radiotracer for neuroendocrine theranostics | |
IL235122A (en) | Labelled quinoxaline derivatives as multimodal radiopharmaceuticals and their precursors | |
Liu et al. | Aggregation-induced emission based PET probe for liver function imaging | |
JP2013534239A (en) | Tuberculosis imaging with pyrazinamide contrast agent | |
AU2023200964A1 (en) | Theranostic agents | |
WO2020045638A1 (en) | Radioactive imidazothiadiazole derivative compound | |
KR20240054325A (en) | Compounds useful for PET-imaging of Bruton's tyrosine kinase | |
WO2023222682A1 (en) | Prostate specific membrane antigen (psma) ligands | |
CN116375709A (en) | Folic acid receptor targeting drug, metal complex, preparation method and application thereof | |
TW202327665A (en) | New peptide-based diagnostic and therapeutic agents | |
CN115746043A (en) | Inhibitor radioactive probe of targeted fibroblast activation protein and preparation method and application thereof | |
Bauwens et al. | Radioiodinated Phenylalkyl Malonic Acid Derivatives as pH-S nsitive SPECT | |
EP2377852A1 (en) | Labelled huprine derivatives and their use in medical imaging |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: THE GENERAL HOSPITAL CORPORATION, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:REINER, THOMAS;KELIHER, EDMUND J.;WEISSLEDER, RALPH;SIGNING DATES FROM 20130625 TO 20130626;REEL/FRAME:054213/0900 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |